and cash dividend declaration for the six months ended 31 December 2023 Unaudited Interim Results -- 1 of 105 -- DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 CONTENTS A. Notes to the summarised financial statements 15 A.1. Segment information 24 A.2. Normalised profit from operations 25 A.3. Earnings, headline earnings and normalised headline earnings 27 A.4. Revenue from non-insurance activities 27 A.5. Borrowings at amortised cost 29 A.6. Fair value hierarchy of financial instruments B. Other significant items in these results 33 B.1. Exchange rates to South African Rand used in the preparation of these results 33 B.2. Capital management, financial leverage ratio and covenants 35 B.3. Impact of and volatility in long-term interest rates in the SA and UK markets 35 B.4. Change in hedge strategy – VitalityLife business 36 B.5. Consolidation of Discovery Unit Trusts 36 B.6. Material transactions with related parties 36 B.7. Major customers and other Discovery entities not part of Discovery Group 37 B.8. Changes in directorate 37 B.9. Dividend declaration in respect of the six months ended 31 December 2023 C. Accounting policies 39 C.1. New Accounting Standards and amendments to published Accounting Standards not yet effective 39 C.2. Normalised headline earnings 39 C.3. Basis of preparation 01 Results commentary 08 Group statement of financial position 09 Group income statement 10 Group statement of other comprehensive income 11 Group statement of cash flows 12 Group statement of changes in equity D. New standards and interpretations and restatements 41 D.1.1. IFRS 17 Insurance Contracts (IFRS 17) 45 D.1.2. Restatement as a result of prior period errors 45 D.1.3. Changes in presentation of specified line items on the statement of financial position 46 D.1.4. Reconciliation of restated Group statement of financial position 48 D.2. IFRS 17 Accounting policies 58 D.3. Critical estimates and judgements 60 D.4. Insurance and reinsurance contract notes E. Review opinion 110 External review and comparative information Embedded value statement 113 Table 1: Group embedded value 115 Table 2: Value of in-force covered business 116 Table 3: Group embedded value earnings 116 Table 4: Components of Group embedded value earnings 117 Table 5: Experience variances 118 Table 6: Methodology and assumption changes 119 Table 7: Embedded value of new business 120 Table 8: Embedded value economic assumptions 122 Table 9: Embedded value sensitivity 122 Table 10: Value of new business sensitivity Annexure A 125 New business annualised premium income 126 Income from non-insurance business lines ibc Administration -- 2 of 105 -- 1 Results commentary GROUP OVERVIEW AND SALIENT GROUP RESULTS The period under review was characterised by continued macroeconomic complexities. Global inflation rates declined from the prior- period highs, but remained elevated, and cumulative interest rate increases heightened consumer pressures in many regions constraining economic growth. Many markets in Asia experienced post-COVID-19 relief, however, China continued to face significant macroeconomic and growth constraints. Discovery Group delivered a robust performance for the period ended 31 December 2023, demonstrating resilience and strong underlying growth dynamics in a complex operating environment. At a Group level, normalised operating profit increased 13% to R5 622 million; headline earnings were largely unchanged at R3 260 million; normalised headline earnings increased 11% to R3 320 million; and new business annual premium income (API) increased 28% to R14 197 million. Salient Group results for the period ended 31 December 2023 (IFRS 17 reporting) Unit December 2023 December 2022 % Change Group earnings Normalised profit from operations R million 5 622 4 973 13% Normalised headline earnings R million 3 320 3 004 11% Headline earnings R million 3 260 3 276 0% Basic earnings per share Cents 492.9 487.9 1% Basic headline earnings per share Cents 493.8 498.4 -1% Basic normalised headline earnings per share Cents 502.8 457.0 10% Group net asset value and embedded value Net asset value R million 52 206 43 524 20% Embedded value R million 103 480 92 459 12% Annualised RoEV % 12.1% 14.4% Basic embedded value per share R 156.29 140.43 11% Financial leverage and capital management Financial leverage ratio (FLR) 1 % 19.7% 22.1% Shareholder free cash increase, before ordinary dividend R million 350 (62) Dividend per share Cents 65 n/a Business volume Total income from non-insurance lines2 R million 2 942 2 554 15% New business annualised premium income R million 14 197 11 106 28% 1 FLR allowing for the inclusion of 50% of the contractual service margin (CSM) net of reinsurance and net of tax. 2 Not included in new business API. Delivering strong growth, cash generation and capital resilience across all three composites. 01 The Group’s focus in the period centred on the following: Establishing platforms to accelerate future growth by scaling Discovery Bank and Vitality Global through evolving the Vitality Shared-value Insurance model. Transitioning to the new IFRS 17 Insurance Contracts accounting standard. 02 03 -- 3 of 105 -- 2 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Results commentary continued 01 Delivering strong growth, cash generation and capital resilience across all three composites The Group generated normalised operating profit growth of 13% with positive contributions from each composite, as South Africa (SA) increased 9%, United Kingdom (UK) increased 13%, and Vitality Global (VG) increased 71%. The UK and VG results benefitted from a weaker rand compared with the prior period. New business API for the Group increased by 28% as a result of robust growth across the composites, with Discovery Health’s new business augmented by the successful take-on of Sasolmed closed medical scheme. Excluding Discovery Health, new business for the Group increased 11%, with particularly pleasing trends for Discovery Individual Life business, Ping An Health Insurance and VitalityHealth; while VitalityLife’s growth was modest in sterling and Group Life declined. Normalised headline earnings grew 11% while headline earnings were largely unchanged. The difference is explained by the considerable prior period fair value gain from the UK interest rate swaption. The swaption was realised towards the end of the prior financial year, with no profit impact in the current period. Consistent with prior reporting, headline earnings are normalised for this. The Group demonstrated continued financial resilience over the period. Organic cash generation increased with cash conversion now at 66% of after-tax normalised operating profit and central liquidity remained strong. The financial leverage ratio (FLR) improved to 19.7% and capital ratios remained strong across each business. The Group’s embedded value increased to R103.5 billion, which represents an 12.1% annualised return on embedded value (RoEV), with a positive contribution from experience variances over the period, reflecting the positive dynamics of the Vitality Shared-value Insurance model. 02 Establishing platforms to accelerate future growth by scaling Discovery Bank and Vitality Global through evolving the Vitality Shared-value Insurance model The strong operating performance reflects the continued investment and focus on delivering growth and ensuring financial discipline. This was enabled through diligent capital allocation, growing cash generation, and balance sheet strength. Growth in core businesses remained robust over the period, and the focused investment in Discovery Bank and Vitality Global manifested in exceptional performance, with these businesses being positioned as strong platforms for continued growth. Discovery Bank achieved its stated target of monthly operational break-even before acquisition costs during the period, ahead of plan, and is growing rapidly through the acquisition of quality clients on a scalable platform. The Bank’s rapid scaling and exceptional customer engagement position it to play a central role in advancing the SA Composite through integrated ecosystems. Vitality Global delivered exceptional growth over the period. Ping An Health Insurance has emerged as a specialist health insurer of scale in China, delivering high-quality operating metrics, with a robust balance sheet. Vitality Network’s strong growth demonstrates the global adoption of the Vitality Shared-value Insurance model with key partners. The results also demonstrate the emerging operational leverage inherent within the business, with the evolving model creating opportunities for further growth and even greater impact and global relevance. Summary of the earnings and new business performance by composite: Normalised profit from operations (Current period, in ZAR million) % change (Current period vs prior period) New business API (Current period, in ZAR million) % change (Current period vs prior period) Discovery Health 1 874 +7% 6 835 +52% Discovery Life 2 267 +6% 1 519 +2% Discovery Invest 620 +11% 1 629 +8% Discovery Insure 20 >100% 666 +8% Discovery Bank (339) -15% Other initiatives and central costs1 (87) 12% 451 -13% SA Composite1 4 355 +9% 11 100 +29% VitalityHealth 527 (20%) 1 135 +28% VitalityLife 390 97% 935 +17% Closure costs of VitalityInvest (57) (48%) Other initiatives and central costs (48) 85% UK Composite 812 13% 2 070 +22% Vitality Network 296 +49% VHI – Ping An Health Insurance (PAHI) 344 >100% 1 027 +28% VHI – Other (173) >100% Other initiatives and central costs (12) +33% Vitality Global 455 +71% Normalised profit from operations 5 622 13% Normalised headline earnings 3 320 11% Core new business API 14 197 28% 1 FLR allowing for the inclusion of 50% of the contractual service margin (CSM) net of reinsurance and net of tax, consistent with key credit rating agencies. -- 4 of 105 -- 3 BUSINESS-SPECIFIC PERFORMANCE South Africa, including new initiatives The SA Composite’s normalised operating profit increased by 9% to R4 355 million and new business by 29% to R11 100 million. Discovery Bank in particular continued to show excellent progress across all metrics, with the acquisition of quality clients accelerating, and the Bank reaching monthly operational break-even before acquisition costs during the period. Discovery Health’s growth demonstrates the consistent performance across the business with new business increasing 52%, including the take-on of Sasolmed closed medical scheme. Discovery Individual Life delivered strong earnings growth with improving new business margins, while Group Life declined from the prior year’s exceptional performance. Discovery Invest’s performance was robust with revenues and profit benefitting from higher market levels. Discovery Insure recorded pleasing revenue growth, however, its profit recovery was constrained by two severe weather events. Unit December 2023 December 2022 % Change Net non-interest revenue (NIR) R million 567 438 29% Net interest income (NII) R million 366 268 37% Operating loss before new business acquisition costs R million 154 256 (40%) Normalised loss from operations R million 339 398 (15%) Retail deposits R billion 16.7 12.7 31% Advances R billion 5.7 4.8 19% Average interest-earnings assets (IEA) R billion 15 811 12 585 26% Credit loss ratio (CLR) % 3.7 2.1 74% Number of accounts Number 1 933 839 1 312 970 47% Number of clients Number 825 069 581 457 42% Discovery Bank’s (DB) operating loss, before new business acquisition costs, improved by 40%, and the overall loss was 15% better than the prior year. Growth remains high with DB exceeding 825,000 clients in December 2023 and the total client base growing by 42% compared with the prior year. This momentum is indicative of DB’s accelerated pace towards achieving its ambition of one million clients by 2026, which the Bank is well ahead of target to achieve. In light of challenging macroeconomic conditions, DB has remained focused on high-quality growth with the Bank’s shared-value behavioural banking model proving its efficacy. Deposits grew by 31%, reflecting that clients are increasingly using Discovery Bank as their primary account. Advances have grown steadily by 19% since December 2022, with the Bank maintaining materially lower credit loss ratios than the market, for equivalent products. Average interest-earnings assets increased by 26% and the net interest margin increased by 7% over the period, while NII grew by 37%. Non-interest revenue continued to grow steadily, by 29% year-on-year, driven by the growth in interchange income and fee income per client. In line with the Bank’s growth trajectory, client engagement levels grew, with a 56% increase in payment volumes and a 37% increase in spend values in December 2023 compared to the prior year. DB expanded its lending suite by launching a Revolving Credit Facility in December 2023, which offers clients more flexibility. A revolutionary new home loan proposition will imminently be launched to the market, featuring a unique Shared-value interest rate reduction mechanism. Discovery Bank clients have c. R280 billion in existing home loan balances, which DB is well-positioned to cater for. The Bank is well-funded and positioned to continue to prudently grow advances in these target segments. Discovery Bank Unit December 2023 December 2022 % Change Normalised profit from operations R million 1 874 1 748 7% New business API R million 6 835 4 487 52% Revenue R million 5 334 4 924 8% Non-scheme revenue as % of total revenue % 14.7% 14.4% 2% Lives under administration R billion 3.84 3.81 1% * Including VHI Africa. Discovery Health (DH) maintained its solid revenue and profit delivery record, notwithstanding further investment in enhancing systems infrastructure and the digital health ecosystem, including the new Discovery Health app. The successful take-on of Sasolmed closed medical scheme administration significantly increased new business API, with c. 78,000 lives to be added. Non-medical scheme products – Flexicare, Gap Cover and Healthy Company – continued to perform well with total non-scheme revenue now representing almost 15% of total DH revenue, validating the strategy to grow revenue and profits through adjacent opportunities. DH has fully incorporated Vitality Health International (VHI) Africa, which will continue to support the corporate membership base of DH’s South African clients and more broadly. Discovery Health Medical Scheme (DHMS) remains resilient, maintaining membership levels despite a relatively flat open medical scheme market and challenging macroeconomic environment. DHMS maintains its market share of 57.8% in the open medical scheme market and solvency remains strong at 30.6%, significantly higher than the 25% regulatory requirement. Discovery Health* -- 5 of 105 -- 4 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Results commentary continued Unit December 2023 December 2022 % Change Normalised profit from operations R million 2 267 2 145 6% New business API R million 1 519 1 485 2% Premium income R million 18 211 16 824 8% Solvency ratio1 % 180% 177% RoEV (annualised)1 R million 11.9% 13.7% Total VNB margin % 4.3% 4.5% 1 Including Invest. Discovery Individual Life delivered 12% earnings growth and 7% new business growth for the period. The growth rates were diluted by a reduction in Group Life, following an exceptional result in the prior period. Individual life claims experience improved significantly over the period, being offset by an elevated claims experience in Group Life. The improvement in Discovery Individual Life earnings was driven by strong underlying premium growth, improving claims experience and higher interest income. Lapse experience remained ahead of expectation, but policy alterations were negatively impacted by consumer pressure due to elevated levels of inflation and interest rates. Overall non-economic experience variances were positive and the embedded value for Discovery Life (including Invest) delivered an annualised RoEV of 11.9%, despite negative economic variances from higher real yields. The VNB margin for Discovery Individual Life has shown a significant increase to 5.6% at December 2023, primarily due to efficient expense controls and improved business mix over the last six months. Discovery Life maintained its leading position in the affluent retail protection market with an increase in market share to 27.5% for the 12 months to December 2023, with growth across all key retail distribution channels. The strong improvement in the Discovery Individual Life VNB margin was partially offset by weaker performance in Group Life, due to lower new business volumes versus the prior period. Discovery Life’s resilience is demonstrated by its strong solvency and liquidity positions, with a solvency ratio of 180% and liquidity coverage significantly above 100%. Cash flow for Discovery Life (including Invest) was strong at R771 million, with the cash conversion ratio in excess of 35%. Discovery Life Unit December 2023 December 2022 % Change Normalised profit from operations R million 620 561 11% Assets under administration R billion 144.8 130.8 11% Assets under management R billion 99.0 88.2 12% % linked assets in Discovery funds % 80% 81% (0.6)% Net client cash flows R billion 1.1 2.9 (62)% New business API R million 1 629 1 505 8% Fee income R million 1 375 1 194 15% Discovery Invest’s normalised operating profit increased 11%, following growth in underlying assets. Assets under management ended the period 12% higher, driven largely by positive market performance in the first half of the 2023 calendar year. Average assets under administration were 10.7% higher than the prior year, lifting asset-based revenues. New business improved by 8%, driven by higher sales of guaranteed endowments and linked investment business. Net flows were, however, impacted by higher maturities on guaranteed endowment plans. Discovery Invest Unit December 2023 December 2022 % Change Normalised profit from operations R million 20 8 >100% Personal lines R million 2 25 -92% Equity accounted profits (/losses) R million 18 (17) n/a Operating margin Personal lines % 0.1% 0.9% New business API Personal lines R million 666 616 8% Gross written premiums R million 2 804 2 579 9% Discovery Insure (DI)’s personal lines business recorded pleasing revenue growth and continued its efforts to improve the operating margin, with various initiatives put in place to reduce claims costs and operating expenses. Claims due to loadshedding were successfully brought under control through various actions and the increased severity of vehicle thefts was managed using a combination of risk-based pricing, cover, and tracking device initiatives. However, the business faced unprecedented weather events with floods in the Western Cape in September 2023 and severe hailstorms in Gauteng in November 2023, resulting in a catastrophic event. Discovery Insure -- 6 of 105 -- 5 United Kingdom, including new initiatives The UK Composite‘s normalised operating profit decreased by 2% to £34.7 million (increased 13% to R812 million). Earned premiums increased by 11% year-on-year to £536.8 million (up 27% to R12.6 billion), and total lives insured increased by 5% to 1.83 million. New business API increased 6% to £88 million (22% to R2 070 million). Solvency cover remains strong and was positively impacted by the risk margin reforms passed in UK. The UK Composite is well-positioned with the now completed closure of VitalityInvest and the run-down of VitalityCar progressing ahead of plan. The business continues to focus on actions that position it for strong sustainable growth in the core health and life market, without recourse to funding from the Group, with VitalityLife now fully self-funding. Unit December 2023 December 2022 % Change Normalised profit from operations GBP million 22.5 32.3 (30%) R million 527 658 (20%) Earned premiums GBP million 338.6 304.4 11% R million 7 933 6 204 28% New business API GBP million 48.4 43.7 11% R million 1 135 890 28% Lives covered Number 989 492 903 404 10% VitalityHealth (VH) experienced robust new business growth given increased demand for private medical insurance due to backlogs in the National Health Service (NHS). However, there was a concomitant increase in claims experience due to a change in claim patterns in respect of primary care demand, which impacted profit. Industry claims saw a sharp increase following an extended period of reduced utilisation, caused by the COVID-19 pandemic. Pressure in the NHS resulted in challenges in accessing care and treatment as NHS waiting times reached an all-time high, driving increased utilisation of private healthcare. VH claims authorisations per 1,000 lives per month, which are strongly correlated to NHS waiting times, increased materially, largely due to higher primary care-related authorisations. Increased utilisation was exacerbated by elevated medical and general inflation. Management has taken various corrective actions, which include the implementation of pricing increases in line with the market. Emerging earned premiums are expected to offset the claims increase going forward, however, these take time to come through since increases are applied at policy anniversary. Alongside this, VH has continued to invest in its healthcare risk management capabilities resulting in lower costs per authorisation. Excluding claims, performance across key metrics was strong. Lives covered increased by 10% and earned premiums grew by 11%, reflecting the strong new business and low lapse rates. Retention rates were strong, despite the cost-of-living crisis and higher renewal premium increases. VH continues to prioritise prevention through the Vitality programme, while investing in expansive primary care assets and digital servicing, to achieve cost efficiencies. The business is well-positioned to deliver sustainable growth going forward. Vitality Health Unit December 2023 December 2022 % Change Normalised profit from operations GBP million 16.6 9.7 71% R million 390 198 97% Earned premium GBP million 196.6 178.1 10% R million 4 607 3 647 26% New business API GBP million 39.9 39.3 2% R million 935 801 17% Lives covered Number 782 296 735 202 6% VNB margin % (2.8%) 1.4% n/a VitalityLife’s (VL) normalised operating profit grew by 71%. Earnings were boosted by one-off cashflow variances and increased investment income, in particular on the Prudential Assurance Company (PAC) book, given significantly higher UK interest rates. New business grew modestly in a contracting UK market, with the business focusing on the quality of the portfolio through an improved business mix and an increase in the proportion of index-linked policies. Higher long-term interest rates and expense inflation negatively impacted new business margins. However, the business benefitted from GBP 13.8 million higher indexation on existing premiums given elevated inflation rates. This value is presented in other comprehensive income (OCI) and will emerge as profit in the future. Underlying business performance was robust despite a challenging macroeconomic backdrop, with positive lapse and claims experience reflecting the continued engagement in Vitality – driving positive actuarial dynamics. Lives covered increased by 6%, while earned premiums increased by 10%, highlighting the strong retention performance and high indexation increases. Vitality Life -- 7 of 105 -- 6 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Results commentary continued Vitality Global, including new initiatives Vitality Global (VG) includes Vitality Network (VN), as well as Ping An Health Insurance (PAHI) within Vitality Health International (VHI). VG increased operating profits by 55% to US$24.4 million (71% to R455 million). Unit December 2023 December 2022 % Change Revenue1 US$ million 50.3 43.4 16% R million 942 754 25% Normalised profit from operations US$ million 15.8 11.5 37% R million 296 199 49% Integrated API by insurance partners US$ million 807 696 16% R billion 15.1 12.1 25% Number of lives: Million 4.3 3.4 28% 1 Includes VN solutions revenue. VN grew normalised operating profit 37% to US$15.8 million, following robust revenue and profit growth, with margin expansion. Strong sales, membership, and revenue growth in Asia drove a 16% growth in total revenues, despite continued US dollar strength relative to many Asian currencies, in particular relative to the yen. Revenues remain diversified across emerging and developed market currencies. Total membership growth of 28%, driven largely by sales and growth in existing markets, demonstrates the expanding global relevance of the Vitality Shared-value Insurance model. This reporting period also saw strong growth in India, through Tata AIA Vitality, growing rapidly to over 290,000 members as at December 2023. The business is appropriately scaled for further growth and the capital investment into the V1 Platform has now peaked. The profit margin, now above 30%, is expected to continue to expand through continued revenue growth and a flat US dollar cost base, given the cost bias to South African rand. Vitality Network Unit December 2023 December 2022 % Change PAHI (25%), after Discovery’s costs R million 344 85 305% PAHI (25%), after Discovery’s costs US$ million 18.4 5.2 254% Other VHI US$ million (9.2) (0.5) 1740% Normalised operating profit-total US$ million 9.2 4.7 96% PAHI New business PAHI own licence (100%) RMB million 1 591 1 298 23% New business PAHI Reinsurance RMB million 173 157 11% New business PAHI total (100%) RMB million 1 764 1 455 21% Written premium-own licence RMB million 6 535 5 603 17% Written premium-reinsurance RMB million 2 479 2 603 -5% Total written premium (100%) RMB million 9 014 8 206 10% Earned premiums – Total RMB million 7 524 6 623 14% Lives-own licence Million 26.2 19.6 34% Lives-reinsurance Million 6.1 8.6 (29%) Total lives Million 32.3 28.0 15% PAHI profit before income and gains (100%) RMB million 357 118 203% PAHI investment income and gains (100%) RMB million 202 139 45% PAHI pre-tax profit (100%) RMB million 559 257 117% VHI’s profit increased 96% to US$9.2 million in the period, driven by the Group’s share of PAHI’s after-tax operating profit, less Discovery’s costs, increasing 254% to US$18.4 million. PAHI delivered an excellent performance in a complex operating environment in China, with continued strong operating margins and consistently superior premium income growth compared to the industry. The effective tax rate on net investment income benefitted significantly from higher dividend income over the period. PAHI has maintained a robust balance sheet with a comprehensive solvency ratio of 306% driving increased investment income through a conservative investment strategy. New business on the PAHI insurance licence increased by 23%, propelled by a substantial rise in new business through non-Ping An Life channels and a market shift towards higher-end products. Total written premiums increased by 10%, with premiums written on the PAHI licence increasing by 17%, given the gradual run-down of Ping An Life’s business reinsured by PAHI, which was anticipated. Over the calendar year 2023, growth was just under 10 percentage points ahead of the market growth. This has been driven by an uptick in new business over the reporting period, as well as continued improvements to retention. VHI is leveraging the deep data and unique assets of Discovery Group to take advantage of the rapidly evolving US market. The business is doing this by investing in the technology and capabilities of Vitality USA and is showing early signs of success. Amplify Health has made continued progress in the build of four solutions, with three key products already at the deployment stage with AIA markets. The sales traction has increased, with a pipeline emerging in AIA markets as well as with third-party clients in the region. Quantium Health continues to focus on seeking opportunities outside of its core market in Australia with some traction being shown in the UK and US. Vitality Health International -- 8 of 105 -- 7 03 Transitioning to the new IFRS 17 Insurance Contracts accounting standard Earnings for the period are reported under the new IFRS 17 Insurance Contracts accounting standard for the first time and the earnings for the prior period have been restated. At the Group’s June 2023 financial year results announcement, the Group highlighted that the transition to IFRS 17 would result in a reduction in shareholder equity, with a resulting increase in the contractual service margin (CSM), which should be seen as a store of value to be released as future profit. As such, the transition would not have any material impact on the Group’s underlying economic value, solvency levels or cash flows, but would affect its incidence of profit recognition. The restated normalised profit from operations under IFRS 17 for the prior period to 31 December 2022 was 16% lower than under the previously disclosed IFRS 4 Insurance Contracts accounting standard. The new IFRS 17 reporting disclosures are detailed in this announcement. PROSPECTS AND DIVIDEND Discovery’s growth strategy is based on the efficacy, repeatability and scalability of its Vitality Shared-value Insurance model through organic growth and global partnerships. The performance during the period has enhanced the Group’s confidence in this strategy. In addition to the robust growth expected from its core operations, Discovery has established strong platforms for growth after periods of investment, in particular, Discovery Bank and Vitality Global. These are expected to deliver strong revenue growth and operational leverage, supporting strong earnings growth and cash generation for the Group. At the Group’s June 2023 financial year results announcement, Discovery described its dividend policy under IFRS 17. The annual ordinary dividend is expected to be covered approximately five times by normalised headline earnings, with interim ordinary dividends expected to be paid in the range of 30%-40% of the expected total annual ordinary dividend, with the remainder of the dividend to be paid as a final dividend. The Group has declared its interim ordinary dividends for period at 65 cents per share. NOTES TO ANALYSTS Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company’s external auditors. Discovery has published supplemental unaudited information on the website. For this and other results information, visit https://www.discovery.co.za/corporate/financial-results and go to Financial and annual reports. On behalf of the Board ME Tucker A Gore Chairperson Group Chief Executive Sandton 19 March 2024 -- 9 of 105 -- 8 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Group statement of financial position at 31 December 2023 R million Notes Group December 2023 Unaudited Restated 1 Group June 2023 Unaudited Restated 1 Group 1 July 2022 Unaudited Assets Goodwill 5 353 5 406 4 912 Intangible assets 7 094 7 064 6 584 Property and equipment 3 918 3 910 3 811 Assets arising from insurance contracts issued D.4.1. 37 791 32 914 30 863 Assets arising from reinsurance contracts held D.4.1. 791 604 873 Deferred tax asset 5 359 6 320 5 688 Assets arising from contracts with customers 2 473 2 221 1 709 Investment in equity-accounted investees 7 867 7 398 6 338 Financial assets – Loans and advances to customers at amortised cost 5 219 4 702 3 944 – Investments at amortised cost 10 257 9 910 7 161 – Investments at fair value through profit or loss 155 172 155 426 141 494 – Derivative financial instruments at fair value through profit or loss 157 119 276 Contract receivables and other receivables 5 755 5 684 5 223 Non-current assets held for sale – – 171 Current tax asset 211 41 220 Cash and cash equivalents 14 507 16 260 13 787 TOTAL ASSETS 261 924 257 979 233 054 Equity Capital and reserves Ordinary share capital and share premium 10 794 10 351 10 178 Perpetual preference share capital 779 779 779 Other reserves 3 860 3 045 2 243 Retained earnings 36 769 34 209 27 617 Equity attributable to equity holders of the Company 52 202 48 384 40 817 Non-controlling interest 4 4 5 TOTAL EQUITY 52 206 48 388 40 822 Liabilities Liabilities arising from insurance contracts issued D.4.1. 99 527 95 695 85 055 Liabilities arising from reinsurance contracts held D.4.1. 5 684 4 843 5 207 Deferred tax liability 6 687 6 222 6 313 Contract liabilities to customers 591 656 944 Third-party interest in consolidated funds 29 704 28 346 24 320 Financial liabilities – Borrowings at amortised cost A.5. 20 491 20 586 20 584 – Other financial payables at amortised cost 6 834 9 112 8 492 – Deposits from customers 16 667 14 333 10 881 – Investment contracts at fair value through profit or loss 21 980 28 903 28 955 – Derivative financial instruments at fair value through profit or loss 35 20 202 Other payables and provisions 1 481 710 752 Current tax liability 37 165 527 TOTAL LIABILITIES 209 718 209 591 192 232 TOTAL EQUITY AND LIABILITIES 261 924 257 979 233 054 1 The comparative information has been restated for the initial application of IFRS 17, changes in the presentation of specified line items and the correction of prior period errors. Refer to section D, note D.1.1. – D.1.4. for more detail. -- 10 of 105 -- 9 Group income statement for the six months ended 31 December 2023 R million Notes Group six months ended December 2023 Unaudited Restated1 Group six months ended December 2022 Unaudited Restated 1 Group year ended June 2023 Unaudited Insurance revenue D.4.11. 26 117 22 532 47 208 Insurance service expenses (22 953) (19 663) (41 634) Net (expenses)/income from reinsurance contracts (609) 13 (188) Insurance service result 2 555 2 882 5 386 Net financial result from insurance finance income and expense D.4.12. (2 892) (4 233) (7 458) – Net finance expense from insurance contracts (2 730) (4 085) (7 172) – Net finance expense from reinsurance contracts (162) (148) (286) Investment income using the effective interest rate method 412 248 616 Net fair value gains on financial assets at fair value through profit or loss 6 670 8 587 16 726 Fair value adjustment to liabilities under investment contracts (691) (1 092) (2 593) Third party interest: fair value adjustment to liabilities under investment contracts (1 149) (1 539) (2 978) Other gains on financial instruments 5 – – Net insurance and investment results 4 910 4 853 9 699 Fee income from administration businesses A.4. 6 903 6 348 13 224 Vitality income A.4. 2 135 1 943 3 891 Net banking fee and commission income 581 449 965 – Banking fee and commission income A.4. 845 583 1 292 – Banking fee and commission expense (264) (134) (327) Net bank interest and similar income 366 268 574 – Bank interest and similar income using the effective interest rate 869 591 1 318 – Bank interest and similar expense using the effective interest rate (503) (323) (744) Other income 779 743 1 544 Non-insurance revenue and income 10 764 9 751 20 198 Net income 15 674 14 604 29 897 Acquisition costs (456) (423) (880) Expected credit losses (93) (43) (139) Marketing and administration expenses (9 573) (8 674) (18 439) Impairment of goodwill – – (9) Operating profit before integral equity-accounted investments 5 552 5 464 10 430 Loss on dilution and disposal of equity-accounted investments – – (5) Share of net profits from equity-accounted investments 278 55 525 Profit before finance costs and tax 5 830 5 519 10 950 Finance costs (1 025) (924) (1 919) Foreign exchange (losses)/gains (40) 28 151 Profit before tax 4 765 4 623 9 182 Income tax expense (1 422) (1 385) (2 516) Profit for the period/year 3 343 3 238 6 666 Profit attributable to: – Ordinary shareholders 3 304 3 207 6 604 – Preference shareholders 44 31 69 – Non-controlling interest (5) – (7) 3 343 3 238 6 666 Earnings per share for profit attributable to ordinary shareholders of the Company during the period/year (cents): – Basic 492.9 487.9 986.5 – Diluted 490.4 480.9 981.6 1 The comparative information has been restated for the initial application of IFRS 17 as well as for changes in the presentation of equity-accounted investments to enhance the understandability of the Group income statement. -- 11 of 105 -- 10 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Group statement of other comprehensive income for the six months ended 31 December 2023 R million Notes Group six months ended December 2023 Unaudited Restated1 Group six months ended December 2022 Unaudited Restated 1 Group year ended June 2023 Unaudited Profit for the period/year 3 343 3 238 6 666 Items that are or may be subsequently reclassified to profit or loss: Currency translation differences (344) 444 3 172 – Unrealised (losses)/gains (356) 444 3 287 – Tax on unrealised losses/(gains) 12 – (115) Cash flow hedges (70) 32 76 – Unrealised (losses)/gains (72) 36 76 – Gains/(losses) reclassified to profit or loss 2 (5) (1) – Tax on reclassified gains – 1 1 Net finance income/(expense) from insurance contracts issued D.4.12. 1 805 (1 423) (3 712) – Unrealised income/(expense) 2 413 (1 925) (5 072) – Tax on unrealised (income)/expense (608) 502 1 360 Net finance (expense)/income from reinsurance contracts held D.4.12. (455) 298 433 – Unrealised (expense)/income (608) 400 589 – Tax on unrealised expense/(income) 153 (102) (156) Share of other comprehensive income/(loss) from equity-accounted investments 18 (36) 433 – Change in fair value of debt instruments at fair value through other comprehensive income (1) (12) (10) – Currency translation differences 19 (24) 443 Items that may not be reclassified to profit or loss: Share of other comprehensive (loss)/income from equity-accounted investments (2) 2 8 – Change in fair value of equity instruments at fair value through other comprehensive income (2) 2 8 Other comprehensive income/(loss) for the period/year, net of tax 952 (683) 410 Total comprehensive income for the period/year 4 295 2 555 7 076 Attributable to: – Ordinary shareholders 4 251 2 523 7 014 – Preference shareholders 44 31 69 – Non-controlling interest – 1 (7) Total comprehensive income for the period/year 4 295 2 555 7 076 1 The comparative information has been restated for the initial application of IFRS 17. Refer to section D, notes D.1.1. – D.1.4. for detail. -- 12 of 105 -- 11 Group statement of cash flows for the six months ended 31 December 2023 R million Group six months ended December 2023 Unaudited Restated1 Group six months ended December 2022 Unaudited Restated 1 Group year ended June 2023 Unaudited Cash flows from operating activities (1 009) 1 163 5 293 Cash (utilised)/generated by operations (1 042) 5 876 11 052 Purchase of investments held to back policyholder liabilities (31 756) (35 314) (62 773) Proceeds from disposal of investments held to back policyholder liabilities 30 931 30 303 55 908 Cash (utilised)/generated from operating activities (1 867) 865 4 187 Dividends received 367 186 728 Interest received 2 085 2 086 3 718 Interest paid (802) (932) (1 501) Taxation paid (792) (1 042) (1 839) Cash flows from investing activities 556 (740) (2 236) Purchase of financial assets (14 243) (16 295) (30 966) Proceeds from disposal of financial assets 16 020 16 567 30 932 Purchase of property and equipment (246) (210) (551) Proceeds from disposal of property and equipment – 2 2 Purchase of intangible assets (800) (751) (1 760) Acquisition of business net of cash – – (3) Additional investment in equity-accounted investments (176) (109) (182) Proceeds from sale of non-current asset held for sale – – 184 Dividends from equity-accounted investments 1 56 108 Cash flows from financing activities (1 150) (651) (1 234) Dividends paid to ordinary shareholders (739) – – Dividends paid to preference shareholders (44) (31) (69) Proceeds from borrowings 500 3 856 7 442 Repayment of borrowings (867) (4 476) (8 607) Net (decrease)/increase in cash and cash equivalents (1 603) (228) 1 823 Cash and cash equivalents at beginning of the period/year 16 227 13 631 13 631 Effects of exchange rate changes on cash and cash equivalents (117) 94 773 Cash and cash equivalents at end of the period/year 14 507 13 497 16 227 Reconciliation to statement of financial position Cash and cash equivalents 14 507 13 497 16 260 Bank overdraft included in borrowings at amortised cost – – (33) Cash and cash equivalents at end of the period/year 14 507 13 497 16 227 1 The comparative information has been restated for the initial application of IFRS 17. Refer to section D, notes D.1.1. – D.1.4. for detail. -- 13 of 105 -- 12 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 13 Group statement of changes in equity for the six months ended 31 December 2023 Attributable to equity holders of the Company Attributable to equity holders of the Company R million Share capital and share premium Perpetual preference share capital Share-based payment reserve Investment reserve 1 Insurance finance reserve Foreign currency translation reserve Hedging reserve Retained earnings Total Non- controlling interest Total Period ended 31 December 2023 At beginning of the period – July 2023 10 351 779 1 190 19 (4 685) 6 480 41 34 209 48 384 4 48 388 Total comprehensive income for the period – 44 – (3) 1 350 (330) (70) 3 304 4 295 – 4 295 Profit for the period – 44 – – – – – 3 304 3 348 (5) 3 343 Other comprehensive income – – – (3) 1 350 (330) (70) – 947 5 952 Transactions with owners 443 (44) (132) – – – – (744) (477) – (477) Share issue 432 – – – – – – – 432 – 432 Increase in treasury shares (432) – – – – – – – (432) – (432) Delivery of treasury shares 443 – (438) – – – – (5) – – – Employee share option schemes: – Value of employee services, net of tax – – 306 – – – – – 306 – 306 Dividends paid to preference shareholders – (44) – – – – – – (44) – (44 ) Dividends paid to ordinary shareholders – – – – – – – (739) (739) – (739) At end of the period 10 794 779 1 058 16 (3 335) 6 150 (29) 36 769 52 202 4 52 206 Period ended 31 December 2022 At beginning of the period – July 2022 10 178 779 798 35 – 2 823 (35) 38 972 53 550 5 53 555 – New IFRS transitional adjustment2 – – – (14) (1 406) – – (11 150) (12 570) – (12 570) – Prior period error adjustments – – – – – 42 – (205) (163) – (163) Restated balance at beginning of the period 10 178 779 798 21 (1 406) 2 865 (35) 27 617 40 817 5 40 822 Total comprehensive income for the period – 31 – (10) (1 125) 419 32 3 207 2 554 1 2 555 Profit for the period – 31 – – – – – 3 207 3 238 – 3 238 Other comprehensive income – – – (10) (1 125) 419 32 – (684) 1 (683) Transactions with owners 172 (31) 22 – – – – (16) 147 – 147 Share issue 514 – – – – – – – 514 – 514 Increase in treasury shares (514) – – – – – – – (514) – (514) Delivery of treasury shares 172 – (156) – – – – (16) – – – Employee share option schemes: – Value of employee services – – 178 – – – – – 178 – 178 Dividends paid to preference shareholders – (31) – – – – – – (31) – (31) At end of the period 10 350 779 820 11 (2 531) 3 284 (3) 30 808 43 518 6 43 524 1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments. 2 The comparative information has been restated for the initial application of IFRS 17. -- 14 of 105 -- 14 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Notes to the summarised financial statements A.1. Segment information A.2. Normalised profit from operations A.3. Earnings, headline earnings and normalised headline earnings A.4. Revenue from non-insurance activities A.5. Borrowings at amortised cost A.6. Fair value hierarchy of financial instruments A -- 15 of 105 -- 15 A.1. Segment information Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes strategic decisions regarding these businesses. An operating segment is a component of an entity: (a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses relating to transactions with other components of the same entity. (b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to the segment and assess its performance; and (c) For which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds: (a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of the combined revenue, internal and external, of all operating segments. (b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; and (c) Its assets are 10 percent or more of the combined assets of all operating segments. Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. Discovery may combine information about operating segments that do not meet the quantitative thresholds with information about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the operating segments have similar economic characteristics. The Group has identified its reportable segments based on a combination of products and services offered to customers and the location of the markets served. A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS DISCLOSURE for the six months ended 31 December 2023 -- 16 of 105 -- 16 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued A.1. Segment information continued The following summary describes the operations of each of the Group’s reportable segments: SA Health  Administers and provides managed care services to medical schemes in South Africa.  Renders administration services to other business segments within the Group.  Together with Medical Services Organisation International (MSO), a subsidiary company, deliver health insurance, healthcare risk management and third-party administration services within rest of Africa markets. SA Life Offers a range of insurance and financial solutions to the Group’s clients against the financial impact of lifestyle-changing events in South Africa. SA Invest Offers, through a range of investment fund choices, including Discovery managed unit trusts, a comprehensive and flexible range of investment choices. These products are sold through a number of investment wrappers including Discovery Life policies and are offered to individuals in South Africa. SA Insure Offers a range of personal line insurance (motor, building, household content and portable possessions) to the Group’s SA clients against the financial impact of loss or damage. The segment also includes Discovery’s equity-accounted interests including Cambridge Mobile Telematics (CMT). SA Bank Offers retail banking solutions, including deposits and loans and advances, to clients in the South African market. The Bank is still in a start-up phase. UK Health Offers consumer-engaged private medical insurance products to employer groups and individuals in the UK. All contracts in this segment are short-term insurance contracts. UK Life Offers a risk-only life assurance product. All contracts in this segment are long-term assurance contracts offered to both employer groups and individuals in the UK. All other segments Includes those segments that do not meet the quantitative thresholds set out in IFRS 8 Operating Segments and cannot be aggregated with another reportable segment. It includes the following operating segments:  SA Composite: – SA Vitality, which offers health and lifestyle benefits with selected partners to the Group’s SA clients. – SA Insure commercial: provides commercial short-term risk insurance products to the South African market. – Discovery Umbrella: offers pension and provident fund solutions that encourage employees to reach their retirement goals with unique rewards, benefits and digital engagement. – SA Distribution: provides sales and distribution services in respect of all SA products. – Other new group initiatives, including Vitality Green, as well as unallocated central costs.  UK Composite: – Includes immaterial interests in equity-accounted interests, UK Invest which is currently in Other initiatives and central costs.  Vitality Global Composite: – Vitality Health International, leverages Discovery Health and Vitality’s intellectual property to create strategic partnerships through equity-accounted interests in health insurance and health technology and solutions businesses, which includes the equity-accounted interests in Ping An Health Insurance and Amplify Health. – Vitality Network, which provides a Vitality platform to international insurance businesses. – Central costs. -- 17 of 105 -- 17 A.1. Segment information continued The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/loss from operations. Items which are excluded from the normalised profit/loss from operations are separately disclosed in the segment information to reconcile to the segment results and Group income statement. The segment information is presented on the same basis as reported to the CODM. The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant with the IFRS Accounting Standards., i.e. IFRS reporting adjustments, these adjustments include the following: (a) Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties. (b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and (c) The effects of reclassifying items to align to the IFRS Group income statement. Effective 1 July 2023, the following changes have been made to the Segment information and the comparative information has been restated accordingly: 1. The Segment information has been updated, consistent with the changes to the Group income statement, to reflect the new presentation requirements of IFRS 17. 2. SA Vitality is no longer presented as a separate reportable segment. Instead, SA Vitality is presented as part of ‘All other segments’. 3. Africa Health results are included in the SA Health segment as management control of this operation had been moved from Vitality Global to Discovery Health. This was previously disclosed in ‘All other segments’ as a new initiative and comparative information has been restated accordingly. 4. Definitions of ’Investment income on assets backing policyholder liabilities‘ and ’Investment income earned on shareholder investments and cash‘ have been refined in order to achieve consistent treatment across the regulated insurance entities of the Group. Discovery includes in ’Investment income on assets backing policyholder liabilities‘ all investment income from those assets backing client and policyholder liabilities, including those assets held for regulatory capital requirements and related additional risk appetite margins. This refinement resulted in a reallocation of investment income such that the component attributable to normalised profit from operations, increased by R67 million for the six months ended 31 December 2022 (30 June 2023: R186 million) while investment income earned on shareholder investments and cash decreased by the same amount. For the six months ended 31 December 2023, as a result of the increases in interest rate and increasing insurance book, the consistently applied reallocation amounted to R177 million of interest earned being included in normalised profit from operations rather than investment income earned on shareholder investments and cash. These reallocations had no effect on total investment income nor total earnings. -- 18 of 105 -- 18 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 19 A.1. Segment information continued R million SA Health SA Life SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments IFRS total 31 December 2023 Income statement Insurance revenue 193 8 595 1 866 2 792 – 7 960 4 368 343 26 117 – 26 117 – Contracts measured under the General measurement model/Variable fee approach – 6 859 1 866 – – – 4 368 – 13 093 – 13 093 – Contracts measured under Premium allocation approach 193 1 736 – 2 792 – 7 960 – 343 13 024 – 13 024 Insurance service expenses (139) (7 489) (1 174) (2 810) – (7 197) (3 768) (376) (22 953) – (22 953) – Claims and benefits (77) (5 700) (202) (1 838) – (4 297) (2 281) (236) (14 631) – (14 631) – Insurance service expense and other (62) (819) (525) (452) – (2 051) (209) (140) (4 258) – (4 258) – Insurance acquisition cash flows – (970) (447) (520) – (849) (1 278) – (4 064) – (4 064) Insurance service result (pre-reinsurance) 54 1 106 692 (18) – 763 600 (33) 3 164 – 3 164 Net (expense)/income from reinsurance contracts – (410) – 19 – (5) (214) 1 (609) – (609) – Reinsurance expense – (1 800) – (249) – (5) (2 675) (135) (4 864) – (4 864) – Insurance claims recovered from reinsurers – 1 390 – 268 – – 2 461 136 4 255 – 4 255 Insurance service result 54 696 692 1 – 758 386 (32) 2 555 – 2 555 Net financial result from insurance finance income and expense – 1 318 (3 939) – – – 76 – (2 545) (347) (2 892) – Net finance income/(expense) from insurance contracts – 1 414 (3 939) – – – 142 – (2 383) (347) (2 730) – Net finance expense from reinsurance contracts – (96) – – – – (66) – (162) – (162) Investment income earned on assets backing policyholder liabilities – 10 26 103 – 83 41 10 273 139 412 Net fair value (losses)/gains on financial instruments at fair value through profit or loss (4) 520 3 911 4 – 56 – 424 4 911 1 759 6 670 Fair value adjustments to liabilities under investment contracts – (1) (260) – – – – (430) (691) – (691) Third party interest: fair value adjustments to liabilities under investment contracts – – – – – – – – – (1 149) (1 149) Intersegment funding – (121) 121 – – – – – – – – Other gains on financial instruments – – – – 5 – – – 5 – 5 Net insurance and investment results 50 2 422 551 108 5 897 503 (28) 4 508 402 4 910 Fee income from administration businesses 4 452 – 812 4 – 25 – 1 610 6 903 – 6 903 Vitality income – – – – – 301 131 1 703 2 135 – 2 135 Net banking fee and commission income – – – – 567 – – 14 581 – 581 – Banking fee and commission income – – – – 845 – – – 845 – 845 – Banking fee and commission expense – – – – (278) – – 14 (264) – (264) Net bank interest and similar income – – – – 366 – – – 366 – 366 – Bank interest and similar income using the effective interest rate – – – – 869 – – – 869 – 869 – Bank interest and similar expense using the effective interest rate – – – – (503) – – – (503) – (503) Other income 689 1 – 11 – 12 – 66 779 – 779 Non-insurance revenue and income 5 141 1 812 15 933 338 131 3 393 10 764 – 10 764 Net income 5 191 2 423 1 363 123 938 1 235 634 3 365 15 272 402 15 674 Acquisition costs – – (402) – – – – (54) (456) – (456) Expected credit losses – – – – (93) – – – (93) – (93) Marketing and administration expenses – depreciation and amortisation (79) – (7) (35) (175) (228) (23) (409) (956) (84) (1 040) – derecognition of intangible assets and property and equipment – – – (3) – (1) – (4) (8) – (8) – other expenses (3 238) (156) (334) (84) (1 009) (480) (221) (2 917) (8 439) (86) (8 525) Share of net profits from equity-accounted investments – – – 19 – 1 – 282 302 (24) 278 Normalised profit/(loss) from operations 1 874 2 267 620 20 (339) 527 390 263 5 622 208 5 830 Investment income earned on shareholder investments and cash 54 13 6 – – – – 66 139 (139) – Intercompany investment income – – – – – – – 823 823 (823) – Net fair value gains/(losses) on financial assets at fair value through profit or loss – 29 27 – – – – – 56 (56) – Amortisation of intangibles from business combinations – – – (24) – – – (28) (52) 52 – Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – (59) (59) 59 – Restructuring costs – – – – – – – (20) (20) 20 – Finance costs (11) (1) – – – (8) (112) (749) (881) (144) (1 025) Intercompany finance costs (201) – – – – – (227) (395) (823) 823 – Foreign exchange gains/(losses) 1 (4) (12) – – – – (25) (40) – (40) Profit/(loss) before tax 1 717 2 304 641 (4) (339) 519 51 (124) 4 765 – 4 765 Income tax expense (470) (612) (228) (1) 108 (152) (26) (41) (1 422) – (1 422) Profit/(loss) for the period 1 247 1 692 413 (5) (231) 367 25 (165) 3 343 – 3 343 Profit attributable to: – Ordinary shareholders 1 252 1 692 413 (5) (231) 367 25 (209) 3 304 – 3 304 – Preference shareholders – – – – – – – 44 44 – 44 – Non-controlling interest (5) – – – – – – – (5) – (5) A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued -- 19 of 105 -- 20 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 21 A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued A.1. Segment information continued R million SA Health SA Life SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments IFRS total 31 December 2022 Income statement Insurance revenue 136 8 221 1 504 2 536 – 6 425 3 458 252 22 532 – 22 532 – Contracts measured under the General measurement model/Variable fee approach – 6 591 1 504 – – – 3 458 – 11 553 – 11 553 – Contracts measured under Premium allocation approach 136 1 630 – 2 536 – 6 425 – 252 10 979 – 10 979 Insurance service expense (103) (7 255) (993) (2 461) – (5 415) (3 101) (335) (19 663) – (19 663) – Claims and benefits (65) (5 585) (156) (1 629) – (3 200) (1 938) (210) (12 783) – (12 783) – Insurance service expense and other (38) (799) (447) (421) – (1 573) (176) (125) (3 579) – (3 579) – Insurance acquisition cash flows – (871) (390) (411) – (642) (987) – (3 301) – (3 301) Insurance service result (pre-reinsurance) 33 966 511 75 – 1 010 357 (83) 2 869 – 2 869 Net income/(expense) from reinsurance contracts – 40 – (22) – (4) (19) 18 13 – 13 – Reinsurance expense (1) (1 680) – (206) – (787) (1 670) (100) (4 444) – (4 444) – Insurance claims recovered from reinsurers 1 1 720 – 184 – 783 1 651 118 4 457 – 4 457 Insurance service result 33 1 006 511 53 – 1 006 338 (65) 2 882 – 2 882 Net financial result from insurance finance income and expense – 1 003 (5 028) – – – (82) – (4 107) (126) (4 233) – Net finance income/(expense) from insurance contracts – 1 114 (5 028) – – – (45) – (3 959) (126) (4 085) – Net finance expense from reinsurance contracts – (111) – – – – (37) – (148) – (148) Investment income earned on assets backing policyholder liabilities – 3 20 62 – 29 26 6 146 102 248 Net fair value (losses)/gains on financial instruments at fair value through profit or loss (12) 394 5 244 (6) – (10) – 709 6 319 2 268 8 587 Fair value adjustments to liabilities under investment contracts – (3) (383) – – – – (706) (1 092) – (1 092) Third party interest: fair value adjustments to liabilities under investment contracts – – – – – – – – – (1 539) (1 539) Intersegment funding – (102) 102 – – – – – – – – Net insurance and investment results 21 2 301 466 109 – 1 025 282 (56) 4 148 705 4 853 Fee income from administration businesses 4 121 – 746 9 – 18 – 1 454 6 348 – 6 348 Vitality income – – – – – 185 113 1 645 1 943 – 1 943 Net banking fee and commission income – – – – 438 – – 11 449 – 449 – Banking fee and commission income – – – – 583 – – – 583 – 583 – Banking fee and commission expense – – – – (145) – – 11 (134) – (134) Net bank interest and similar income – – – – 268 – – – 268 – 268 – Bank interest and similar income using the effective interest rate – – – – 591 – – – 591 – 591 – Bank interest and similar expense using the effective interest rate – – – – (323) – – – (323) – (323) Other income 667 2 – 6 – 13 – 55 743 – 743 Non-insurance revenue and income 4 788 2 746 15 706 216 113 3 165 9 751 – 9 751 Net income 4 809 2 303 1 212 124 706 1 241 395 3 109 13 899 705 14 604 Acquisition costs – – (374) – – – – (49) (423) – (423) Expected credit losses – – – – (43) – – – (43) – (43) Marketing and administration expenses – depreciation and amortisation (70) – (5) (32) (157) (207) (28) (371) (870) (84) (954) – derecognition of intangible assets and property and equipment – – – (4) – (60) (18) (5) (87) – (87) – other expenses (2 991) (158) (272) (64) (904) (316) (151) (2 724) (7 580) (53) (7 633) Share of net profits from equity-accounted investments – – – (16) – – – 93 77 (22) 55 Normalised profit/(loss) from operations 1 748 2 145 561 8 (398) 658 198 53 4 973 546 5 519 Fair value losses on VitalityLife interest rate derivatives – – – – – – 391 – 391 (391) – Investment income earned on shareholder investments and cash 34 7 13 – – – – 48 102 (102) – Intercompany investment income – – – – – – – 530 530 (530) – Net fair value (losses)/gains on financial assets at fair value through profit or loss – (2) 34 – – – – (2) 30 (30) – Amortisation of intangibles from business combinations – – – (22) – – – (28) (50) 50 – Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – (73) (73) 73 – Finance costs – – – – – (4) (77) (697) (778) (146) (924) Intercompany finance costs (166) – – – – – (129) (235) (530) 530 – Foreign exchange gains/(losses) 1 5 6 – – – (2) 18 28 – 28 Profit/(loss) before tax 1 617 2 155 614 (14) (398) 654 381 (386) 4 623 – 4 623 Income tax expense (441) (581) (214) (7) 110 (143) (57) (52) (1 385) – (1 385) Profit/(loss) for the period 1 176 1 574 400 (21) (288) 511 324 (438) 3 238 – 3 238 Profit attributable to: – Ordinary shareholders 1 176 1 574 400 (21) (288) 511 324 (469) 3 207 – 3 207 – Preference shareholders – – – – – – – 31 31 – 31 – Non-controlling interest – – – – – – – – – – – -- 20 of 105 -- 22 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 23 A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued A.1. Segment information continued R million SA Health SA Life SA Invest SA Insure SA Bank UK Health UK Life All other segments Segment total IFRS reporting adjustments IFRS total 30 June 2023 Income statement Insurance revenue 303 16 758 3 231 5 176 – 13 670 7 535 535 47 208 – 47 208 – Contracts measured under the General measurement model/Variable fee approach – 13 464 3 231 – – – 7 535 1 24 231 – 24 231 – Contracts measured under Premium allocation approach 303 3 294 – 5 176 – 13 670 – 534 22 977 – 22 977 Insurance service expense (234) (14 699) (2 050) (4 993) – (12 178) (6 819) (661) (41 634) – (41 634) – Claims and benefits (152) (11 282) (331) (3 246) – (7 341) (3 891) (409) (26 652) – (26 652) – Insurance service expense and other (82) (1 632) (957) (831) – (3 435) (827) (252) (8 016) – (8 016) – Insurance acquisition cash flows – (1 785) (762) (916) – (1 402) (2 101) – (6 966) – (6 966) Insurance service result (pre-reinsurance) 69 2 059 1 181 183 – 1 492 716 (126) 5 574 5 574 Net (expense)/income from reinsurance contracts – (225) – (70) – (9) 92 24 188 – 188 – Reinsurance expense (1) (3 549) – (413) – (1 846) (3 464) (221) (9 494) – (9 494) – Insurance claims recovered from reinsurers 1 3 324 – 343 – 1 837 3 556 245 9 306 – 9 306 Insurance service result 69 1 834 1 181 113 – 1 483 808 (102) 5 386 – 5 386 Net financial result from insurance finance income and expense – 2 225 (9 815) – – – (89) – (7 679) 221 (7 458) – Net finance income/(expense) from insurance contracts – 2 450 (9 815) – – – (28) – (7 393) 221 (7 172) – Net finance expense from reinsurance contracts – (225) – – – – (61) – (286) – (286) Investment income earned on assets backing policyholder liabilities – 28 51 145 – 90 71 15 400 216 616 Net fair value (losses)/gains on financial instruments at fair value through profit or loss (6) 760 10 904 – – – – 1 282 12 940 3 786 16 726 Fair value adjustments to liabilities under investment contracts – (3) (1 326) – – – – (1 264) (2 593) – (2 593) Third party interest: fair value adjustments to liabilities under investment contracts – – – – – – – – – (2 978) (2 978) Intersegment funding – (126) 126 – – – – – – – – Net insurance and investment results 63 4 718 1 121 258 – 1 573 790 (69) 8 454 1 245 9 699 Fee income from administration businesses 8 575 – 1 566 17 – 46 – 3 020 13 224 – 13 224 Vitality income – – – – – 462 238 3 191 3 891 – 3 891 Net banking fee and commission income – – – – 943 – – 22 965 – 965 – Banking fee and commission income – – – – 1 292 – – – 1 292 – 1 292 – Banking fee and commission expense – – – – (349) – – 22 (327) – (327) Net bank interest and similar income – – – – 574 – – – 574 – 574 – Bank interest and similar income using the effective interest rate – – – – 1 318 – – – 1 318 – 1 318 – Bank interest and similar expense using the effective interest rate – – – – (744) – – – (744) – (744) Other income 1 381 3 – 14 – 48 – 98 1 544 – 1 544 Non-insurance revenue and income 9 956 3 1 566 31 1 517 556 238 6 331 20 198 – 20 198 Net income 10 019 4 721 2 687 289 1 517 2 129 1 028 6 262 28 652 1 245 29 897 Acquisition costs – – (780) – – – – (100) (880) – (880) Expected credit losses – – – – (139) – – – (139) – (139) Marketing and administration expenses – depreciation and amortisation (144) – (12) (64) (314) (420) (49) (799) (1 802) (168) (1 970) – derecognition of intangible assets and property and equipment (4) – – (3) – (241) (19) (57) (324) – (324) – impairment of intangible assets and property and equipment – – – – – (45) – – (45) – (45) – other expenses (6 173) (346) (622) (133) (1 831) (790) (373) (5 726) (15 994) (106) (16 100) Share of net profits from equity-accounted investments – – – (16) – 1 2 584 571 (46) 525 Normalised profit/(loss) from operations 3 698 4 375 1 273 73 (767) 634 589 164 10 039 925 10 964 Fair value losses on VitalityLife interest rate derivatives – – – – – – 516 – 516 (516) – Investment income earned on shareholder investments and cash 92 – 20 – – – – 104 216 (216) – Intercompany investment income – – – – – – – 1 184 1 184 (1 184) – Net fair value gains/(losses) on financial assets at fair value through profit or loss – 45 95 – – – – (2) 138 (138) – Loss from dilution of equity accounted investments – – – (5) – – – – (5) – (5) Impairment of goodwill – – – – – – – (9) (9) – (9) Amortisation of intangibles from business combinations – – – (46) – – – (56) (102) 102 – Market rentals related to Head Office building adjusted for finance costs and depreciation – – – – – – – (134) (134) 134 – Finance costs (2) (1) – – – (8) – (1 617) (1 628) (291) (1 919) Intercompany finance costs (348) – – – – – (316) (520) (1 184) 1 184 – Foreign exchange (losses)/gains (4) 33 36 – – 1 – 85 151 – 151 Profit/(loss) before tax 3 436 4 452 1 424 22 (767) 627 789 (801) 9 182 – 9 182 Income tax expense (941) (1 192) (377) (24) 226 (141) (95) 28 (2 516) – (2 516) Profit/(loss) for the year 2 495 3 260 1 047 (2) (541) 486 694 (773) 6 666 – 6 666 Profit attributable to: – Ordinary shareholders 2 502 3 260 1 047 (2) (541) 486 694 (842) 6 604 – 6 604 – Preference shareholders – – – – – – – 69 69 – 69 – Non-controlling interest (7) – – – – – – – (7) – (7) -- 21 of 105 -- 24 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 A.2. Normalised profit from operations The following table shows the main components of the normalised profit from operations for the six months ended 31 December 2023: R million Group December 2023 Unaudited Restated Group December 2022 Unaudited % Change Restated Group June 2023 Unaudited Discovery Health 1 874 1 748 7 3 698 Discovery Life 2 267 2 145 6 4 375 Discovery Invest 620 561 11 1 273 Discovery Insure – Personal lines 20 8 >100 73 Discovery Bank (339) (398) (15) (767) Other initiatives and central costs* (87) (78) 12 (281) – Discovery Vitality 22 21 16 – Other initiatives and central costs (109) (99) (297) Normalised profit from SA composite 4 355 3 986 9 8 371 VitalityHealth 527 658 (20) 634 VitalityLife 390 198 97 589 Closure costs of VitalityInvest in rundown* (57) (109) (48) (266) Group other initiatives and central costs* (48) (26) 85 (79) Normalised profit from UK composite 812 721 13 878 Vitality Health International – Ping An Health Insurance* 344 85 >100 609 Vitality Health International – Other* (173) (9) >100 (195) Vitality Network* 296 199 49 411 Group other initiatives and central costs* (12) (9) 33 (35) Normalised profit from Vitality Global composite 455 266 71 790 Normalised profit from operations 5 622 4 973 13 10 039 * Presented in ‘All other segments’ on the Segment information disclosure note A.1. A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued -- 22 of 105 -- A.3. Earnings, headline earnings and normalised headline earnings Group six months ended December 2023 Unaudited Restated Group six months ended December 2022 Unaudited Restated Group year ended June 2023 Unaudited Number of shares used in calculation Weighted average number of shares in issue (’000) 660 270 657 288 658 045 Diluted weighted number of shares (’000) 663 670 666 964 661 328 Earnings per share (cents): – basic 492.9 487.9 986.5 – diluted 490.4 480.9 981.6 Headline earnings per share (cents): – basic 493.8 498.4 1 035.3 – diluted 491.2 491.2 1 030.2 Normalised headline earnings per share (cents): – basic 502.8 457.0 1 011.3 – diluted 500.2 450.3 1 006.2 Weighted average number of shares Group six months ended December 2023 Unaudited Group ended December 2022 Unaudited Group year ended June 2023 Unaudited Issued ordinary shares at 1 July 658 424 656 957 656 957 Effect of treasury shares vested 1 834 310 1 052 Effect of share options exercised and vesting of share awards 12 21 36 Weighted average number of ordinary shares (basic) 660 270 657 288 658 045 Effect of share options exercised and vesting of share awards 3 400 9 676 3 283 Weighted average number of ordinary shares (diluted) 663 670 666 964 661 328 Earnings reconciliation R million Group six months ended December 2023 Unaudited Restated Group six months ended December 2022 Unaudited Restated Group year ended June 2023 Unaudited Profit attributable to ordinary shareholders adjusted for: 3 304 3 207 6 604 – Profit attributable to non-forfeitable dividend share plan (50) – (113) Profit attributable to ordinary shareholders of the Company (basic) 3 254 3 207 6 491 25 -- 23 of 105 -- 26 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued A.3. Earnings, headline earnings and normalised headline earnings continued Headline earnings reconciliation Headline earnings per share is disclosed per the Johannesburg Stock Exchange (JSE) Limited Listings Requirements and is calculated in accordance with the circular titled: Headline Earnings, issued by the South African Institute of Chartered Accountants (SAICA), as amended from time to time. Headline earnings per share is based on the net profit after tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares in issue. Group six months ended 31 December 2023 Unaudited Restated Group six months ended 31 December 2022 Unaudited Restated Group year ended 30 June 2023 Unaudited R million Gross Tax Net Gross Tax Net Net Profit attributable to the ordinary shareholders 3 254 3 207 6 491 Adjusted for: – Loss on derecognition of intangible assets 5 (1) 4 82 (17) 65 230 – Loss on derecognition of property and equipment 3 (1) 2 5 (1) 4 27 – Loss on disposal of property and equipment – – – – – – 7 – Impairment of goodwill – – – – – – 9 – Impairment of property and equipment – – – – – – 45 Adjustments attributable to equity-accounted investments: – Loss on dilution and disposal of equity-accounted investments – – – – – – 4 Headline earnings (basic and diluted) 3 260 3 276 6 813 Normalised headline earnings reconciliation Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in section C.2. Management considers that Normalised headline earnings is an appropriate alternative performance measure to enhance the comparability and understanding of the financial performance of the Group. Group six months ended 31 December 2023 Unaudited Restated Group six months ended 31 December 2022 Unaudited Restated Group year ended 30 June 2023 Unaudited R million Gross Tax Net Gross Tax Net Net Headline earnings 3 260 3 276 6 813 Adjusted for: – Gain on fair value changes in respect of swaption contract in VitalityLife – – – (391) 80 (311) (248) – Amortisation of intangible assets arising from business combinations 28 (7) 21 27 (5) 22 44 – Restructuring cost 20 (5) 15 – – – – Adjustments attributable to equity-accounted investments: – Amortisation of intangible assets arising from business combinations 24 – 24 17 – 17 46 Normalised headline earnings (basic and diluted) 3 320 3 004 6 655 -- 24 of 105 -- 27 A.4. Revenue from non-insurance activities Discovery Group’s Revenue includes: Fee income from administration business, Vitality Income and Banking fee and commission income. The split of revenue per geographical region and reportable segment can be viewed in Note A.1. Segment information. The split of revenue according to the timing of satisfaction of performance obligations, i.e. over time or a point-in-time, is as follows: R million Group December 2023 Unaudited Restated Group December 2022 Unaudited Fee income from administration business 6 903 6 348 – Over time 6 886 6 330 – Point-in-time 17 18 Vitality Income 2 135 1 943 – Over time 1 362 1 317 – Point-in-time 773 626 Banking fee and commission income 845 583 – Over time 471 249 – Point-in-time 374 334 A.5. Borrowings at amortised cost R million Reference December 2023 Unaudited June 2023 Audited Borrowing from banks and listed debt 16 226 16 328 – UK borrowings A.5.1. 3 621 3 682 – South African borrowings A.5.2. 12 605 12 646 Bank overdraft in underlying liabilities of consolidated Unit Trusts – 33 Lease liabilities 4 265 4 225 – 1 Discovery Place (1 DP) 3 294 3 326 – Other lease liabilities 971 899 Total borrowings at amortised cost 20 491 20 586 A.5.1 UK borrowings Carrying value GBP/Rand million Facility amount GBP million Variable rate Capital repayment and maturity date December 2023 Unaudited June 2023 Audited GBP R GBP R 25 SONIA + 2.75% 1 At maturity – 23 December 2025 25 587 25 597 75 SONIA + 3.00%1 At maturity – 21 December 2025 75 1 762 75 1 793 55 SONIA + 2.85%1 At maturity – 12 December 2025 54 1 272 54 1 292 Total UK borrowings at amortised cost 154 3 621 154 3 682 1 Interest payable quarterly in arrears. Total finance costs in respect of the UK borrowings for the period ended 31 December 2023 was £6.5 million (R153 million) (31 December 2022: £4.3 million (R88 million)). -- 25 of 105 -- 28 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued A.5. Borrowings at amortised cost continued A.5.2 South African borrowings CREDIT RATING In December 2023 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer rating of Ba3 and the national-scale long-term issuer rating at A1.za. The outlook remained unchanged as stable, aligned to the outlook of the country. A5.2.1 DISCOVERY LIMITED Carrying value R million Facility amount R million Variable rate Interest rate per annum Capital repayment and maturity date December 2023 Unaudited June 2023 Audited Listed DMTN1 500 3-month Jibar + 205 bps 4.25%2,3 At maturity – 21 August 2023 – 505 200 – 10.46%4 At maturity – 21 November 2024 202 202 800 3-month Jibar + 191 bps 8.40%2,3 At maturity – 21 November 2024 809 808 1 200 3-month Jibar + 191 bps 7.30%2,3 At maturity – 21 November 2024 1 217 1 218 700 3-month Jibar + 180 bps 8.49%2,3 At maturity – 21 August 2026 707 707 300 3-month Jibar + 180 bps 7.60%2,3 At maturity – 21 August 2026 304 304 792 3-month Jibar + 173 bps 7.98%3,5 At maturity – 21 May 2027 800 799 226 3-month Jibar + 180 bps 7.98%3,5 At maturity – 21 May 2029 228 228 Unlisted DMTN 2 500 – 9.62%3 At maturity – 22 February 2025 2 524 2 522 1 650 – 9.55%3 At maturity – 10 March 2026 1 658 1 658 Other 1 000 3-month Jibar + 190 bps 8.38%2 At maturity – 2 March 2028 996 997 500 3-month Jibar + 190 bps At maturity – 2 March 2028 499 – Total Discovery Limited borrowings 9 944 9 948 1 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017. 2 The interest rate has been fixed through interest rate swaps. 3 Interest is payable quarterly in arrears. 4 Interest is payable semi-annually in arrears. 5 The interest rate has been fixed through interest rate swaps and/or subject to interest rate caps. A5.2.2 DISCOVERY CENTRAL SERVICES Carrying value R million Facility amount R million Interest rate per annum Capital repayment and maturity date December 2023 Unaudited June 2023 Audited 1 400 9.97% 1,2 At maturity – 20 December 2028 1 404 1 408 650 11.56%3 At maturity – 29 October 2027 412 445 691 3-month Jibar + 1.9% At maturity – 30 June 2027 694 694 1 500 3-month Jibar + 1.45% At maturity – 8 June 2024 151 151 Total Discovery Central Services borrowings 2 661 2 698 1 Interest payable quarterly in arrears. 2 The interest rate on the facility has changed from a floating interest rate of 3-month Jibar +2.05% to a fixed interest rate of 9.97% due to refinancing of the loan during the current financial period. 3 Instalments of interest and capital are monthly. Total finance costs in respect of South African borrowings and related hedges for the six months ended 31 December 2023 was R640 million (31 December 2022: R615 million). -- 26 of 105 -- 29 A.6. Fair value hierarchy of financial instruments The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three levels that reflect the significance of the inputs used in measuring fair value. These are as follows: Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis. Level 2: includes financial instruments that are valued using techniques based significantly on observable market data. Instruments in this category are valued using: (a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or (b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable market data. Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than observable market data and where at least one input (which could have a significant effect on the instruments’ valuation) cannot be based on observable market data. R million (unaudited) December 2023 Level 1 Level 2 Level 3 Total Financial assets Financial instruments mandatorily at fair value through profit or loss: – Equity portfolios 61 141 6 917 – 68 058 – Debt portfolios 44 380 1 367 – 45 747 – Money market portfolios – 17 707 – 17 707 – Multi-asset portfolio – 23 660 – 23 660 Derivative financial instruments at fair value: – used as cash flow hedges – 20 – 20 – not designated as hedging instruments – 137 – 137 Total financial assets 105 521 49 808 – 155 329 Financial liabilities Third-party interest in consolidated funds – 29 704 – 29 704 Investment contracts at fair value through profit or loss – 21 980 – 21 980 Derivative financial instruments at fair value: – used as cash flow hedges – 35 – 35 Total financial liabilities – 51 719 – 51 719 There were no transfers between level 1 and 2 during the current financial period. -- 27 of 105 -- 30 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 A.6. Fair value hierarchy of financial instruments continued June 2023 R million (unaudited) Level 1 Restated Level 2 Level 3 Restated Total Financial assets Financial instruments mandatorily at fair value through profit or loss: – Equity portfolios 50 204 6 321 – 56 525 – Debt portfolios 40 852 1 721 – 42 573 – Money market portfolios – 22 656 – 22 656 – Multi-asset portfolios – 33 672 – 33 672 Derivative financial instruments at fair value: – used as cash flow hedges – 59 – 59 – not designated as hedging instruments – 60 – 60 Total financial assets 91 056 64 489 – 155 545 Financial liabilities Third-party interest in consolidated funds – 28 346 – 28 346 Investment contracts at fair value through profit or loss – 28 903 – 28 903 Derivative financial instruments at fair value: – used as cash flow hedges – 1 – 1 – not designated as hedging instruments – 19 – 19 Total financial liabilities – 57 269 – 57 269 Specific valuation techniques used to value financial instruments in level 2 If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices obtained in actual market transactions. A. NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued -- 28 of 105 -- 31 A.6. Fair value hierarchy of financial instruments continued Valuation techniques used in determining the fair value of assets and liabilities: Instruments Valuation technique Main inputs and assumptions for level 2 fair value hierarchy items Within equity portfolios, Equity-linked notes The calculation of the daily value of the equity-linked investments is made by the provider of the note. Discovery has procedures in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds and movement since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed to the policyholders, which is recalculated by Discovery in order to check if the price provided by the provider is correct. – discount rate – spot price of the underlying Debt portfolios and Money market instruments Money market instruments are valued by discounting the future cash flows using a risk-adjusted discount rate. – discount rate, credit spread Multi-assets The fair values of third-party financial liabilities arising on the consolidation of mutual funds are determined using the quoted put (exit) price provided by the fund manager and discounted for the applicable notice period. The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. – discount rate Third-party interest in consolidated funds and Investment contracts at fair value through profit or loss Unit-linked policies: assets which are linked to the investment contract liabilities are accounted for by the Group. The investment contract obliges the Group to use these assets to settle these liabilities. Therefore, the fair value of third-party interest in consolidated funds and investment contract liabilities is determined with reference to the fair value of the underlying assets (i.e. amount payable on surrender of the policies). Annuity: certain discounted cash flow models are used to determine the fair value of the stream of future payments. – discount rate – spot price of the underlying Derivatives Standard derivative contracts are valued using market accepted models and quoted parameter inputs. More complex derivative contracts are modelled using more sophisticated modelling techniques applicable to the instrument. Techniques include:  Discounted cash flow model  Black-Scholes model  Combination technique models – discount rate – spot price of the underlying – correlation factors – volatilities – earnings yield – valuation multiples -- 29 of 105 -- 32 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Other significant items in these results B.1. Exchange rates to the South African Rand used in the preparation of these results B.2. Capital management, financial leverage ratio and covenants B.3. Impact of and volatility in long-term interest rates in the SA and UK markets B.4. Change in hedge strategy – VitalityLife business B.5. Consolidation of Discovery Unit Trusts B.6. Material transactions with related parties B.8. Changes in directorate B.7. Major customers and other Discovery entities not part of Discovery Group B.9. Dividend declaration in respect of the six months ended 31 December 2023 B -- 30 of 105 -- 33 B.1. Exchange rates to the South African Rand used in the preparation of these results Closing rates Average rates Exchange rate to SA rand December 2023 June 2023 Change % June 2022 December 2023 December 2022 June 2023 US dollar 18.54 18.87 (2) 16.47 18.71 17.35 17.79 Pound sterling 23.57 23.99 (2) 20.00 23.43 20.38 21.43 Chinese Yuan 2.61 2.60 – 2.46 2.58 2.48 2.55 B.2. Capital management, financial leverage ratio and covenants The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of financial position. The Group’s objectives when managing capital are:  To comply with the statutory capital requirements required by the regulators of the insurance markets in which the Group operates;  To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory requirements in the event of deviations from the main assumptions affecting the Group’s insurance businesses;  To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;  To achieve an optimal and efficient capital funding profile; and  To consider capital management needs both in the short term and over a five-year planning horizon. Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the Group ultimately overseen by the Board. A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares, debt, reinsurance arrangements and other hybrid instruments. Financial leverage ratio As part of the capital management process, the Group monitors its capital structure utilising various measures, one of which is the Financial Leverage Ratio (FLR). This ratio is calculated as total debt1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of 28.0% per the Group Risk Appetite statement. However, the 28.0% measure is merely a risk appetite indicator and does not necessarily indicate any form of a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR position as at the end of the reporting period. With the adoption of IFRS 17, a significant amount has been reallocated to contractual service margin (CSM) and risk adjustment. In line with developing market practice this CSM balance, representing the present value of margins to be released in future, is taken into account in the calculation of the FLR. While some insurers recognise more, it appears that most ratings agencies the inclusion of at least 50% of the CSM into the equity denominator. R million December 2023 Unaudited June 2023 restated Audited 1 July 2022 restated Unaudited – Borrowings at amortised cost1 16 226 16 361 16 464 – Guaranteed deposit facilities – – 300 Total debt and guarantees1 16 226 16 361 16 764 Total equity 52 206 48 388 40 822 Total Contractual Service Margin (CSM) 2 27 838 28 064 25 938 Financial leverage ratio % (no CSM factored in) 2 23.7% 25.3% 29.1% Financial leverage ratio % (50% CSM factored in)2 19.7% 20.8% 23.8% 1 Excluding all lease liabilities under IFRS 16 Leases of R4 265 million (30 June 2023: R4 225 million). 2 CSM net of reinsurance and net of tax. The FLR at 31 December 2023 is within Discovery’s risk appetite. B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS -- 31 of 105 -- 34 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued B.2. Capital management, financial leverage ratio and covenants continued Regulatory capital For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required capital must be maintained at all times throughout the period. Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime. The table below summarises the capital requirements on the statutory basis, across the Group subsidiaries, and the actual solvency capital held in relation to these requirements as at the end of the reporting period. December 2023 June 2023 Statutory capital requirements Cover Statutory capital requirements Cover Discovery Life 1 R22 173 million 1.8 times R20 814 million 1.9 times Discovery Insure R1 191 million 1.5 times R1 113 million 1.6 times VitalityHealth £135.5 million 1.4 times £130.8 million 1.4 times R3 194 million R3 139 million VitalityLife £303.4 million 2.3 times £272.1 million 2.1 times R7 150 million R6 528 million Debt covenants As per JSE Limited Listings and Debt Listings disclosure requirements, the following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial covenants. Debt covenant Minimum requirement December 2023 June 2023 Restated Group debt1 to EBITDA Ratio2 Less than 2.5 times 1.4 times 1.4 times Group financial indebtedness to embedded value – Group financial indebtedness is as per Group debt in the calculation above Less than 30% of Group Embedded value 16.7% 17.6% Discovery Life Statutory Capital Requirement (SCR) SCR cover must be more than 1.1 times 1.8 times 1.9 times Group embedded value Greater than R30 billion R103 480 million R98 176 million New business embedded value must not be negative Positive value of new business for 3 consecutive 6-month periods December 2023: R684 million June 2023: R500 million December 2022: R940 million June 2023: R500 million December 2022: R940 million June 2022: R1 234 million 1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the 1 DP lease and includes guarantees issued to third parties. 2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1DP and excludes items deemed extraordinary and specified Financial Reinsurance (FinRe) arrangements. -- 32 of 105 -- 35 B.3. Impact of and volatility in long-term interest rates in the SA and UK markets The long-term insurance businesses in South Africa (SA) and the United Kingdom (UK) are exposed to long-term nominal and real interest rates, given the impact of rates on the long-term assumptions applicable to the valuation of insurance contracts. Under IFRS 17, Discovery reflects the effects of financial risk, such as interest rates, as insurance finance income and expense (IFIE) in profit or loss and other comprehensive income (OCI). (Refer to section D for further discussion on accounting for financial risk under IFRS 17). As communicated previously, the year ended 30 June 2023 was characterised by aggressive global monetary policy tightening by central banks following sustained inflationary pressures, which resulted in rapidly increasing global bond yields. Economic and political pressures in SA further contributed to increasing SA bond yields. For Discovery Life, increasing long-term interest rates mainly manifest as a lower discounted value of future cash flows and, therefore, a lower valuation of those contracts. The significant increase in interest rates during the three preceding financial years resulted in Discovery Life recognising an accumulated IFIE expense in both profit or loss and OCI arising from changes in the valuation of insurance contracts. For the six months ended 31 December 2023, long-term interest rates have remained relatively stable against the levels at 30 June 2023, resulting in minor changes in the IFIE due to the valuation change. The IFIE expense within profit or loss for the six months includes the effect of the IFIE previously recognised in OCI reclassifying to profit or loss. In the UK, as noted at the time, the UK bond markets experienced significant volatility following political changes and rising inflation levels resulting in interest rates increasing for the year ended 30 June 2023. For UK Life, within the PAC arrangement, the effect of interest rates is largely hedged, resulting in limited IFIE impact due to changes in the valuation of insurance contracts. For VitalityLife, increasing long-term interest rates manifest mainly as a lower discounted value of future cash flows and, therefore, a lower valuation of those contracts. The effect of higher inflation rates within the UK market reflected positively on the inflation-linked policies, resulting in a positive impact on valuation. For the six months ended 31 December 2023, long-term interest rates have decreased significantly, resulting in a significant IFIE income recognised in OCI, with some value also being realised in profit or loss due to the valuation change. B.4. Change in hedge strategy – VitalityLife business The introduction of IFRS 17 enabled VitalityLife to use the OCI election to remove the volatility of reported financial performance arising from changes in economic assumptions and present a more reflective performance of the business over the long term. Given this change, several of the VitalityLife swaps were exited shortly before the end of the year ended 30 June 2023. In addition, the swaption purchased in June 2022 was sold in June 2023 as the business is now able to manage any remaining risk within its risk appetite without incurring the ongoing costs of purchasing swaptions. The net fair value gain on this swaption for the comparative six-month period ended 31 December 2022 of £15.3 million, net of tax, (R311 million) was excluded in the presentation of normalised profit from operations measure and other normalised measures. VitalityLife continues to hold certain interest rate swaps and total returns swaps (“TRS”) to manage the interest rate risk on the legacy PAC book of business. These instruments are now contracted on the balance sheet of the PAC and, therefore, deemed integral to the underlying insurance contracts entered into under IFRS17, and valuation movements are treated accordingly. -- 33 of 105 -- 36 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 B. OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued B.5. Consolidation of Discovery Unit Trusts Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds. As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders. Assets and liabilities of these Discovery Unit Trusts however increased by R1 618 million, compared to the prior financial year ended 30 June 2023, with movements in the following line items on the Group’s statement of financial position: R million December 2023 Restated June 2023 Movements Investments at fair value through profit or loss 27 306 25 439 1 867 Contract receivables and other receivables 669 643 26 Cash and cash equivalents 2 071 2 435 (364) Other assets 89 – 89 Total change in assets 30 135 28 517 1 618 Third-party interest in consolidated funds 29 704 28 346 1 358 Borrowings at amortised costs (bank overdraft) – 33 (33) Other payables and provisions 431 482 (51) Liabilities arising from insurance contracts issued1 – (346) 346 Other liabilities1 – 2 (2) Total change in liabilities 30 135 28 517 1 618 1 The comparative balances have been restated for the reclassification of balances between Liabilities arising from insurance contracts issued and Other liabilities. There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The cash flow impact of the movement in policyholder investments for the period is included in the following line items on the Group’s statement of cash flows:  Purchase of investments held to back policyholder liabilities includes cash outflows of R16 626 million.  Proceeds from the disposal of investments held to back policyholder liabilities includes cash inflows of R15 707 million. B.6. Material transactions with related parties Discovery Long-term Incentive Plan Trust At the Annual General Meeting (AGM) held on 28 November 2019, the shareholders approved the establishment of the Discovery Long- term Incentive Plan Trust (Trust) with the purpose, inter alia, to subscribe, purchase and/or otherwise acquire and hold Discovery ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the requirements of the Trust. During December 2023, 3 227 675 (31 December 2022: 4 182 946) new shares were issued by Discovery Limited to the Trust at a value of R432 million (31 December 2022: R514 million). In addition, during the six months ended 31 December 2023, shares of 3 650 844 vested with participants. In terms of IFRS Accounting Standards, while held in the Trust, these shares are treated as treasury shares and not treated as issued for accounting purposes. B.7. Major customers and other Discovery entities not part of Discovery Group Discovery Health Medical Scheme (DHMS) Discovery Health administers DHMS and provides managed care services, for which it charges an administration fee and a managed healthcare fee, respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled R3 857 million for the six months ended 31 December 2023 (31 December 2022: R3 546 million). Discovery offers the members of DHMS access to the Vitality programme. -- 34 of 105 -- 37 B.8. Changes in directorate Changes to the Board of Discovery Limited from 1 July 2023 to the date of this announcement are as follows:  Ms L Chiume was appointed to the board as an independent non-executive director effective from 18 September 2023. She is a member of the Discovery Limited Audit Committee and the Group and South African Risk and Compliance Committees. She brings a wealth of financial services and investment experience.  Ms KC Ramon was appointed to the board as an independent non-executive director effective from 18 September 2023 and as a member of the Discovery Limited Audit Committee and the Social and Ethics Committee. She brings diverse leadership and board experience in multiple sectors. Effective 17 November 2023, she was appointed as a member of both the Treating Customers Fairly and Remuneration Committees.  Dr TV Maphai retired from the board as non-executive director effective 16 November 2023 at the conclusion of the AGM to pursue other external opportunities. He served on various committees in a range of capacities over his tenure. He also retired as a member of the Nominations Committee.  Ms S Zilwa retired from the board as non-executive director effective 16 November 2023 at the conclusion of the AGM to pursue other external opportunities. She served as a non-executive director of the Company since 2003 and on various Committees in a range of capacities over the years. She also retired as a member and Chairperson of the Social and Ethics and a member of the Risk and Compliance Committees.  Mr T Mboweni has been appointed as a member of the Nominations Committee effective 17 November 2023.  Ms FN Khanyile has been nominated as the chairperson of the Social and Ethics Committee effective 17 November 2023. B.9. Dividend declaration in respect of the six months ended 31 December 2023 B Preference share cash dividend declaration On Wednesday, 28 February 2024 the Board of Directors declared an interim gross cash dividend of 592.32877 cents (473.86302 cents net of dividend withholding tax) per B preference share for the period 1 July 2023 to 31 December 2023, payable from the income reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The issued preference share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend will be as follows: Last day of trade to receive a dividend Monday, 18 March 2024 Shares commence trading “ex” dividend Tuesday, 19 March 2024 Record date Friday, 22 March 2024 Payment date Monday, 25 March 2024 B preference share certificates may not be dematerialised or rematerialised between Tuesday 19 March 2024 and Friday 22 March 2024, both days inclusive. Ordinary share cash dividend declaration On Tuesday, 19 March 2024, the Board of Directors declared an interim gross cash dividend of 65.00000 cents (52.00000 cents net of dividend withholding tax) per ordinary share, out of the income reserves of Discovery Limited. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The number of ordinary shares in issue at the date of declaration is 676 374 092. The salient dates for the dividend will be as follows: Last day of trade to receive a dividend Tuesday, 16 April 2024 Shares commence trading “ex” dividend Wednesday, 17 April 2024 Record date Friday, 19 April 2024 Payment date Monday, 22 April 2024 Share certificates may not be dematerialised or rematerialised between Wednesday 17 April 2024 and Friday 19 April 2024, both days inclusive. -- 35 of 105 -- 38 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Accounting policies C.1. New Accounting Standards and amendments to published Accounting Standards not yet effective C.2. Normalised headline earnings C.3. Basis of preparation C -- 36 of 105 -- 39 C. ACCOUNTING POLICIES C.1. New Accounting Standards and amendments to published Accounting Standards not yet effective  For new Accounting Standards and interpretations that became effective for the financial year commencing 1 July 2023, refer to Section D New Standards and interpretations and restatements. The section also includes the first-time adoption of IFRS 17.  Discovery has not early adopted any IFRS Accounting Standards, amendments, or interpretations that have been issued but have yet to be effective. Discovery does not expect any new IFRS® Accounting Standards, amendments, or interpretations that have been issued but have yet to be effective to have a material impact on recognised amounts. C.2. Normalised headline earnings Discovery assesses its performance using normalised headline earnings, an alternative profit measure not under the IFRS Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and understanding of the financial performance of the Group. Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures and disclosures provided by other entities. Discovery calculates headline earnings in accordance with the latest SAICA circular ’Headline Earnings’. NHEPS is calculated by starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal operations as follows:  Once-off transactions – for example, restructuring costs, transaction costs related to interest rate derivatives and initial deferred tax assets raised on previously unrecognised assessed losses.  Unusual items – Discovery considers items to be unusual when they have limited predictive value, or it is reasonable that items of a similar nature would not necessarily arise for several future reporting periods.  Income or expenses not considered to be part of Discovery’s normal operations – for example, amortisation of intangibles from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges. Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency. C.3. Basis of preparation Statement of compliance Discovery Limited is a company incorporated in South Africa. The unaudited condensed consolidated interim financial statements for the six months ended 31 December 2023 (interim results) consolidate the results of Discovery and its subsidiaries (together the Group) and equity account for the Group’s interest in associates and joint ventures. The interim results comprise the condensed Group statement of financial position at 31 December 2023, condensed Group income statement, condensed Group statement of comprehensive income, condensed Group statement of changes in equity, and condensed Group statement of cash flows for the six months ended 31 December 2023, and selected explanatory notes. The interim results have been prepared in accordance with the JSE Limited Listings and Debt Listings Requirements, IFRS Accounting Standards and its interpretations adopted by the IASB including IAS 34 Interim Financial Reporting (IAS 34), the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council as well as the requirements of the South African Companies Act 71 of 2008. The accounting policies adopted are consistent with the accounting policies applied in the prior Annual financial statements, except for the application of the newly adopted Accounting Standard IFRS 17 Insurance Contracts. Amendments to IFRS Accounting Standards effective from 1 July 2023 do not have a material effect on the Group’s interim results. These interim results do not include all the notes typically included in the annual financial statements and must be read together with the Group audited consolidated financial statements for the year ended 30 June 2023. Independent Auditors’ review The interim results for the six months ended 31 December 2023 and the 31 December 2022 comparative information have not been reviewed or audited by the Group’s independent auditors Deloitte & Touche and KPMG Inc. The independent auditors have reviewed the restated impacted financial statement captions following the adoption of IFRS 17 “Insurance Contracts” and the specific financial statement captions impacted by other restatements and other presentation changes as at 30 June 2023 and 1 July 2022, as detailed in notes D1.1, D1.2 and D1.3. Refer to the independent auditors’ Review Report on the restated IFRS 17 and Other Presentation Changes and Restated Financial information pages 110 to 111. Comparative information Comparative information presented at and for the year ended 30 June 2023 within these financial statements has been extracted from the Group’s audited consolidated financial statements for the year ended 30 June 2023, except as restated per notes D1.1, D1.2, D1.3. -- 37 of 105 -- 40 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 New standards and interpretations and restatements D.1.1. IFRS 17 Insurance Contracts (IFRS 17) D.1.2. Restatement as a result of prior period errors D.1.3. Changes in presentation of specified line items on the statement of financial position D.2. IFRS 17 Accounting policies D.3. Critical estimates and judgements D.4. Insurance and reinsurance contract notes D -- 38 of 105 -- 41 D.1.1 IFRS 17 Insurance Contracts Introduction IFRS 17 became effective for the Discovery Group from 1 July 2023, with comparative restatement of the preceding year, namely the financial year ended 30 June 2023, including a restatement of the opening Group statement of financial position as at 1 July 2022. IFRS 17 is a new Accounting Standard for insurance contracts that provides guidelines on recognising, measuring, presenting, and disclosing insurance contracts. It was introduced by the International Accounting Standards Board (IASB)® in May 2017. IFRS 17 replaces the previous Accounting Standard, IFRS 4, issued in 2005 as an interim Accounting Standard with limited prescribed changes to pre-existing insurance accounting practices applied by insurers. IFRS 17 represents a positive step towards enhancing transparency, comparability, and understanding of how insurers earn profits from insurance contracts, namely insurance service result and financial results. The framework established by IFRS 17 outlines the specific requirements that companies must adhere to when reporting information related to both the insurance contracts they issue and the reinsurance contracts they hold. One of the noteworthy distinctions introduced by IFRS 17 pertains to the level of granularity at which insurance contracts are recognised and measured. Discovery was well-prepared to embrace this enhanced granularity, as it aligns with the Group’s actuarial approach. IFRS 17 is not limited to insurance companies but also those companies that issue any contract that results in transfer of significant insurance risk. For Discovery, the contracts within the scope of IFRS 17 are almost entirely aligned with those recognised in IFRS 4. Whilst the underlying contractual terms and economic risks and rewards of each insurance contract remain unaltered, IFRS 17 impacts the accounting treatment of insurance contracts and most notably the timing of recognition of insurance related profits and losses for accounting purposes. Importantly, it also separates the insurance related profit or losses between those arising from insurance service results and those arising from financial results. IFRS 17 does not result in a change in the underlying business value of contracts, including:  No direct change to cash flows or underlying risk and reward of contracts. Future tax cash flow impacts are expected to be immaterial.  Immaterial impact on regulatory or economic solvency, capital position and capital management.  The ability to pay dividends unaffected as cash flows and solvency remain unchanged.  Immaterial impact on Embedded Value. Transition to IFRS 17 Upon first-time adoption, IFRS 17 requires the Accounting Standard to be applied fully retrospectively as if it has always applied unless impracticable. If impracticable to do so, the entity can elect to either apply a modified retrospective approach or use the fair value approach. Discovery applied a fully retrospective restatement from inception for all material groups of insurance contracts, other than the businesses accounted for using the VFA approach, which relates to the Discovery Invest portfolios as detailed in note D.2.7. Discovery did not measure any of its portfolios using the fair value approach. Note D2.7. contains a summary of those less material instances where a modified retrospective approach was applied. The fully retrospective approach requires that Discovery identify, recognise, and measure groups of insurance contracts as if IFRS 17 had always applied. The restatement is much more pronounced for the long-term insurance business of Discovery Life in SA and VitalityLife in the UK. In contrast, the impact of the retrospective restatement is limited for the short-term businesses except for VitalityHealth where the impact is more significant due to the change in the treatment of insurance acquisition costs. The changes resulting from the transition to IFRS 17 can be summarised as follows:  Those changes that result in differences to the IFRS 17 margins relative to the IFRS 4 margins. These changes result in concomitant temporary changes in equity. For example, to the extent that changes resulted in the strengthening of contractual service margins that will release to profit in future periods, such changes are mirrored by a reduction in shareholders’ equity upon transition.  Other changes, such as remeasurement basis of the expected future cash flows or recognised assets and liabilities from short- term insurance, e.g., deferred acquisition costs. These remeasurements result in a change in equity on transition without a visible offset of insurance margins but similarly will indirectly result in higher or lower net profits in future periods (for a reduction or increase in equity respectively). In the case of Discovery, increases in insurance margins, most notably contractual service margin (CSM), have a far more material impact. Such resulting increases of additional IFRS 17 margins on transition will be available as future profit. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued -- 39 of 105 -- 42 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.1.1 IFRS 17 Insurance Contracts continued Transition to IFRS 17 continued The most significant changes that result in an increase in IFRS 17 margins relative to margins under IFRS 4 can be summarised as follows:  The measurement under IFRS 17 includes only those cash inflows and outflows relating directly to the fulfilment of the group of insurance contracts, termed directly attributable expenses. In addition to claims and benefits, these may include certain directly attributable overhead expenses. However, non-directly attributable expenses such as general marketing and sponsorships, allocated group executive and group function costs and research and development activities of new products, are not included in the initial recognition value of the contract. Under IFRS 17, these non-directly attributable expenses are immediately expensed and are therefore not considered when determining the expected fulfilment cash flows (EFCF) of the insurance contracts being measured. The immediate expensing of such non-directly attributable expenses increases the available margin on the portfolio compared to the IFRS 4 treatment where such expenses were brought into account when determining the available margins. It should be noted that such expenses are brought into consideration when determining the pricing of products and these increased IFRS 17 margins are therefore similarly available for recognition as profits in future or to absorb adverse changes.  Contracts are measured at a more granular level where portfolios are established and as a minimum with annual business cohorts of no more than twelve months apart. Each of these cohorts is further categorised into separate groups based on expected profitability being profitable, profitable at risk, and onerous groups. Losses are immediately expensed when they arise on onerous contracts, effectively eliminating any cross-subsidisation or set-off applied within a portfolio. This immediate write- off of shortfalls on contracts effectively increases the available margin on the remainder of the portfolio, which will be recognised to profit in future.  Other items, including, amongst others, the different treatment of certain basis changes and variances through the margin, the different rates at which interest is accreted on the margins, and small differences in the run-off of the margins over time are less material in the case of Discovery. Unlike IFRS 4, IFRS 17 separately recognises the finance related consequences of insurance contracts from the underlying insurance activities. Finance income and expense related to insurance contracts and the changes in the measurement of finance related items are recognised as insurance finance income and expense (IFIE) either immediately in profit or loss or disaggregated and allocated using a systematic allocation to profit or loss with variances being recognised through other comprehensive income (OCI).  Discovery has elected to apply the OCI option to predominantly certain long-term insurance and reinsurance contracts. The exclusion of certain elements of IFIE from the profit or loss is largely aligned to the existing treatment where Discovery excludes the impact of economic assumptions, net of associated derivatives, from its normalised profit and normalised headline earnings. The use of OCI removes the need for this normalisation after adoption of IFRS 17. Other changes, resulting in a change in equity on transition without a visible offset of insurance margins:  The remeasurement of best estimates of the future fulfilment cash flows and measurement and accounting treatment of insurance acquisition cash flows, i.e., deferred acquisition costs, on the short-term business lines and  Associated deferred tax and future tax impacts of the changes noted above. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued -- 40 of 105 -- 43 IFRS 17 acknowledges that different companies may manage their insurance contracts differently. As a result, IFRS 17 is principle based and permits several accounting policy elections. The following is a summary of these material accounting elections and specific elections made by Discovery: Election Options Discovery elections Transition approach Three transition approaches  IFRS 17 requires full retrospective unless impracticable.  If full retrospective is impracticable, then accounting election of modified retrospective, or  fair value approach.  Given the availability of reliable and accurate data and actuarial models, Discovery is required to apply IFRS 17 fully retrospectively to all material portfolios.  For the remainder of portfolios, when full retrospective adoption was impracticable, then the modified retrospective approach was applied.  Discovery has not applied the fair value approach to any portfolio. Changes in time value of money (IFIE presentation) Two alternatives:  Present all IFIE and IFIE changes in profit or loss.  Include IFIE in profit or loss using systematic allocation. Remainder recognised in OCI.  The use of the OCI removes the volatility from changes in IFIE (previously economic assumptions) in the measurement of the insurance contract. The amount recognised in OCI is then reclassified to profit or loss using a systematic allocation.  Discovery has elected OCI on its long-term life-insurance business lines in Discovery Individual Life and VitalityLife and associated reinsurance contracts. Discovery has also elected OCI for its long-term claims in GroupLife business. For the remainder of business lines, the change in measurement of the insurance contracts is offset by a change in the measurement of the assets backing those insurance contracts. Risk adjustment  No prescriptive approach is provided under IFRS 17.  Discovery uses the confidence level approach.  For its long-term businesses and group life insurance, Discovery sets the confidence level at 90%.  For its short-term businesses, Discovery sets the confidence level at 75%. Acquisition cost (for portfolios at (PAA)) Two alternatives:  The default under IFRS 17 for contracts with PAA is to defer the insurance acquisitions cash flows and allocate the expense to initial and renewal periods, i.e., defer acquisition costs and amortise.  Entity can elect to immediately expense insurance acquisition cash flows.  VitalityHealth applies the default requirement of IFRS 17. This treatment results in a largely similar treatment to the FinRe arrangements VitalityHealth held under IFRS 4.  For other insurance portfolios measured using the PAA, Discovery has elected to immediately expense in profit or loss the insurance acquisition cash flows as these are not significant. Reflect time value of money (i.e., discount) in measuring coverage units Two alternatives, accounting policy election:  Reflect time value of money in measuring coverage units.  Do not reflect time value of money in measuring coverage units.  Discovery elected to reflect time value of money in the measurement of coverage units. The discounting of coverage units provides the most reasonable emergence of profit, considering the projected level of future margins on retained business for Discovery. D.1.1 IFRS 17 Insurance Contracts continued -- 41 of 105 -- 44 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.1.1 IFRS 17 Insurance Contracts continued Tax changes To transition to and implement IFRS 17, amendments in tax legislation in both South Africa (Section 28 and 29A of the South African Income Tax Act) and the United Kingdom (The Insurance Contracts (Tax) Change in Accounting Standards Regulations 2022, 2022. No. 1165). The amendments legislated phasing-in periods of the impact, which were 3 years for Discovery Insure, 6 years for Discovery Life Limited, and 10 years for Vitality Life Limited. The main impact on the consolidated group at transition was the recognition and remeasurement of the related deferred tax assets and liabilities on the respective reduction in equity on transition, reflecting the change in the timing of income tax. D.1.2 Restatement as a result of prior period errors Item 1: Measurement of the pre-existing relationship of receivables and payables During the six-month period ended 31 December 2023, Discovery identified that it had incorrectly adjusted specified debtors and creditors that were reflective of pre-existing relationships in its business acquisition of Standard Life Healthcare in July 2010 and the DiscoveryCard acquisition in March 2019. The incorrect treatment did not affect the goodwill at acquisition. It did, however, result in an overstatement of debtors and understatement of creditors as well as an overstatement of profit in the periods to 30 June 2022. Discovery corrected the error in the earliest period presented, 1 July 2022. The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior or current reported period Group income statement, basic or diluted earnings per share. Item 2: Calculation of deferred tax asset During the six months ended 31 December 2023, Discovery reviewed the interest expense deductions in its UK business lines with the assistance of external specialists and identified restrictions that impacted income tax in a prior period. This resulted in the overstatement of the deferred tax asset as at 30 June 2022. Discovery corrected the error in the earliest period presented, being 1 July 2022. The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior or current reported period Group income statement, basic or diluted earnings per share. Item 3: Calculation of foreign currency translation reserve During the six-month period ended 31 December 2023, Discovery identified that it had incorrectly calculated the foreign currency translation reserve (FCTR), a component of equity, for specified assets and liabilities. In this transaction, balances arising from an intergroup transaction for the year ended 30 June 2019 were incorrectly eliminated. This treatment resulted in certain foreign- denominated intangible assets not being revalued. Discovery corrected the error in the earliest period presented, being 1 July 2022. The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior or current reported period income statement, basic or diluted earnings per share. -- 42 of 105 -- 45 D.1.2 Restatement as a result of prior period errors continued The tables below summarise the restatement’s impact on the Group statement of financial position: STATEMENT OF FINANCIAL POSITION R million Group 30 June 2022 (previously reported) Item 1 Correction Increase (decrease) Item 2 Correction Increase (decrease) Item 3 Correction Increase (decrease) Group 1 July 2022 Restated Intangible assets 6 539 – – 45 6 584 Deferred tax asset 4 455 – (105) – 4 350 Insurance receivables, contract receivables and other receivables 13 113 (42) – – 13 071 Other reserves 1 3 621 – – 42 3 663 Retained earnings 38 972 (103) (105) 3 38 767 Other financial payables at amortised cost 15 123 61 – – 15 184 1 Other reserves reflect the impact on foreign currency translation reserve (FCTR). STATEMENT OF FINANCIAL POSITION R million Group 30 June 2023 (previously reported) Item 1 Correction Increase (decrease) Item 2 Correction Increase (decrease) Item 3 Correction Increase (decrease) Group 30 June 2023 Restated Intangible assets 6 982 – – 82 7 064 Deferred tax asset 4 404 – (126) – 4 278 Insurance receivables, contract receivables and other receivables 16 059 (42) – – 16 017 Other reserves 1 8 622 (7 ) (21) 79 8 673 Retained earnings 44 218 (103) (105) 3 44 013 Other financial payables at amortised cost 14 780 68 – – 14 848 1 Other reserves reflect the impact on foreign currency translation reserve (FCTR). D.1.3 Changes in presentation of specified line items on the Group statement of financial position Discovery has improved the presentation of specified transactions in the Group statement of financial position by adding new line items. The changes have no impact on the total value of liabilities but enable the user to better understand the financial information. The following changes were made:  The new line item: Third-party interest in consolidated funds was added to separately reflect the interest of third parties in the consolidated unit funds. These third-party interests were previously included as part of Investment contracts at fair value through profit or loss.  The new line item: Other payables and provisions, includes Employee benefits which was previously separately disclosed in the Group statement of financial position, as well as the non-financial payables which was previously included as part of Other payables. Other payables have been renamed to Other financial payables at amortised cost. In addition, the order in which individual line items are presented in the Group statement of financial position has been amended to better reflect their respective liquidity, as far as possible, from least liquid to the most liquid items. Assets from reinsurance contracts held has moved from being above cash and cash equivalents to being above deferred tax asset. No values were reclassified or restated between line items other than those noted above. -- 43 of 105 -- 46 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Below is the reconciliation of the restated Group statement of financial position as at 1 July 2022: Group R million 30 June 2022 As previously reported Audited Reviewed D.1.1 IFRS 17 remeasurement and reclassifications D.1.2 Other restatements D.1.3 Other presentation changes 1 July 2022 Restated Assets Goodwill 4 912 – – – 4 912 Intangible assets 6 539 – 45 – 6 584 Property and equipment 3 811 – – – 3 811 Assets arising from insurance contracts issued 56 645 (25 782) – – 30 863 Assets arising from reinsurance contracts held 511 362 – – 873 Deferred tax asset 4 455 1 338 (105) – 5 688 Deferred acquisition costs 1 640 (623) – (17) – Assets arising from contracts with customers 1 692 – – 17 1 709 Investment in equity-accounted investees 6 008 330 – – 6 338 Financial assets – Loans and advances to customers at amortised cost 3 944 – – – 3 944 – Investments at amortised cost 7 161 – – – 7 161 – Investments at fair value through profit or loss 141 494 – – – 141 494 – Derivative financial instruments at fair value through profit or loss 276 – – – 276 Contract receivables and other receivables2 13 113 (7 848) (42) – 5 223 Non-current assets held for sale 171 – – – 171 Current tax asset 220 – – – 220 Cash and cash equivalents3 19 775 (5 988) – – 13 787 TOTAL ASSETS 271 367 (38 211) (102) – 233 054 Equity Capital and reserves Ordinary share capital and share premium 10 178 – – – 10 178 Perpetual preference share capital 779 – – – 779 Other reserves 4 3 621 (1 420) 42 – 2 243 Retained earnings 38 972 (11 150) (205) – 27 617 Equity attributable to equity holders of the Company 53 550 (12 570) (163) – 40 817 Non-controlling interest 5 – – – 5 TOTAL EQUITY 53 555 (12 570) (163) – 40 822 Liabilities Liabilities arising from insurance contracts issued 108 067 (23 012) – 85 055 Liabilities arising from reinsurance contracts held 13 192 (7 985) – – 5 207 Deferred tax liability 9 335 (3 022) – – 6 313 Contract liabilities to customers 944 – – – 944 Third-party interest in consolidated funds – – – 24 320 24 320 Financial liabilities – Borrowings at amortised cost 20 584 – – – 20 584 – Other financial payables at amortised cost 15 123 (6 280) 61 (412) 8 492 – Deposits from customers 10 881 – – – 10 881 – Investment contracts at fair value through profit or loss 38 637 14 638 – (24 320) 28 955 – Derivative financial instruments at fair value through profit or loss 202 – – – 202 Other payables and provisions – 20 – 732 752 Employee benefits 320 – – (320) – Current tax liability 527 – – – 527 TOTAL LIABILITIES 217 812 (25 641) 61 – 192 232 TOTAL EQUITY AND LIABILITIES 271 367 (38 211) (102) – 233 054 1 The deferred acquisition costs will no longer be presented separately under IFRS 17 as all insurance cash flows, payables and receivables are presented on a net basis, either as a liability or an asset arising from insurance contract issued. 2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance receivables as under IFRS 17 all insurance cash flows, payables and receivables are presented on a net basis, either as a liability or an asset arising from insurance contract issued. 3 The treatment of the PAC arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery is required to reflect the underlying assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an overarching insurance contract. Discovery is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to 31 December 2015). One key difference is the manner in which the cash and cash equivalents, which are held as the required capital backing for the policies, are reflected. Under IFRS 17, the cash backing the capital requirement is presented and measured as a non-distinct investment component. This differs from IFRS 4, where the cash and cash equivalents of the capital backing the arrangement were treated as separable components and accordingly disclosed separately. In addition to the resultant change in cash and cash equivalents on 1 July 2022 of R5 988 million (30 June 2023 R4 110 million), it also resulted in a change in cash utilized and generated by operations of R1 953 million for the period ending 31 December 2022 (30 June 2023 R2 744 million). 4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.1.4 Reconciliation of restated Group statement of financial position -- 44 of 105 -- 47 Below is the reconciliation of the restated Group statement of financial position as at 30 June 2023: Group R million 30 June 2023 As previously reported Audited Reviewed D.1.1 IFRS 17 remeasurement and reclassifications D.1.2 Other restatements D.1.3 Other presentation changes 30 June 2023 Restated Assets Goodwill 5 406 – – – 5 406 Intangible assets 6 982 – 82 – 7 064 Property and equipment 3 910 – – – 3 910 Assets arising from insurance contracts issued 63 865 (30 951) – – 32 914 Assets arising from reinsurance contracts held 709 (105) – – 604 Deferred tax asset 4 404 2 042 (126) – 6 320 Deferred acquisition costs1 799 (779) – (20) – Assets arising from contracts with customers 2 201 – – 20 2 221 Investment in equity-accounted investments 7 024 374 – – 7 398 Financial assets – Loans and advances to customers at amortised cost 4 702 – – – 4 702 – Investments at amortised cost 9 910 – – – 9 910 – Investments at fair value through profit or loss 155 426 – – – 155 426 – Derivatives financial instruments at fair value through profit or loss 119 – – – 119 Contract receivables and other receivables2 16 059 (10 333) (42) – 5 684 Non-current assets held for sale – – – – – Current tax asset 41 – – – 41 Cash and cash equivalents3 20 370 (4 110) – – 16 260 TOTAL ASSETS 301 927 (43 862) (86) – 257 979 Equity Capital and Reserves Ordinary share capital and share premium 10 351 – – – 10 351 Perpetual preference share capital 779 – – – 779 Other reserves4 8 622 (5 628) 51 – 3 045 Retained earnings 44 218 (9 804) (205) – 34 209 Equity attributable to equity holders of the Company 63 970 (15 432) (154) – 48 384 Non-controlling interest 4 – – – 4 TOTAL EQUITY 63 974 (15 432) (154) – 48 388 Liabilities Liabilities arising from insurance contracts issued 114 807 (19 112) – 95 695 Liabilities arising from reinsurance contracts held 14 669 (9 826) – – 4 843 Deferred tax liability 9 559 (3 337) – – 6 222 Contract liabilities to customers 656 – – – 656 Third-party interest in consolidated funds – – – 28 346 28 346 Financial liabilities – Borrowings at amortised cost 20 586 – – – 20 586 – Other financial payables at amortised cost 14 780 (5 375) 68 (361) 9 112 – Deposits from customers 14 333 – – – 14 333 – Investment contracts at fair value through profit or loss 48 044 9 205 – (28 346) 28 903 – Derivate financial instruments at fair value through profit or loss 20 – – – 20 Other payables and provisions – 15 – 695 710 Employee Benefits 334 – – (334) – Current tax liability 165 – – – 165 TOTAL LIABILITIES 237 953 (28 430) 68 – 209 591 TOTAL EQUITY AND LIABILITIES 301 927 (43 862) (86) – 257 979 1 The deferred acquisition costs will no longer be presented separately under IFRS 17 as all insurance cash flows, payables and receivables are presented on a net basis, either as a liability or an asset arising from insurance contract issued. 2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance receivables as under IFRS 17 all insurance cash flows, payables and receivables presented on a net basis, either as a liability or an asset arising from insurance contract issued. 3 The treatment of the PAC arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery is required to reflect the underlying assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an overarching insurance contract. Discovery is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to 31 December 2015). One key difference is the manner in which the cash and cash equivalents, which are held as the required capital backing for the policies, are reflected. Under IFRS 17, the cash backing the capital requirement is presented and measured as a non-distinct investment component. This differs from IFRS 4, where the cash and cash equivalents of the capital backing the arrangement were treated as separable components and accordingly disclosed separately. In addition to the resultant change in cash and cash equivalents on 1 July 2022 of R5 988 million (30 June 2023 R4 110 million), it also resulted in a change in cash utilized and generated by operations of R1 953 million for the period ending 31 December 2022 (30 June 2023 R2 744 million). 4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI. D.1.4 Reconciliation of restated Group statement of financial position continued -- 45 of 105 -- 48 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.2 IFRS 17 Accounting policies Abbreviations Meaning CSM Contractual Service Margin DAC Deferred Acquisition Costs DISCOVERY Discovery Group DPF Direct Participation Features DRO Discovery Retirement Optimiser EFCF/FCF Expected Fulfilment Cash Flows/Fulfilment Cash Flows FINANCIAL RISK The risk of a possible future change in one or more of a specified interest rate, financial instrument price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit index or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. GMM General Measurement Model IACF Initial Acquisition Cash Flows IFIE Insurance finance income and expense comprises the change in the carrying amount of the group of insurance contracts arising from:  the effect of the time value of money and changes in the time value of money, and  the effect of financial risk and changes in financial risk. IFRS IFRS Accounting Standards IFRS 4 IFRS 4 Insurance Contracts (effective pre 1 July 2023) IFRS 17 IFRS 17 Insurance Contracts (effective post 1 July 2023) IFRS 17 margins IFRS 17 margins reference to the contractual service margin plus the risk adjustments ISE Insurance Service Expenses LIC Liability for Incurred Claims LRC Liability for Remaining Coverage OCI Other Comprehensive Income PAA Premium Allocation Approach PVFCF Present Value of Future Cash Flows VFA Variable Fee Approach D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued -- 46 of 105 -- 49 D.2.1 Insurance contracts scope and grouping D.2.1.1 DEFINITION AND CLASSIFICATION Insurance contracts are contracts under which Discovery accepts significant insurance risk from a policyholder by agreeing to compensate the policyholder should a specified uncertain future event adversely affect the policyholder. Insurance contracts are contracts under which Discovery accepts all significant insurance risk from a policyholder by agreeing to compensate the policyholder should a specified uncertain future event adversely affect the policyholder. Reinsurance contracts are contracts under which the reinsurer accepts significant insurance risk from Discovery. Even in situations where the contract does not expose the reinsurer to the possibility of a significant loss, the contract will still be deemed to be a reinsurance contract transferring significant risk if it transfers substantially all of the insurance risk resulting from the reinsured portions of the underlying reinsurance contracts. Discovery determines whether it has assumed significant insurance risk by comparing benefits payable after an insured event with benefits payable if the insured event had not occurred. Insurance and reinsurance contracts can also expose Discovery to financial risk, which is not taken into account in the determination of significant insurance risk. D.2.1.2 SEPARATING COMPONENTS WITHIN INSURANCE CONTRACTS IFRS 17 requires an analysis of whether the contract contains components that should be separated from the insurance contract and accounted for under different IFRS Accounting Standards. IFRS 17 requires that cash flows relating to embedded derivatives, cash flows relating to distinct investment components and promises to transfer distinct goods or distinct services, other than insurance contract services, be accounted for separately. Discovery presently has no contracts requiring further separation or a combination of insurance contracts. D.2.1.3 UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS Under IFRS 17, the unit of account is defined as a group of insurance contracts. The way insurance contracts are grouped affects the timing of profit recognition for insurance services but does not affect the measurement of the estimated cash flows to fulfil the insurance contracts. In terms of IFRS 17, the unit of account is determined by first establishing a portfolio of insurance contracts and then creating separate cohorts within the portfolio based on the date of origination. Each such cohort is further grouped into three groupings based on estimated profitability. Insurance contracts that are subject to similar risks and managed together E.g., whole-of-life insurance, guarantee endowments, household insurance Only contracts issued within a given 12-month period (cohort) can be included in the same group. Annual cohorts are further grouped into one of the following: Portfolio Cohort Groups Onerous at initial recognition (Onerous) At initial recognition, no significant possibility of becoming onerous (Profitable) Other (Profitable at risk) IFRS 17 Illustration of principles 1: Unit of account At initial recognition, groups of insurance contracts issued are recognised from the earliest of the following:  The beginning of the coverage period.  The date when the policyholder’s first payment is due or received if there is no due date.  When Discovery determines that a group of insurance contracts become onerous D.2 IFRS 17 Accounting policies continued -- 47 of 105 -- 50 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.2.1 Insurance contracts scope and grouping continued D.2.1.4 MEASUREMENT MODELS IFRS 17 provides three possible measurement models. 1. The default model is the General Measurement Model (GMM). The GMM is typically used for measuring long-term insurance risk and annuity contracts. The basic principles are set out below. 2. The GMM is supplemented by the Variable Fee Approach (VFA) for contracts where policyholders have purchased investment- linked insurance contracts integrated with insurance coverage (meaning insurance contracts with direct participating features). 3. The Premium Allocation Approach (PAA) is a simplified approach of the GMM for short-duration contracts such as group risk, personal lines and private medical insurance. Direct participating contracts are contracts for which, at inception:  The contractual terms specify that the policyholder participates in a share of a clearly identified pool of underlying items.  Discovery expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the underlying items; Discovery considers that a substantial share is a majority of returns, and  Discovery expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the change in fair value of the underlying items. Discovery considers that a substantial proportion is a majority proportion of change on a present value probability-weighted average of all scenarios. Within Discovery the unit-linked products and Discovery Optimiser products offered by Discovery Life are examples of insurance contracts with DPFs. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.2 IFRS 17 Accounting policies continued -- 48 of 105 -- 51 D.2.2 Overview of the Discovery Group portfolios, measurement models and accounting policy elections The table below summarises the material insurance contracts Discovery issues and reinsurance contracts it holds. It sets out the measurement model applied and key assumptions and elections. Measurement Model Risk adjustment confidence level 1 Elections on IFIE PAA only – election for treatment of initial acquisition cash flows (IACF) Insurance contract issued and business lines Individual life insurance contracts: Discovery Life and VitalityLife GMM 90% Elected to present changes in IFIE in OCI and profit or loss. n/a Insurance-linked investment contracts: General endowments in Discovery Invest Elected to present changes in IFIE in OCI and profit or loss. Investment contracts: Unit-linked and DRO in Discovery Invest VFA Group life insurance contracts: Discovery Life PAA 90% Elected to present changes in IFIE in OCI and profit or loss for long-tail claims. Elected not to reflect the interest for cash flows less than 12 months. Elected to immediately expense initial acquisition cash flows (IACF) Car, household and business insurance: Discovery Insure 75% Elected not to reflect interest for cash flows less than 12 months Elected to immediately expense initial acquisition cash flows (IACF) Health insurance: VitalityHealth Consistent with default IFRS 17 requirement, defer IACF and amortise over the initial and renewal periods Reinsurance contracts held Individual life: Quota share reinsurance for Discovery Individual Life and VitalityLife GMM 90% Elected to present changes in IFIE in OCI and profit or loss. n/a Individual life: Excess of loss reinsurance Group life insurance contracts: Catastrophe, group continuation and mass lapse treaties PAA 90% Elected not to reflect interest for cash flows less than 12 months Elected to immediately expense initial acquisition cash flows (IACF) Car, household and business insurance: Quota share reinsurance and excess of loss insurance 75% Health insurance: Quota share reinsurance 1 Risk adjustment was determined using the confidence level technique unless otherwise stated. D.2 IFRS 17 Accounting policies continued -- 49 of 105 -- 52 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.2.3 Contracts measured under the GMM and VFA Under IFRS 17, any company that issues insurance contracts must report those contracts on the Group statement of financial position as the total of  The expected fulfilment cash flows (EFCF): the current estimates of amounts that the company expects to collect from premiums net of and payout for claims, benefits, and expenses, including an adjustment for the timing and risk of those amounts, and  The CSM: the expected profit for providing insurance coverage recognised in profit or loss over the period of insurance coverage. Under IFRS 17, Insurance Contracts are measured as the sum of: the expected fulfilment cash flows (EFCF), representing the present value of current estimates of amounts that the insurer expects to collect from premiums net of and pay out for claims, benefits and expenses, including an adjustment for the risk of those cash flows. Those cash flows for future services are known as “liability for remaining coverage” (LRC) and those cash flows for services already incurred constitutes liability for incurred claims (LIC) the contractual service margin (CSM), represents the remaining inherent value of the cohort and is similar to unearned profit for providing future insurance coverage. On initial recognition, for profitable contracts, the CSM is the equal and opposite amount of the net cash inflow, resulting in no income or expense arising on initial recognition. + EFCF – Inflow EFCF – Outflow EFCF – Risk adj CSM EFCF – discounting = +Insurance contracts Present value of expected fulfilment cash flows Unearned profit IFRS 17 Illustration of principles 2: General Measurement Model (GMM) D.2.3.1 EXPECTED FULFILMENT CASH FLOWS (EFCF) The measurement of a group of insurance contracts includes all future cash flows expected to arise within the contract boundary of each contract in the group. Cash flows are within the contract boundary if they arise from substantive rights and obligations that exist during the reporting period in which Discovery can compel the policyholder to pay premiums or has a substantive obligation to provide services (including insurance coverage and any investment services). EFCF include payments to (or on behalf of) policyholders, insurance acquisition cash flows and other costs incurred in fulfilling contracts. Other costs incurred to fulfil a group of contracts include direct costs and an allocation of fixed and variable overheads directly attributable to fulfilling the group of insurance contracts. The estimates of these future cash flows are based on probability-weighted expected future cash flows. Discovery estimates which cash flows are expected and the probability that they will occur as at the measurement date. When estimating, Discovery uses information about past events, current conditions and forecasts of future conditions. Insurance acquisition cash flows arise from activities of selling, underwriting and commencing a group of contracts that are directly attributable to the portfolio of contracts to which the group belongs. D.2 IFRS 17 Accounting policies continued D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued -- 50 of 105 -- 53 D.2.3 Contracts measured under the GMM and VFA continued D.2.3.2 REFLECTING THE TIME VALUE OF MONEY AND DISCOUNT RATES Discounting adjusts the estimates of expected cash flows to reflect the time value of money and the financial risks associated with those cash flows, to the extent that the financial risks are not already included in the cash flow estimates. The following table shows which discount rate to apply throughout measuring a group of insurance contracts and the general objective of determining that discount rate. Element of measurement model Fulfilment cash flows Current discount rates CSM interest accretion for contracts without direct participation features (i.e., portfolios under GMM). Discount rates are determined on initial recognition of the group, i.e., locked-in at inception. Adjustments to the CSM for changes in the fulfilment cash flows for contracts without direct participation features (DPF) (i.e., portfolios under GMM). Discount rates are determined on initial recognition of the group, i.e., locked-in at inception. Adjustments to the CSM for changes in the fulfilment cash flows for DPF contracts that do not vary based on the returns on underlying items (i.e., portfolios under VFA), excluding the change in the effect of the time value of money and financial risks. Current discount rates. The bottom-up approach is used to derive the discount rate for the cash flows. Under this approach, the discount rate is determined as the risk-free yield, adjusted for differences in liquidity characteristics of the insurance contracts sold. For portfolios of contracts where the insurance contract liability is materially matched with assets, a top-down approach is used to derive the discount rate for the cash flows. For Discovery, the risk-free yield curve will be ‘current’ and reflect the risk-free yield curve derived on the last day of the reporting period. The nominal risk-free yield curve is used to discount nominal cash flows, while real cash flows are discounted using the real risk-free yield curve. D.2.3.3 RISK ADJUSTMENT The risk adjustment for non-financial risk for a group of insurance contracts, determined separately from the other estimates, is the compensation required for bearing uncertainty about the amount and timing of the cash flows that arise from non-financial risk as Discovery fulfils insurance contracts. It measures the compensation that the entity would require to make it indifferent between:  Fulfilling a liability that has a range of possible outcomes arising from non-financial risk and  Fulfilling a liability that will generate fixed cash flows with the same expected present value as the insurance contract. A lower risk adjustment would be observed for those insurance contracts with shorter durations, high frequency and low severity type products and narrow probability of distribution. A higher risk adjustment would be observed for insurance contracts that are longer in duration, have a low frequency and high severity and have a wide probability of distribution. IFRS 17 does not prescribe methods for determining the risk adjustment for non-financial risk. Therefore, management’s judgement is necessary to determine an appropriate risk adjustment technique. When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there is an equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best estimate. The risk adjustment is then calculated such that there is a specified percentage probability that the reserves will be sufficient to cover future claims. For the specified percentages applied, refer to section D.2.2. D.2 IFRS 17 Accounting policies continued -- 51 of 105 -- 54 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.2.3 Contracts measured under the GMM and VFA continued D.2.3.4 CONTRACTUAL SERVICE MARGIN (CSM) The CSM represents the future unearned profit. On initial recognition of a group of insurance contracts, if the total of the fulfilment cash flows, including insurance acquisition cash flows:  Is a net inflow, then the group is profitable. In this case, the CSM is measured as the equal and opposite amount of the net inflow, which results in no income or expenses arising on initial recognition.  Is a net outflow, then the group is onerous. In this case, the net outflow is recognised immediately as a loss in profit or loss. A loss component is created to depict the amount of the net cash outflow, which determines the amounts that are subsequently presented in profit or loss as reversals of losses on onerous contracts and are excluded from insurance revenue. D.2.3.5 SUBSEQUENT MEASUREMENT The carrying amount of a group of insurance contracts at each reporting date is the sum of the liability for remaining coverage (LRC) and the liability for incurred claims (LIC).  The LRC comprises the fulfilment cash flows related to services that will be provided under the contracts in future periods and any remaining CSM at that date.  The LIC includes the fulfilment cash flows for incurred claims and expenses that have not yet been paid, including claims that have been incurred but not yet reported. IFRS 17 requires a company to update the EFCF at each reporting date, using current estimates of the amount, timing, and uncertainty of cash flows and discount rates. Discovery:  accounts for changes to estimates of future cash flows from one reporting date to another, either as an amount in profit or loss or as an adjustment to the expected profit for providing insurance coverage, depending on the type of change and the reason for it; and  chooses where to present IFIE either: – All in profit or loss, or – Include IFIE in profit or loss using systematic allocation. The remainder of IFIE is recognised in OCI. The treatment can be summarised as follows: Fulfilment cash inflows OCI P/L CSM CSM allocation Financial risk assumptions (e.g., interest rates & inflation index) Past and current service Future service Reclassify Either Or IFRS 17 Illustration of principles 3: Subsequent measurement D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.2 IFRS 17 Accounting policies continued -- 52 of 105 -- 55 D.2.3 Contracts measured under the GMM and VFA continued D.2.3.5 SUBSEQUENT MEASUREMENT continued D.2.3.5.1 Changes in EFCF Changes in expected fulfilment cash flows from the estimates at the previous reporting date or inceptions of the contracts are recognised as follows: Nature of change Treatment Changes relating to current or past services Recognised in the insurance service results in profit or loss. Changes relating to future services Adjusted against the CSM (or recognised in the insurance service results in profit or loss if the group is onerous). Effects of the time value of money, financial risk and changes therein on estimated future cash flows Recognised as insurance finance income or expenses. Changes in the obligation to pay policyholders an amount equal to the fair value of the underlying items for a group of direct participating contracts (VFA) Recognised in the insurance service results in profit or loss. Accounting policy election: Presentation of IFIE Discovery has elected to disaggregate IFIE for the period in OCI and present in profit or loss IFIE using a systematic allocation on its long-term life insurance business lines in Discovery Life, VitalityLife and associated reinsurance contracts and long-tail claims in its GroupLife business. For the remainder of business lines, the IFIE and changes therein relating to insurance contracts are presented in profit or loss, offset by the changes in the value of assets backing the insurance contracts. Changes in CSM As noted in D.2.3.4, the CSM represents the future unearned profit. The movement in the CSM during a financial reporting period can be summarised as follows: CSM at the end of previous reporting period 1. New business written during the period 2. Interest accretion at locked-in rate 3. Changes in fullfillment cash flows for future services (Non IFIE) 4. Effect of currency exchange differences on CSM 5. VFA only – change in the amount of the entity’s share in FV of underlying items 6. Amounts in CSM recognised in profit or loss for any insurance service for period (coverage units) CSM at the end of the current reporting period Movement of the CSM in sequence of which changes are made IFRS 17 Illustration of principles 4: Subsequent changes in CSM D.2 IFRS 17 Accounting policies continued -- 53 of 105 -- 56 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.2.3 Contracts measured under the GMM and VFA continued D.2.3.5 SUBSEQUENT MEASUREMENT continued D.2.3.5.1 Changes in EFCF continued The carrying amount of the CSM at each reporting date is the carrying amount at the start of the financial year, adjusted for: 1. The CSM of any new contracts added to the group in the year. 2. I nterest accreted on the carrying amount of the CSM during the year. As noted in D.2.3.2, discount rates are determined on initial recognition of the group, meaning locked-in at inception. As noted in D.2.3.2., the CSM for group of insurance contracts in VFA is not locked-in. 3. Changes in fulfilment cash flows that relate to future services, except to the extent that: a. Any increases in the fulfilment cash outflows exceed the carrying amount of the CSM, in which case the excess is recognised immediately in profit or loss. b. Any decreases in the fulfilment cash outflows are allocated to the loss component, reversing losses previously recognised in profit or loss. 4. Reflects changes in exchange rates for those contracts denominated in different currency than the functional currency of the insurer that issued the policy 5. For contracts measured using the VFA, the change in the amount of the insurer’s share of the fair value of the underlying item. 6. The amount recognised as insurance revenue because of the services provided in the year, meaning release of CSM using coverage units. In determining the coverage units, Discovery has elected to reflect the time value of money in the coverage units using a real rate of return for insurance contracts measured using the GMM. For insurance contracts measured using the VFA, Discovery has elected to reflect the time value of money in the coverage units using a nominal rate of return. D.2.4 Contracts measured under the PAA As permitted in IFRS 17, Discovery has elected to apply the premium allocation approach (PAA) to measure a group of insurance contracts issued or reinsurance contracts held if, at the inception of the group:  The coverage period of each contract in the group of insurance contracts is one year or less, or  Discovery reasonably expects that the PAA would produce a measurement of the LRC for a group of insurance contracts that would not differ materially from the measurement achieved by applying the GMM. The PAA simplifies the general measurement model. At initial recognition, the insurance contract is measured as:  The premiums, if any, received at initial recognition.  Minus any insurance acquisition cash flows (applicable only if the group has elected to defer the insurance acquisition cash flows), and  Plus/minus non-acquisition assets or liabilities previously recognised for cash flows related to the group of insurance contracts. Where insurance acquisition cash flows are directly attributable to a group of contracts, Discovery allocates costs to that group and the groups that will include renewals of those contracts. Discovery expects to recover part of the related insurance acquisition cash flows through renewals of these contracts. The allocation to renewals is based on how Discovery expects to recover those cash flows. At each reporting date, Discovery revises the amounts allocated to groups to reflect any changes in assumptions that determine the inputs to the allocation method used. Amounts allocated to a group are not revised once all contracts have been added to the group. At each reporting date, if facts and circumstances indicate that an asset for insurance acquisition cash flows may be impaired, Discovery:  Recognises an impairment loss in profit or loss so that the carrying amount of the asset does not exceed the expected net cash inflow for the related group, and  If the asset relates to future renewals, Discovery recognises an impairment loss in profit or loss to the extent that it expects those insurance acquisition cash flows to exceed the net cash inflow for the expected renewals, and this excess has not already been recognised as an impairment loss. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.2 IFRS 17 Accounting policies continued -- 54 of 105 -- 57 D.2.4 Contracts measured under the PAA continued Discovery reverses any impairment losses in profit or loss and increases the asset’s carrying amount to the extent that the impairment conditions have improved. IFRS 17 permits an accounting policy election on a group-by-group basis:  Not to adjust the components of the insurance contracts and onerous contracts for the time value of money (i.e., no discounting).  An entity may elect to immediately expense insurance acquisition cash flows when incurred. Accounting policy elections For those contracts that apply the PAA, Discovery has elected not to reflect the time value of money in the measurement of the LRC and the LIC when:  LRC: On initial recognition of the contract, the time between the insurance service and the related premium is less than a year.  LIC: The cash flows are expected to be paid or received in less than one year from the date the claim is incurred. In some instances, claims might be disputed. If the claim is expected to be disputed and settlement deferred beyond 12 months, the exception would not apply. Discovery has elected to immediately expense insurance acquisition cash flows for the following material portfolios:  Group Life  Discovery Insure – Discovery Insure has the following portfolios: Personal lines for motor and household, Business insurance, Medical gap, trauma cover and travel insurance.  AfricaHealth portfolios. D.2.4.1 RISK ADJUSTMENT Refer to section D.2.3.3 for the detailed accounting policy on risk adjustment. For the specified percentages applied, refer to section D.2.2. D.2.5 Reinsurance contracts Groups of reinsurance contracts are established such that each treaty is allocated to the applicable group of reinsurance contracts, which differs from the group in which the underlying insurance contract is included. Discovery concludes that the reinsurance contract’s legal form as a single contract reflects the substance of Discovery’s contractual rights and obligations. A group of reinsurance contracts is recognised, as required under IFRS 17, on the following dates.  Reinsurance contracts initiated by Discovery that provide proportionate coverage: The date on which any underlying insurance contract is initially recognised. This applies to Discovery’s quota share reinsurance contracts.  Other reinsurance contracts initiated by Discovery: The beginning of the coverage period of the group of reinsurance contracts. Where Discovery recognises an onerous group of underlying insurance contracts on an earlier date and the related reinsurance contract was entered into before that earlier date, in that case, the group of reinsurance contracts is recognised on that earlier date. This applies to Discovery’s excess of loss and stop-loss reinsurance contracts.  Reinsurance contracts acquired: The date of acquisition. Discovery applies the same accounting policies to measure a group of reinsurance contracts, adapted where necessary to reflect features that differ from those of the underlying insurance contracts. When a loss-recovery component is created for a group of reinsurance contracts measured under the PAA, Discovery will adjust the asset’s carrying amount for remaining coverage instead of adjusting the CSM. D.2 IFRS 17 Accounting policies continued -- 55 of 105 -- 58 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.2.6 Derecognition and modifications Discovery derecognises a contract when it is extinguished, meaning when the specified obligations in the contract expire or are discharged the contract is cancelled. Discovery also derecognises a contract if its terms are modified in a way that would have changed the accounting for the contract significantly had the new terms always existed, in which case a new contract based on the modified terms is recognised. If a contract modification does not result in derecognition, Discovery treats the changes in cash flows caused by the modification as changes in estimates of fulfilment cash flows. On derecognition of a contract from within a group of contracts not measured under the PAA:  The fulfilment cash flows allocated to the group are adjusted to eliminate those that relate to the rights and obligations derecognised.  The CSM of the group is adjusted for the change in the fulfilment cash flows, except where such changes are allocated to a loss component.  The number of coverage units for the expected remaining services is adjusted to reflect the coverage units derecognised from the group. If a contract is derecognised because it is transferred to a third party, then the CSM is also adjusted for the premium charged by the third party unless the group is onerous. D.2.7. Exceptions where the modified retrospective approach was applied DISCOVERY INDIVIDUAL LIFE PORTFOLIO Discovery has applied the modified retrospective approach within the Discovery Individual Life portfolio by aggregating contracts issued more than one year apart prior to 2003 into a single group of insurance contracts in respect of insurance contracts issued before June 2003. The application of the full retrospective approach on transition for these groups were determined to be impracticable as Discovery Life does not have the model used nor data of sufficient quality to either retrospectively model business sold before the June 2002 financial year or to identify new business policies sold in the June 2002 financial year. It should be noted that these portfolios or cohorts of business are immaterial in the context as Discovery Life only commenced business in 2000. DISCOVERY INVEST PORTFOLIOS - THE UNIT-LINKED AND DRO PORTFOLIO AND THE GENERAL ENDOWMENTS PORTFOLIO Discovery has applied the modified retrospective approach within the Discovery Invest portfolios by aggregating contracts issued more than one year apart into a single group of insurance contracts issued before June 2016 for the DRO portfolio and groups of insurance contracts issued before June 2012 for the general endowments and unit-linked portfolio. The application of the fully retrospective approach on transition for these portfolios was determined to be impracticable for Discovery Invest as it did not collect the data of policies sold with sufficient granularity in the periods prior to June 2012. Discovery Invest only commenced trading in 2007. VITALITYHEALTH PRIVATE MEDICAL INSURANCE CONTRACTS Discovery applied the modified approach to identify, recognise, and measure assets arising from insurance acquisition cash flows for the VitalityHealth PMI portfolio as of 1 July 2022. It is impracticable to apply the full retrospective approach as eight years ago (of the ten years that DAC is being applied for), the data was not collected with sufficient granularity for the purposes of setting up a deferred acquisition cost reserve, and its omission has an immaterial impact on the equity. D.3. Critical estimates and judgements D.3.1 Insurance contracts scope and grouping DEFINITION AND CLASSIFICATION IFRS 17 does not specify what significant insurance risk is. Discovery’s policy defines significant insurance risk as follows: The possibility that the present value of losses arising on the insurance contract exceeds 10% of the present value of income and receipts collected when applying a worst-case scenario upon the inception of the insurance contract. UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS Discovery uses judgement to determine at what level of granularity Discovery has reasonable and supportable information that is sufficient to conclude that all contracts within a set are sufficiently homogeneous and will be allocated to the same group without performing an individual contract assessment. Discovery performs stress testing on portfolios measured using GMM and VFA. The stresses may differ between portfolios but will correspond to the most significant non-financial stresses currently running as part of the risk appetite work. If any policy that was originally determined to be profitable becomes onerous under any of the three additional stresses calculated, that policy is classified as profitable-at-risk. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.2 IFRS 17 Accounting policies continued -- 56 of 105 -- 59 D.3.2 Contracts measured under the GMM and VFA D.3.2.1 FULFILMENT CASH FLOWS In line with the requirements of IFRS 17, Discovery applies judgement to determine which cash flows within the boundary of insurance contracts relate directly to the fulfilment of the contracts, including the extent to which fixed and variable overheads are directly attributable to fulfilling insurance contracts. IFRS 17 does not specify a methodology for attributing directly attributable fixed overhead expenses to the respective groups of insurance contracts and to individual policies. It requires that the methods used be systematic and rational. Discovery has applied judgement in developing its methodology and has consistently applied this methodology period-to-period, except as noted below. Given the diversified product range in UK Life, from 1 July 2022, UK Life has further refined its methodology used for allocating the directly attributable fixed overhead expenses related to new business activities (i.e. directly attributable but fixed initial expenses). As the change in methodology is a change in estimate, this change has been applied prospectively and therefore differs from the estimate used in performing the fully retrospective approach used with the initial transition to IFRS 17 given practicality and availability of historical information. The new methodology better reflects the drivers of fixed initial expenses given the core strategy and mix of business written by UK Life as well as the related effort to underwrite and administer the various products. This change in estimate has been implemented for both the current period under review and retrospectively for the restated comparative for the 2023 financial year and six month period. Discovery primarily uses deterministic projections to estimate the present value of future cash flows, and for some groups, it uses stochastic modelling techniques. The following assumptions were used when estimating future cash flows:  Mortality and morbidity rates.  Surrender and lapse rates.  Economic assumptions or investment returns.  Vitality status assumptions.  Expense assumptions.  Policy alterations and automatic premium increases D.3.2.2 RISK ADJUSTMENT When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there is an equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best estimate. The risk adjustment is then calculated such that there is a specified percentage probability that the reserves will be sufficient to cover future claims. For Discovery, the determination of specified percentage is set out in D.2.2. D.3.3 Contracts measured under the PAA D.3.3.1 INSURANCE ACQUISITION CASH FLOWS Discovery uses judgement in determining the initial and renewal periods for which the insurance acquisition cash flows are attributed to groups. For VitalityHealth, the initial and subsequent renewal period is set at ten years. For contracts measured under the PAA, the explicit risk adjustment for non-financial risk is estimated to measure the LIC. The risk adjustment will be determined by applying a confidence level technique. For Discovery, the determination of specified percentage is set out in D.2.2. D.3. Critical estimates and judgements continued -- 57 of 105 -- 60 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.4. Insurance and reinsurance contracts related disclosures The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance contracts held on Discovery’s financial position, financial performance and cash flows. In addition to the disclosures on significant judgements and estimates above, the following disclosures provide a quantitative summary of the amount recognised in the financial statements. IFRS 17 requires that in determining the level at which to aggregated group of insurance contracts to provide useful information to the user, Discovery considers:  The type of contract which would consider the nature of the product and the measurement model.  The geographical areas may expose the entity to different sets of risks, even for similar products.  Reportable segments. Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued SA Life and Invest (Risk) | GMM (Life: Individual Life, Dollar LifePlan, Health Protection Plans, Standalone Global Educator; Invest: Guaranteed endowments) SA Life and Invest (Participating) | VFA (Unit-linked invest products, Discovery Retirement Optimiser) SA Life and Invest: Group Life and other | PAA (Group Risk, Funeral and other including Discovery Card Protector, Standalone Cancer Protector and LifeDrive) SA Insure and other | PAA (Personal and Commercial lines, GAP and Trauma Cover, Travel Cover and AfricaHealth) UK Life (Risk) | GMM (Own Licence and PAC book) UK Health | PAA (Private Medical Insurance) SA Composite UK Composite -- 58 of 105 -- 61 D.4. Insurance and reinsurance contracts related disclosures continued The following index is a summary of all the quantitative disclosures set out in the notes: Note Description Analysis of Statement of financial position D.4.1 Summary of insurance contracts issued and reinsurance contracts held The note summarises the total value of insurance and reinsurance contracts held across the disclosed portfolios showing separately those insurance and reinsurance contracts in a net liability or net asset position. D.4.2 Insurance acquisition assets The note provides a movement in the Insurance acquisition assets, reflecting the movement in the capitalised initial acquisition cash flows of the VitalityHealth portfolio. Reconciliation of insurance contracts Analysis by remaining coverage and incurred claims GMM  D.4.3.1 SA Life and Invest (Risk)  D.4.3.2 UK Life (Risk) VFA  D.4.5.1 SA Life and Invest (Participating) PAA  D.4.7.1 SA Life and Invest: Group Life and other  D.4.7.2 SA Insure and other  D.4.7.3 UK Health Reconciliation of reinsurance contracts Analysis by remaining coverage and incurred claims GMM  D.4.8.1 SA Life and Invest (Risk)  D.4.8.2 UK Life (Risk) The notes provide a detailed reconciliation of disclosed portfolios showing the build-up of:  The liability for remaining coverage (LRC) reflects Discovery's obligation for the unexpired portion of the coverage period. For contracts measured using the simplified approach, LRC includes the unearned premium.  The liability of incurred claims (LIC) reflects Discovery’s obligation to cover the insured events that have occurred. Reconciliation of insurance contracts Analysis by measurement component GMM  D.4.4.1 SA Life and Invest (Risk)  D.4.4.2 UK Life (Risk) VFA  D.4.6.1 SA Life and Invest (Participating) Reconciliation of reinsurance contracts Analysis by measurement component GMM  D.4.9.1 SA Life and Invest (Risk)  D.4.9.2 UK Life (Risk) PAA  D.4.10.1 SA Life and Invest: Group Life and other  D.4.10.2 SA Insure and other  D.4.10.3 UK Health The notes provide a detailed reconciliation of disclosed portfolios showing the build-up of the measurement components, namely:  Estimates of the present value of expected fulfilment cash flows.  The Risk adjustment.  The Contractual service margin reflects unearned profit. The CSM is further separated to reflect how the CSM was calculated at transition, being modified retrospectively or fully retrospectively. -- 59 of 105 -- 62 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued Note Description Analysis of Income statement D.4.11 Insurance revenue The note provides a breakdown of the makeup of insurance revenue for each disclosed portfolio business unit. For those contracts not measured using the PAA approach, the amount reflects the change in the LRC, namely  CSM recognised during the period for the service provided.  The change in the Risk adjustment for non-financial risk.  Expected claims and insurance services expenses.  Experience adjustments.  Recovery of insurance acquisition cash flows. D.4.12 Net investment result The note provides a holistic combined view of the following:  The investment returns on financial assets held.  The insurance and reinsurance finance income and expenses, including the amounts recognised in profit or loss and other comprehensive income (OCI). Additional information Effect of contracts initially recognised in the year:  D.4.13 Effects of insurance contracts initially recognised in the year  D.4.14 Effect of reinsurance contracts initially recognised in the year. The notes provide a breakdown of the contracts initially recognised during the period for each disclosed portfolio business unit.  For insurance contracts, differentiate between profitable contracts recognised with CSM and onerous contracts.  Reinsurance contracts reflect contracts originated with and without the loss-recovery component. D.4.15 Contractual service margin The note provides, for each disclosed portfolio business unit, the expected recognition of CSM, with interest accretion over the lifetime of the group of insurance contracts. The note also sets out the release of accumulated IFIE OCI balances into profit or loss. D.4. Insurance and reinsurance contracts related disclosures continued -- 60 of 105 -- 63 D.4.1 Summary of insurance contracts issued and reinsurance contracts held Group R million (Assets)/Liabilities Navigation SA Life and Invest Risk (GMM) SA Life and Invest Participating (VFA) UK Life Risk (GMM) SA Life Group Risk (PAA) SA Insure (PAA) UK Health (PAA) Total Six months ended 31 December 2023 Insurance contracts A=D+E 3 337 69 286 (13 151) 5 670 981 (4 387) 61 736 Reinsurance contracts B=F 740 – 4 944 (605) (172) (14) 4 893 Total C=A+B 4 077 69 286 (8 207) 5 065 809 (4 401) 66 629 Insurance contracts issued Insurance contract assets – Insurance contract balances (19 901) – (13 151) – – – (33 052) – Assets for insurance acquisition cash flows – – – – – (4 739) (4 739) D (19 901) – (13 151) – – (4 739) (37 791) Insurance contract liabilities – Insurance contract balances 23 238 69 286 – 5 670 981 352 99 527 Total E 23 238 69 286 – 5 670 981 352 99 527 Reinsurance contracts held Reinsurance contract assets – – – (605) (172) (14) (791) Reinsurance contract liabilities 740 – 4 944 – – – 5 684 Total F 740 – 4 944 (605) (172) (14) 4 893 Year ended 30 June 2023 Insurance contracts 4 365 66 308 (10 314) 5 109 822 (3 509) 62 781 Reinsurance contracts 567 – 4 276 (529) (71) (4) 4 239 Total 4 932 66 308 (6 038) 4 580 751 (3 513) 67 020 Insurance contracts issued Insurance contract assets – Insurance contract balances (18 056) – (10 314) – – – (28 370) – Assets for insurance acquisition cash flows – – – – – (4 544) (4 544) (18 056) – (10 314) – – (4 544) (32 914) Insurance contract liabilities – Insurance contract balances 22 421 66 308 – 5 109 822 1 035 95 695 22 421 66 308 – 5 109 822 1 035 95 695 Reinsurance contracts held – Reinsurance contract assets – – – (529) (71) (4) (604) – Reinsurance contract liabilities 567 – 4 276 – – – 4 843 Total 567 – 4 276 (529) (71) (4) 4 239 Cross reference to related notes of insurance contracts issued – Analysis by remaining coverage and incurred claims D.4.3.1. D.4.5.1. D.4.3.2. D.4.7.1. D.4.7.2. D.4.7.3. – Analysis by measurement components D.4.4.1. D.4.6.1. D.4.4.2. – Insurance acquisition assets D.4.2. Cross reference to related notes of reinsurance contracts issued – Analysis by remaining coverage and incurred claims D.4.8.1. D.4.8.2. D.4.10.1. D.4.10.2. D.4.10.3. – Analysis by measurement components D.4.9.1. D.4.9.2. D.4. Insurance and reinsurance contracts related disclosures continued -- 61 of 105 -- 64 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued D.4.2 Insurance acquisition assets Group R million UK Health (PAA) Year ended 30 June 2023 Balance at the beginning of the year 3 358 Amounts Incurred during the year 1 355 Amounts derecognised and included in the measurement of insurance contracts (893) Effect of movements in exchange rates 724 Balance at the end of the year 4 544 Six months ended 31 December 2023 Amounts Incurred during the period 795 Amounts derecognised and included in the measurement of insurance contracts (521) Effect of movements in exchange rates (79) Balance at the end of the period 4 739 Balance as at 1 July 2022 Presented in insurance contract assets 3 358 Balance as at 30 June 2023 Presented in insurance contract assets 4 544 Balance as at 31 December 2023 Presented in insurance contract assets 4 739 -- 62 of 105 -- 65 The following table sets out when the Group expects to derecognise assets for insurance acquisition cash flows after the reporting date. Group R million UK Health (PAA) 31 December 2023 Year 1 914 Year 1 – 2 763 Year 3 – 5 1 319 Year 6 – 10 1 208 >10 years – 30 June 2023 Year 1 878 Year 1 – 2 734 Year 3 – 5 1 790 Year 6 – 10 1 142 >10 years – D.4. Insurance and reinsurance contracts related disclosures continued D.4.2 Insurance acquisition assets continued -- 63 of 105 -- 66 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 67 D.4.3 Reconciliation of insurance contracts – GMM D.4.3.1 SA LIFE AND INVEST (RISK) Analysis by remaining coverage and incurred claims December 2023 June 2023 Group R million (Assets)/Liabilities Liabilities for remaining coverage Liabilities for incurred claims Total Liabilities for remaining coverage Liabilities for incurred claims Navigation Excluding loss component Loss component Excluding loss component Loss component Total Opening assets arising from insurance contracts issued (26 510) 1 833 6 621 (18 056) (27 422) 1 424 6 339 (19 659) Opening liabilities arising from insurance contracts issued 22 236 185 – 22 421 21 091 133 – 21 224 Net balance at beginning of the period/year (4 274) 2 018 6 621 4 365 (6 331) 1 557 6 339 1 565 Adjust: transfer of product from SA Life and Invest (Participating) to SA Life and Invest (Risk) (22) 128 – 106 Opening assets arising from insurance contracts issued (rebased) (27 444) 1 552 6 339 (19 553) Opening liabilities arising from insurance contracts issued (rebased) 21 091 133 – 21 224 Net balance at beginning of the period/year (rebased) A (4 274) 2 018 6 621 4 365 (6 353) 1 685 6 339 1 671 Changes in the income statement and OCI Insurance revenue transitional split Contracts under the modified retrospective approach (172) – – (172) (334) – – (334) Contracts under the full retrospective approach on transition (6 467) – – (6 467) (12 790) – – (12 790) Subsequent to transition: All other contracts (6 964) – – (6 964) (13 503) – – (13 503) B (7 136) – – (7 136) (13 837) – – (13 837) Insurance service expenses Incurred claims and other insurance service expenses – – 5 084 5 084 – – 10 348 10 348 Amortised assets for insurance acquisition cash flows 970 – – 970 1 713 – – 1 713 Losses and reversal of losses on onerous contracts – 99 – 99 – 304 – 304 C 970 99 5 084 6 153 1 713 304 10 348 12 365 Investment components D (2 964) – 2 964 – (3 817) – 3 817 – Insurance service result E=B+C+D (9 130) 99 8 048 (983) (15 941) 304 14 165 (1 472) Net finance (income)/expense from insurance contracts F (931) 48 226 (657) 3 046 29 191 3 266 Net changes to income statement and OCI G=E+F (10 061) 147 8 274 (1 640) (12 895) 333 14 356 1 794 Cash Flows Premiums received 9 913 – – 9 913 17 477 – – 17 477 Insurance acquisition cash flows (1 436) – – (1 436) (2 503) – – (2 503) Claims and other directly attributable expenses paid – – (7 865) (7 865) – – (14 074) (14 074) Total cash flows H 8 477 – (7 865) 612 14 972 – (14 074) 898 Net balance at the end of the period/year J=A+G+H (5 858) 2 165 7 030 3 337 (4 274) 2 018 6 621 4 365 Closing assets arising from insurance contracts issued (28 918) 1 987 7 030 (19 901) (26 510) 1 833 6 621 (18 056) Closing liabilities arising from insurance contracts issued 23 060 178 – 23 238 22 236 185 – 22 421 Net balance at the end of the period/year (5 858) 2 165 7 030 3 337 (4 274) 2 018 6 621 4 365 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 64 of 105 -- 68 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 69 D.4.3 Reconciliation of insurance contracts – GMM continued D.4.3.2 UK LIFE (RISK) Analysis by remaining coverage and incurred claims December 2023 June 2023 Group R million (Assets)/Liabilities Navigation Liabilities for Remaining Coverage Liabilities for incurred claims Total Liabilities for Remaining Coverage Liabilities for incurred Claims Excluding loss Component Loss component Excluding Loss Component Loss component Total Opening assets arising from insurance contracts issued (17 021) 5 076 1 631 (10 314) (13 527) 4 239 1 157 (8 131) Net balance at beginning of the period/year A (17 021) 5 076 1 631 (10 314) (13 527) 4 239 1 157 (8 131) Changes in the income statement and OCI Insurance revenue transitional split Contracts under the full retrospective approach on transition (4 368) – – (4 368) (7 535) – – (7 535) B (4 368) – – (4 368) (7 535) – – (7 535) Insurance service expenses Incurred claims and other insurance service expenses – – 2 560 2 560 – – 4 414 4 414 Amortised assets for insurance acquisition cash flows 1 278 – – 1 278 2 101 – – 2 101 Losses and reversal of losses on onerous contracts – (70) – (70) – 304 – 304 C 1 278 (70) 2 560 3 768 2 101 304 4 414 6 819 Insurance service result D=B+C (3 090) (70) 2 560 (600) (5 434) 304 4 414 (716) Net finance (income)/expense from insurance contracts E (2 255) (17) – (2 272) 706 (211) – 495 Net changes to income statement and OCI F=D+E (5 345) (87) 2 560 (2 872) (4 728) 93 4 414 (221) Cash Flows Premiums received 4 606 – – 4 606 7 771 – – 7 771 Insurance acquisition cash flows (2 355) – – (2 355) (4 074) – – (4 074) Claims and other directly attributable expenses paid – – (2 382) (2 382) – – (4 168) (4 168) Total cash flows G 2 251 – (2 382) (131) 3 697 – (4 168) (471) Effect of movements in exchange rates H 284 (90) (28) 166 (2 463) 744 228 (1 491) Net balance at the end of the period/year I= A+F+G+H (19 831) 4 899 1 781 (13 151) (17 021) 5 076 1 631 (10 314) Closing assets arising from insurance contracts issued (19 831) 4 899 1 781 (13 151) (17 021) 5 076 1 631 (10 314) Net balance at the end of the period/year (19 831) 4 899 1 781 (13 151) (17 021) 5 076 1 631 (10 314) D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 65 of 105 -- 70 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 71 D.4.4 Reconciliation of insurance contracts – GMM D.4.4.1 SA LIFE AND INVEST (RISK) Analysis by measurement component Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Estimates of PVFCF RA for non- financial risk CSM Total Estimates of PVFCF RA for non- financial risk CSM Total Other contracts Other contracts Opening assets arising from insurance contracts issued (52 454) 6 960 27 438 (18 056) (55 257) 7 765 27 833 (19 659) Opening liabilities arising from insurance contracts issued 21 521 86 814 22 421 20 578 72 574 21 224 Net balance at beginning of the period/year (30 933) 7 046 28 252 4 365 (34 679) 7 837 28 407 1 565 Adjust: transfer of product from SA Life and Invest (Participating) to SA Life and Invest (Risk) 1 731 (183) (1 442) 106 Opening assets arising from insurance contracts issued (rebased) (53 526) 7 582 26 391 (19 553) Opening liabilities arising from insurance contracts issued (rebased) 20 578 72 574 21 224 Net balance at beginning of the period/year (rebased) A (30 933) 7 046 28 252 4 365 (32 948) 7 654 26 965 1 671 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (954) (954) – – (1 835) (1 835) Change in Risk Adjustment for non-financial risk that relates to expired risk – (272) – (272) – (599) – (599) Experience adjustments 48 – – 48 513 – – 513 Changes that relate to future services – – Contracts initially recognised in the period (1 259) 236 1 064 41 (2 203) 450 1 836 83 Changes in estimates that adjust CSM 371 225 (596) – 1 548 (193) (1 355) – Changes in estimates that result in onerous contract losses or reversal of losses 124 10 – 134 350 (16) – 334 Servicing expenses and commission for onerous contracts 20 – – 20 32 – – 32 Changes that relate to past services Adjustment to liability for incurred claims – – – – – 2 – 2 Insurance service result B (696) 199 (486) (983) 240 (356) (1 354) (1 470) Net finance (income)/expense from insurance contracts C (2 136) 390 1 089 (657) 877 (252) 2 641 3 266 Net changes to income statement and OCI D=B+C (2 832) 589 603 (1 640) 1 117 (608) 1 287 1 796 Cash flows E 612 – – 612 898 – – 898 Net balance at the end of the period/year G=A+D+E (33 153) 7 635 28 855 3 337 (30 933) 7 046 28 252 4 365 Closing assets arising from insurance contracts issued (55 267) 7 530 27 836 (19 901) (52 454) 6 960 27 438 (18 056) Closing liabilities arising from insurance contracts issued 22 114 105 1 019 23 238 21 521 86 814 22 421 Net balance at the end of the period/year (33 153) 7 635 28 855 3 337 (30 933) 7 046 28 252 4 365 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 66 of 105 -- 72 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 73 D.4.4 Reconciliation of insurance contracts – GMM model continued D.4.4.2 UK LIFE (RISK) Analysis by measurement component December 2023 June 2023 Group R million (Assets)/Liabilities Navigation Estimates of PVFCF RA for non- financial risk CSM Total Estimates of PVFCF RA for non- financial risk CSM Total Other contracts Other contracts Opening assets arising from insurance contracts issued (26 042) 2 016 13 712 (10 314) (21 126) 1 741 11 432 (7 953) Net balance at beginning of the period/year A (26 042) 2 016 13 712 (10 314) (21 126) 1 741 11 432 (7 953) Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (633) (633) – – (1 074) (1 074) Change in Risk Adjustment for non-financial risk that relates to expired risk – (112) – (112) – (308) – (308) Experience adjustments 51 – – 51 115 – – 115 Changes that relate to future services Contracts initially recognised in the period (477) 163 427 113 (1 227) 330 1 167 270 Changes in estimates that adjust CSM 48 12 (60) – 189 46 (235) – Changes in estimates that result in onerous contract losses or reversal of losses (35) 16 – (19) 265 15 – 280 Insurance service result B (413) 79 (266) (600) (658) 83 (142) (717) Net finance (income)/expense from insurance contracts C (2 530) 164 94 (2 272) 500 (147) 142 495 Net changes to income statement and OCI D=B+C (2 943) 243 (172) (2 872) (158) (64) – (222) Cash flows E (6) – – (6) (22) – – (22) Effect of movements in exchange rates F 319 (34) (244) 41 (4 736) 339 2 280 (2 117) Net closing balance at the end of the period/year G=A+D+E+F (28 672) 2 225 13 296 (13 151) (26 042) 2 016 13 712 (10 314) Closing assets arising from insurance contracts issued (28 672) 2 225 13 296 (13 151) (26 042) 2 016 13 712 (10 314) Net closing balance at the end of the period/ year (28 672) 2 225 13 296 (13 151) (26 042) 2 016 13 712 (10 314) D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 67 of 105 -- 74 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 75 D.4.5 Reconciliation of insurance contracts – VFA D.4.5.1 SA LIFE AND INVEST (PARTICIPATING) Analysis by remaining and incurred claims Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Liabilities for remaining coverage Liabilities for incurred Claims Total Liabilities for remaining coverage Liabilities for incurred claims Total Excluding loss component Loss component Excluding loss component Loss component Opening liabilities arising from insurance contracts issued 66 236 72 – 66 308 56 983 136 – 57 119 Net opening balance at beginning of the period/year 66 236 72 – 66 308 56 983 136 – 57 119 Adjust: transfer of product from SA Life and Invest (Participating) to SA Life and Invest (Risk) 2 (64) – (62) Opening liabilities arising from insurance contracts issued (rebased) 56 985 72 – 57 057 Net balance at beginning of the period/year (rebased) A 66 236 72 – 66 308 56 985 72 – 57 057 Changes in the statement of profit or loss and OCI Insurance revenue transitional split Contracts under the modified retrospective approach (1 417) – – (1 417) (2 809) – – (2 809) Other contracts (172) – – (172) (53) – – (53) B (1 589) – – (1 589) (2 862) – – (2 862) Insurance service expenses Incurred claims and other insurance service expenses – – 559 559 – – 1 020 1 020 Experience adjustments adjusting CSM (10) – – (10) (77) – – (77) Amortised assets for insurance acquisition cash flows 370 – – 370 694 – – 694 Losses and reversal of losses on onerous contracts – 8 – 8 – – – – C 360 8 559 927 617 – 1 020 1 637 Investment components D (5 593) – 5 593 – (9 191) – 9 191 – Insurance service result E=B+C+D (6 822) 8 6 152 (662) (11 436) – 10 211 (1 225) Net finance (income)/expense from insurance contracts F 3 025 – – 3 025 8 283 – – 8 283 Net changes to income statement and OCI G=E+F (3 797) 8 6 152 2 363 (3 153) – 10 211 7 058 Cash Flows Premiums received 7 104 – – 7 104 13 089 – – 13 089 Insurance acquisition cash flows (337) – – (337) (685) – – (685) Claims and other directly attributable expenses paid – – (6 152) (6 152) – – (10 211) (10 211) Total cash flows H 6 767 – (6 152) 615 12 404 – (10 211) 2 193 Net balance at the end of the period/year J=A+G+H 69 206 80 – 69 286 66 236 72 – 66 308 Closing liabilities arising from insurance contracts issued 69 206 80 – 69 286 66 236 72 – 66 308 Net balance at the end of the period/year 69 206 80 – 69 286 66 236 72 – 66 308 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 68 of 105 -- 76 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 77 D.4.6 Reconciliation of insurance contracts – VFA D.4.6.1 SA LIFE AND INVEST (PARTICIPATING) Analysis by measurement component Navigation December 2023 June 2023 Group R million (Assets)/Liabilities CSM CSM Estimates of PVFCF RA for non-financial risk Transition: Modified retrospective Other contracts Total Estimates of PVFCF RA for non-financial risk Transition: Modified Retrospective Other contracts Total Opening liabilities arising from insurance contracts issued 59 328 912 5 430 638 66 308 52 546 663 3 910 – 57 119 Net balance at beginning of the period/year 59 328 912 5 430 638 66 308 52 546 663 3 910 – 57 119 Adjust: transfer of product from SA Life and Invest (Participating) to SA Life and Invest (Risk) (1 729) 166 1 501 – (62) Opening liabilities arising from insurance contracts issued (rebased) 50 817 829 5 411 – 57 057 Net balance at beginning of the period/year A 59 328 912 5 430 638 66 308 50 817 829 5 411 – 57 057 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – (507) (60) (567) – – (1 072) (29) (1 101) Change in Risk Adjustment for non-financial risk that relates to expired risk – (97) – – (97) – (149) – – (149) Experience adjustments 43 – (25) (29) (11) 7 – 2 (9) – Changes that relate to future services Contracts initially recognised in the period (334) 35 – 314 15 (831) 70 – 782 21 Changes in estimates that adjust CSM 326 (118) (145) (63) – (531) 116 362 53 – Changes in estimates that result in onerous contract losses or reversal of losses 1 (2) – – (1) 1 3 – – 4 Insurance service result B 36 (182) (677) 162 (661) (1 354) 40 (708) 797 (1 225) Net finance (income)/expense from insurance contracts C 2 537 41 493 (47) 3 024 7 672 43 727 (159) 8 283 Net changes to income statement and OCI D=B+C 2 573 (141) (184) 115 2 363 6 318 83 19 638 7 058 Cash flows E 615 – – – 615 2 193 – – – 2 193 Net balance at the end of the period/year G=A+D+E 62 516 771 5 246 753 69 286 59 328 912 5 430 638 66 308 Closing liabilities arising from insurance contracts issued 62 516 771 5 246 753 69 286 59 328 912 5 430 638 66 308 Net balance at the end of the period/year 62 516 771 5 246 753 69 286 59 328 912 5 430 638 66 308 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 69 of 105 -- 78 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 79 D.4.7 Reconciliation of insurance contracts – PAA D.4.7.1 SA LIFE AND INVEST: GROUP LIFE AND OTHER Analysis by remaining coverage, incurred claims and measurement component Navigation December 2023 June 2023 Group R million (Assets)/Liabilities Liabilities for remaining coverage (LRC) Liabilities for Incurred Claims (LIC) Liabilities for remaining coverage Liabilities for Incurred Claims Estimates of PV of future cash flows RA for non-financial risk Total Estimates of PV of future cash flows RA for non-financial risk Total Opening liabilities arising from insurance contracts issued (162) 5 167 104 5 109 (127) 4 840 91 4 804 Net balance at the beginning of the period/year A (162) 5 167 104 5 109 (127) 4 840 91 4 804 Insurance revenue B (1 741) – – (1 741) (3 307) – – (3 307) Insurance service expenses C Incurred claims and other insurance service expenses – 1 498 9 1 507 – 2 600 12 2 612 Amortisation of insurance acquisition cash flows 77 – – 77 141 – – 141 77 1 498 9 1 584 141 2 600 12 2 753 Insurance service result D=B+C (1 664) 1 498 9 (157) (3 166) 2 600 12 (554) Net finance (income)/expense from insurance contracts E – 219 5 224 – 200 1 201 Net changes to statement of profit or loss and OCI F=D+E (1 664) 1 717 14 67 (3 166) 2 800 13 (353) Cash flows Premiums received 1 748 – – 1 748 3 272 – – 3 272 Insurance acquisition cash flows (77) – – (77) (141) – – (141) Claims and other directly attributable expenses paid – (1 177) – (1 177) – (2 473) – (2 473) Total cash flows G 1 671 (1 177) – 494 3 131 (2 473) – 658 Net balance at the end of the period/year H=A+F+G (155) 5 707 118 5 670 (162) 5 167 104 5 109 Closing liabilities arising from insurance contracts issued (155) 5 707 118 5 670 (162) 5 167 104 5 109 Net balance at the end of the period/year (155) 5 707 118 5 670 (162) 5 167 104 5 109 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 70 of 105 -- 80 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 81 D.4.7 Reconciliation of insurance contracts – PAA continued D.4.7.2 SA INSURE AND OTHER Analysis by remaining coverage, incurred claims and measurement component Navigation December 2023 June 2023 Liabilities for remaining coverage (LRC) Liabilities for Incurred Claims (LIC) Liabilities for remaining coverage Liabilities for Incurred Claims (LIC) Group R million (Assets)/Liabilities Estimates of PVFCF RA for non-financial risk Total Estimates of PV of future cash flows RA for non-financial risk Total Opening liabilities arising from insurance contracts held 52 758 12 822 77 749 13 839 Net balance at beginning of the period/year A 52 758 12 822 77 749 13 839 Insurance revenue B (3 323) – – (3 323) (6 000) – – (6 000) Insurance service expenses C Incurred claims and other insurance service expenses – 3 224 – 3 224 – 5 744 – 5 744 Gross claims and insurance service expenses – 3 394 – 3 394 – 6 123 – 6 123 Salvages – (170) – (170) – (379) – (379) Adjustment to liability for incurred claims – 96 5 101 – 141 (1) 140 – 3 320 5 3 325 – 5 885 (1) 5 884 Insurance service result D=B+C (3 323) 3 320 5 2 (6 000) 5 885 (1) (116) Net finance (income)/expense from insurance contracts E – – – – – – – – Net changes to statement of profit or loss and OCI F=D+E (3 323) 3 320 5 2 (6 000) 5 885 (1) (116) Cash flows Premiums received 3 334 – – 3 334 5 975 – – 5 975 Claims and other directly attributable expenses paid – (3 177) – (3 177) – (5 877) – (5 877) Gross claims and insurance service expenses paid – (3 373) – (3 373) – (6 262) – (6 262) Salvages – 196 – 196 – 385 – 385 Total cash flows G 3 334 (3 177) – 157 5 975 (5 877) – 98 Effect of movements in exchange rates H – – – – – 1 – 1 Net balance at the end of the period/year I=A+F+G+H 63 901 17 981 52 758 12 822 Closing liabilities arising from insurance contracts issued 63 901 17 981 52 758 12 822 Net balance at the end of the period/year 63 901 17 981 52 758 12 822 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 71 of 105 -- 82 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 83 D.4.7 Reconciliation of insurance contracts – PAA continued D.4.7.3 UK HEALTH Analysis by remaining coverage, incurred claims and measurement component Navigation December 2023 June 2023 Liabilities for remaining coverage (LRC) Liabilities for incurred claims (LIC) Total Liabilities for remaining coverage (LRC) Liabilities for incurred claims Total Group R million (Assets)/Liabilities Estimates of PV of future cash flows RA for non-financial risk Estimates of PV of future cash flows RA for non-financial risk Opening liabilities arising from insurance contracts issued (372) 1 350 57 1 035 105 989 37 1 131 Net balance at the beginning of the period/year A (372) 1 350 57 1 035 105 989 37 1 131 Insurance revenue B (7 960) – – (7 960) (13 670) – – (13 670) Insurance service expenses Incurred claims and other insurance service expenses – 6 367 (20) 6 347 – 10 765 11 10 776 Amortisation of insurance acquisition cash flows 850 – – 850 1 403 – – 1 403 Losses and reversal of losses on onerous contracts – – – – (1) – – (1) C 850 6 367 (20) 7 197 1 402 10 765 11 12 178 Insurance service result D=B+C (7 110) 6 367 (20) (763) (12 268) 10 765 11 (1 492) Net finance (income)/expense from insurance contracts E – – – – – – – – Net changes to income statement and OCI F=D+E (7 110) 6 367 (20) (763) (12 268) 10 765 11 (1 492) Cash flows Premiums received 7 741 – – 7 741 13 324 – – 13 324 Insurance acquisition cash flows (324) – – (324) (607) – – (607) Claims and other directly attributable expenses paid – (6 793) – (6 793) – (10 619) – (10 619) Total cash flows G 7 417 (6 793) – 624 12 717 (10 619) – 2 098 Allocation from assets for insurance acquisition cash flows to group of insurance contracts H (521) – – (521) (893) – – (893) Effect of movements in exchange rates I 5 (27) (1) (23) (33) 215 9 191 Net balance at the end of the period/year J=A+F+G+H+I (581) 897 36 352 (372) 1 350 57 1 035 Closing liabilities arising from insurance contracts issued (581) 897 36 352 (372) 1 350 57 1 035 Net balance at the end of the period/year (581) 897 36 352 (372) 1 350 57 1 035 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 72 of 105 -- 84 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 85 D.4.8 Reconciliation of reinsurance contracts – GMM D.4.8.1 SA LIFE AND INVEST (RISK) Analysis by remaining coverage and incurred claims Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Assets for remaining coverage Assets for incurred claims Total Assets for remaining coverage Assets for incurred claims Total Excluding loss recovery component Loss recovery component Excluding loss recovery component Loss recovery component Opening liabilities arising from insurance contracts issued 3 027 (202) (2 258) 567 3 423 (148) (2 151) 1 124 Net balance at beginning of the period/year A 3 027 (202) (2 258) 567 3 423 (148) (2 151) 1 124 Changes in the income statement and OCI Allocation of reinsurance premiums paid 1 660 – – 1 660 3 268 – – 3 268 Recoveries of incurred claims and other insurance service expenses – – (1 273) (1 273) – – (3 131) (3 131) Recoveries and reversals of recoveries of losses on onerous underlying contracts – (13) – (13) – (55) – (55) Adjustments to assets for incurred claims – – – – – – – – 1 660 (13) (1 273) 374 3 268 (55) (3 131) 82 Net expenses from reinsurance contracts B 1 660 (13) (1 273) 374 3 268 (55) (3 131) 82 Net finance (income)/expense from reinsurance contracts C 230 2 (55) 177 (154) 1 (17) (170) Net changes to income statement and OCI D=B+C 1 890 (11) (1 328) 551 3 114 (54) (3 148) (88) Cash Flows Premiums paid (1 996) – – (1 996) (3 510) – – (3 510) Claims recovered – – 1 618 1 618 – – 3 041 3 041 Total cash flows F (1 996) – 1 618 (378) (3 510) – 3 041 (469) Net balance at the end of the period/year H=A+D+F 2 921 (213) (1 968) 740 3 027 (202) (2 258) 567 Closing liabilities arising from reinsurance contracts held 2 921 (213) (1 968) 740 3 027 (202) (2 258) 567 Net balance at the end of the period/year 2 921 (213) (1 968) 740 3 027 (202) (2 258) 567 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 73 of 105 -- 86 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 87 D.4.8 Reconciliation of reinsurance contracts – GMM continued D.4.8.2 UK LIFE (RISK) Analysis by remaining coverage and incurred claims Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Assets for remaining coverage Assets for incurred claims Total Assets for remaining coverage Assets for incurred claims Total Excluding loss recovery component Loss recovery component Excluding loss recovery component Loss recovery component Opening liabilities arising from reinsurance contracts held 7 679 (2 374) (1 029) 4 276 6 668 (1 810) (683) 4 175 Net balance at beginning of the period/year A 7 679 (2 374) (1 029) 4 276 6 668 (1 810) (683) 4 175 Changes in the income statement and OCI Allocation of reinsurance premiums paid 2 675 – – 2 675 3 464 – – 3 464 Recoveries of incurred claims and other insurance service expenses – – (2 502) (2 502) – – (3 272) (3 272) Recoveries and reversals of recoveries of losses on onerous underlying contracts – 41 – 41 – (284) – (284) 2 675 41 (2 502) 214 3 464 (284) (3 272) (92) Net expenses from reinsurance contracts B 2 675 41 (2 502) 214 3 464 (284) (3 272) (92) Net finance (income)/expense from reinsurance contracts C 596 22 – 618 (162) 60 – (102) Net changes to income statement and OCI D=B+C 3 271 63 (2 502) 832 3 302 (224) (3 272) (194) Cash Flows Premiums paid (2 365) – – (2 365) (3 430) – – (3 430) Claims recovered – – 2 273 2 273 – – 3 069 3 069 Total cash flows F (2 365) – 2 273 (92) (3 430) – 3 069 (361) Effect of movements in exchange rates G (131) 42 17 (72) 1 139 (340) (143) 656 Net balance at the end of the period/year H=A+D+F+G 8 454 (2 269) (1 241) 4 944 7 679 (2 374) (1 029) 4 276 Closing liabilities arising from reinsurance contracts held 8 454 (2 269) (1 241) 4 944 7 679 (2 374) (1 029) 4 276 Net balance at the end of the period/year 8 454 (2 269) (1 241) 4 944 7 679 (2 374) (1 029) 4 276 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 74 of 105 -- 88 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 89 D.4.9 Reconciliation of reinsurance contracts – GMM D.4.9.1 SA LIFE AND INVEST (RISK) Analysis by measurement component Navigation December 2023 June 2023 CSM CSM Group R million (Assets)/Liabilities Estimates of PVFCF RA for non-financial risk Transition: Modified retrospective Other contracts Total Estimates of PVFCF RA for non-financial risk Transition: Modified retrospective Other contracts Total Opening liabilities arising from reinsurance contracts held 6 094 (698) (80) (4 749) 567 6 315 (704) (75) (4 412) 1 124 Net balance at beginning of the period/year A 6 094 (698) (80) (4 749) 567 6 315 (704) (75) (4 412) 1 124 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – 2 161 163 – – 4 307 311 Change in Risk Adjustment for non-financial risk that relates to expired risk – 33 – – 33 – 63 – – 63 Experience adjustments 195 – – – 195 (221) – – – (221) Changes that relate to future services Contracts initially recognised in the period 106 (11) – (100) (5) 221 (25) – (209) (13) Changes in estimates that adjust CSM 30 18 – (20) 28 41 (7) – (31) 3 Changes in estimates that relate to losses and reversal of losses on underlying contracts (24) (17) – – (41) (62) 2 – – (60) Changes that relate to past services Adjustment to assets for incurred claims – 1 – – 1 – (1) – – (1) Net Expenses from reinsurance contracts held B 307 24 2 41 374 (21) 32 4 67 82 Net finance (income)/expense from reinsurance contracts C 409 (33) (4) (195) 177 269 (26) (9) (404) (170) Net changes to income statement and OCI D=B+C 716 (9) (2) (154) 551 248 6 (5) (337) (88) Cash flows E (378) – – – (378) (469) – – – (469) Net balance at the end of the period/year G=A+D+E 6 432 (707) (82) (4 903) 740 6 094 (698) (80) (4 749) 567 Closing liabilities arising from reinsurance contracts held 6 432 (707) (82) (4 903) 740 6 094 (698) (80) (4 749) 567 Net balance at the end of the period/year 6 432 (707) (82) (4 903) 740 6 094 (698) (80) (4 749) 567 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 75 of 105 -- 90 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 91 D.4.9 Reconciliation of reinsurance contracts – GMM continued D.4.9.2 UK LIFE (RISK) Analysis by measurement component Navigation December 2023 June 2023 CSM CSM Group R million (Assets)/Liabilities Estimates of PVFCF RA for non-financial risk Other contracts Total Estimates of PVFCF RA for non-financial risk Other contracts Total Opening liabilities arising from reinsurance contracts held 9 703 (430) (4 997) 4 276 8 515 (438) (3 993) 4 084 Net balance at beginning of the period/year A 9 703 (430) (4 997) 4 276 8 515 (438) (3 993) 4 084 Changes in the income statement and OCI Changes that relate to current services CSM recognised for services provided – – 242 242 – – 399 399 Change in Risk Adjustment for non-financial risk that relates to expired risk – 13 – 13 – 18 – 18 Experience adjustments (21) – – (21) (87) – – (87) Changes that relate to future services Contracts initially recognised in the period 481 (26) (528) (73) 650 (56) (777) (183) Changes in estimates that adjust CSM 9 3 (12) – (298) 77 246 25 Changes in estimates that relate to losses and reversal of losses on underlying contracts 55 (2) – 53 (244) (20) – (264) Net Expenses from reinsurance contracts held B 524 (12) (298) 214 21 19 (132) (92) Net finance (income)/expense from reinsurance contracts C 703 (42) (43) 618 (115) 67 (54) (102) Net changes to income statement and OCI D=B+C 1 227 (54) (341) 832 (94) 86 (186) (194) Cash flows E (92) – – (92) (362) – – (362) Effect of movements in exchange rates F (166) 7 87 (72) 1 644 (78) (818) 748 Net balance at the end of the period/year G=A+D+E+F 10 672 (477) (5 251) 4 944 9 703 (430) (4 997) 4 276 Closing liabilities arising from reinsurance contracts held 10 672 (477) (5 251) 4 944 9 703 (430) (4 997) 4 276 Net balance at the end of the period/year 10 672 (477) (5 251) 4 944 9 703 (430) (4 997) 4 276 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 76 of 105 -- 92 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 93 D.4.10 Reconciliation of reinsurance contracts – PAA D.4.10.1 SA LIFE AND INVEST: GROUP LIFE AND OTHER Analysis by remaining coverage, incurred claims and measurement component Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Asset for remaining coverage Asset for incurred claims Total Asset for remaining coverage Asset for incurred claims Total Estimates of PVFCF RA for non-financial risk Estimates of PVFCF RA for non-financial risk Opening assets arising from reinsurance contracts held 398 (910) (17) (529) 378 (1 054) (15) (691) Net balance at beginning of the period/year A 398 (910) (17) (529) 378 (1 054) (15) (691) Changes in the statement of profit or loss and OCI Net expenses from reinsurance contracts held Reinsurance premiums expense 141 – – 141 282 – – 282 Claims recovered from reinsurer – (102) (2) (104) – (138) (2) (140) Net finance (income)/expense from reinsurance contracts – (28) (1) (29) – (31) – (31) Net changes to statement of profit or loss and OCI B 141 (130) (3) 8 282 (169) (2) 111 Cash Flows Premiums paid net of commissions and other attributable expenses (399) – – (399) (262) – – (262) Reinsurance recoveries – 315 – 315 – 313 – 313 Total cash flows C (399) 315 – (84) (262) 313 – 51 Net balance at end of the period/year D=A+B+C 140 (725) (20) (605) 398 (910) (17) (529) Closing assets arising from reinsurance contracts held 140 (725) (20) (605) 398 (910) (17) (529) Net balance at end of the period/year 140 (725) (20) (605) 398 (910) (17) (529) D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 77 of 105 -- 94 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 95 D.4.10 Reconciliation of reinsurance contracts – PAA continued D.4.10.2 SA INSURE AND OTHER Analysis by remaining coverage and incurred claims Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Asset for remaining coverage Asset for incurred claims Total Asset for remaining coverage Asset for incurred claims Total Estimates of PVFCF RA for non-financial risk Estimates of PVFCF RA for non-financial risk Opening assets arising from reinsurance contracts held 776 (845) (2) (71) 260 (440) (2) (182) Net balance at beginning of the period/year A 776 (845) (2) (71) 260 (440) (2) (182) Changes in the income statement and OCI Net expenses from reinsurance contracts held Reinsurance premiums expense 383 – – 383 635 – – 635 Claims recovered from reinsurer – (403) (1) (404) – (590) – (590) Net changes to statement of profit or loss and OCI B 383 (403) (1) (21) 635 (590) – 45 Cash flows Premiums paid net of commissions and other attributable expenses (800) – – (800) (119) – – (119) Reinsurance recoveries – 720 – 720 – 185 – 185 Total cash flows C (800) 720 – (80) (119) 185 – 66 Net balance at end of the period/year D=A+B+C 359 (528) (3) (172) 776 (845) (2) (71) Closing assets arising from reinsurance contracts held 359 (528) (3) (172) 776 (845) (2) (71) Net balance at the end of the period/year 359 (528) (3) (172) 776 (845) (2) (71) D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 78 of 105 -- 96 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 97 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4.10 Reconciliation of reinsurance contracts – PAA continued D.4.10.3 UK HEALTH Analysis by remaining coverage and incurred claims Group R million (Assets)/Liabilities Navigation December 2023 June 2023 Asset for remaining coverage Asset for Incurred Claims Total Asset for remaining coverage Asset for Incurred Claims Total Estimates of PVFCF RA for non-financial risk Estimates of PVFCF RA for non-financial risk Opening assets arising from reinsurance contracts held 8 (9) (3) (4) 6 (5) (2) (1) Net balance at beginning of the period/year A 8 (9) (3) (4) 6 (5) (2) (1) Changes in the income statement and OCI Net expenses from reinsurance contracts held Reinsurance premiums expense 5 – – 5 1 847 – – 1 847 Claims recovered from reinsurer – – – – – (1 837) (1) (1 838) Net changes income statement and OCI B 5 – – 5 1 847 (1 837) (1) 9 Cash flows Premiums paid net of commissions and other attributable expenses (17) – – (17) (1 845) – – (1 845) Reinsurance recoveries – 1 1 2 – 1 833 – 1 833 Total cash flows C (17) 1 1 (15) (1 845) 1 833 – (12) Net balance at the end of the period/year D=A+B+C (4) (8) (2) (14) 8 (9) (3) (4) Closing assets arising from reinsurance contracts held (4) (8) (2) (14) 8 (9) (3) (4) Net balance at the end of the period/year (4) (8) (2) (14) 8 (9) (3) (4) D.4. Insurance and reinsurance contracts related disclosures continued -- 79 of 105 -- 98 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 99 D.4.11 Insurance revenue Group R million Income/(expense) SA Life and Invest Risk (GMM) SA Life and Invest Participating (VFA) SA Life and Group Risk (PAA) SA Insure and other immaterial (PAA) UK Life Risk (GMM) UK Health (PAA) Total Six months ended 31 December 2023 Contracts not measured under the PAA Amounts relating to changes in liabilities for remaining coverage 6 166 1 219 – – 3 091 – 10 476 – CSM recognised for services provided 953 568 – – 633 – 2 154 – Change in risk adjustment for non-financial risk for risk expired 269 96 – – 109 – 474 – Expected incurred claims and other insurance service expenses 5 022 543 – – 2 470 – 8 035 – Experience adjustments (78) 12 – – (121) – (187) Recovery of insurance acquisition cash flows 970 370 – – 1 277 – 2 617 Contracts not measured under the PAA 7 136 1 589 – – 4 368 – 13 093 Contracts measured under the PAA – – 1 741 3 323 – 7 960 13 024 Total insurance revenue 7 136 1 589 1 741 3 323 4 368 7 960 26 117 Six months ended 31 December 2022 Contracts not measured under the PAA Amounts relating to changes in liabilities for remaining coverage 5 898 1 012 – – 2 471 – 9 381 – CSM recognised for services provided 901 527 – – 587 – 2 015 – Change in risk adjustment for non-financial risk for risk expired 278 61 – – 139 – 478 – Expected incurred claims and other insurance service expenses 4 739 422 – – 2 063 – 7 224 – Experience adjustments (20) 2 – – (318) – (336) Recovery of insurance acquisition cash flows 834 351 – – 987 – 2 172 Contracts not measured under the PAA 6 732 1 363 – – 3 458 – 11 553 Contracts measured under the PAA – – 1 637 2 917 – 6 425 10 979 Total insurance revenue 6 732 1 363 1 637 2 917 3 458 6 425 22 532 Year ended 30 June 2023 Contracts not measured under the PAA Amounts relating to changes in liabilities for remaining coverage 12 122 2 168 – (1) 5 434 – 19 723 – CSM recognised for services provided 1 835 1 101 – – 1 074 – 4 010 – Change in risk adjustment for non-financial risk for risk expired 595 148 – – 299 – 1 042 – Expected incurred claims and other insurance service expenses 9 653 927 – (1) 4 339 – 14 918 – Experience adjustments 39 (8) – – (278) – (247) Recovery of insurance acquisition cash flows 1 713 694 – – 2 101 – 4 508 Contracts not measured under the PAA 13 835 2 862 – (1) 7 535 – 24 231 Contracts measured under the PAA – – 3 307 6 000 – 13 670 22 977 Total insurance revenue 13 835 2 862 3 307 5 999 7 535 13 670 47 208 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 80 of 105 -- 100 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 101 D.4.12 Net investment result The following table analyses the Group’s net investment result in profit or loss and OCI. Group R million Income/(expense) Navigation SA Life and Invest Risk (GMM) SA Life and Invest Participating (VFA) SA Life and Group Risk (PAA) SA Insure and other immaterial (PAA) UK Life Risk (GMM) UK Health (PAA) Other Total Six month period ended 31 December 2023 Investment return Interest revenue from financial assets not measured at FVTPL 10 – – 122 41 83 156 412 Net gains on FVTPL investments 2 210 2 703 – 4 – 56 1 697 6 670 Total investment return 2 220 2 703 – 126 41 139 1 853 7 082 Finance income/(expense) from insurance contracts Changes in fair value of underlying items of direct participation contracts – (3 014) – – – – – (3 014) Interest accreted on CSM (1 134) (446) – – (94) – – (1 674) Interest accreted on FCF and other finance (income)/expense 1 817 436 (186) – 2 366 – – 3 433 Effect of changes in interest rates and other financial assumptions 516 – (40) – – – – 476 Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 488 – – – – – – 488 Effect of movements in exchange rates (28) – 2 – – – – (26) Net finance expense from insurance contracts A 659 (3 024) (224) – 2 272 – – (317) Finance income/(expense) from reinsurance contracts Interest accreted 199 – 26 – 43 – – 268 Other (379) – 3 – (661) – – (1 037) Net finance Income from reinsurance contracts B (180) – 29 – (618) – – (769) Movement in investment contract liabilities – – – – – – (691) (691) Movement in third party interests in consolidated funds – – – – – – (1 149) (1 149) – – – – – – (1 840) (1 840) Represented by: Amounts recognised in statement of profit or loss 250 (3 024) (193) – 76 – – (2 892) Amounts recognised in OCI 229 – (2) – 1 578 – – 1 805 C=A+B 479 (3 024) (195) – 1 654 – – (1 086) Insurance finance income and expenses Net finance expenses from insurance contracts Amounts recognised in statement of profit or loss 377 (3 024) (225) – 142 – – (2 730) Amounts recognised in OCI 282 – 1 – 2 130 – – 2 413 A 659 (3 024) (224) – 2 272 – – (317) Net finance income from reinsurance contracts Amounts recognised in statement of profit or loss (127) – 32 – (66) – – (162) Amounts recognised in OCI (53) – (3) – (552) – – (608) B (180) – 29 – (618) – – (769) D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 81 of 105 -- 102 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 103 D.4.12 Net investment result continued The following table analyses the Group’s net investment result in profit or loss and OCI. Group R million Income/(expense) SA Life and Invest Risk (GMM) SA Life and Invest Participating (VFA) SA Life and Group Risk (PAA) SA Insure and other immaterial (PAA) UK Life Risk (GMM) UK Health (PAA) Other Total Year ended 30 June 2023 Investment return Interest revenue from financial assets not measured at FVTPL 28 – – 181 71 90 246 616 Net gains on FVTPL investments 4 576 8 473 – – 516 1 3 161 16 727 Total investment return 4 604 8 473 – 181 587 91 3 407 17 343 Finance income/(expense) from insurance contracts Changes in fair value of underlying items of direct participation contracts – (8 252) – – – – – (8 252) Interest accreted on CSM (2 280) (599) – – (142) – – (3 021) Interest accreted on FCF and other finance (income)/expense 2 1 571 568 (267) – (353) – – 1 519 Effect of changes in interest rates and other financial assumptions (3 098) – 84 – – – – (3 014) Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 446 – – – – – – 446 Effect of movements in exchange rates 97 – (18) – – – – 79 Net finance expense from insurance contracts (3 264) (8 283) (201) – (495) – – (12 243) Finance income/(expense) from reinsurance contracts Interest accreted 413 – 42 – 54 – – 509 Other (242) – (12) – 48 – – (206) Net finance Income from reinsurance contracts 171 – 30 – 102 – – 303 Movement in investment contract liabilities – – – – – – (2 593) (2 593) Movement in third party interests in consolidated funds – – – – – – (2 978) (2 978) – – – – – – (5 571) (5 571) Represented by: Amounts recognised in statement of profit or loss 1 267 (8 283) (354) – (88) – – (7 458) Amounts recognised in OCI (4 362) – 183 – (304) – – (4 483) (3 095) (8 283) (171) – (392) – – (11 941) Insurance finance income and expenses Net finance expenses from insurance contracts Amounts recognised in statement of profit or loss 1 553 (8 283) (415) – (27) – – (7 172) Amounts recognised in OCI (4 819) – 214 – (467) – – (5 072) (3 266) (8 283) (201) – (494) – – (12 244) Net finance income from reinsurance contracts Amounts recognised in statement of profit or loss (286) – 61 – (61) – – (286) Amounts recognised in OCI 457 – (31) – 163 – – 589 171 – 30 – 102 – – 303 1 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/ expense includes for Individual life finance income of R2 059 million, and guaranteed endowments finance expense of R1 242 million. 2 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/ expense includes for Individual life finance income of R2 284 million, and guaranteed endowments finance expense of R1 293 million D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 82 of 105 -- 104 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 105 D.4.13 Effect of insurance contracts initially recognised in the year Profitable contracts issued Onerous contracts issued Group R million (Assets)/Liabilities SA Life and Invest Risk (GMM) SA Life and Invest Participating (VFA) UK Life Risk (GMM) Total SA Life and Invest Risk (GMM) SA Life and Invest Participating (VFA) UK Life Risk (GMM) Total Six months ended 31 December 2023 Insurance acquisition cash flows (179) (217) – (396) 27 (47) – (20) Claims and other insurance service expenses payable (4 325) (2 949) (1 816) (9 090) (326) (836) (835) (1 997) Estimates of present value of cash outflows (4 504) (3 166) (1 816) (9 486) (299) (883) (835) (2 017) Estimates of present value of cash inflows 5 790 3 513 2 372 11 675 272 870 756 1 898 Risk adjustment for non-financial risk (222) (33) (129) (384) (14) (2) (34) (50) CSM (1 064) (314) (427) (1 805) – – – – Losses recognised on initial recognition – – – – (41) (15) (113) (169) Year ended 30 June 2023 Insurance acquisition cash flows (325) (437) – (762) (9) (66) – (75) Claims and other insurance service expenses payable (6 900) (6 733) (3 930) (17 563) (777) (1 232) (1 728) (3 737) Estimates of present value of cash outflows (7 225) (7 170) (3 930) (18 325) (786) (1 298) (1 728) (3 812) Estimates of present value of cash inflows 9 474 8 019 5 370 22 863 740 1 280 1 515 3 535 Risk adjustment for non-financial risk (413) (67) (273) (753) (37) (3) (57) (97) CSM (1 836) (782) (1 167) (3 785) – – – – Losses recognised on initial recognition – – – – (83) (21) (270) (374) D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued -- 83 of 105 -- 106 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D.4. Insurance and reinsurance contracts related disclosures continued D.4.14 Effects of reinsurance contracts initially recognised in the year REINSURANCE CONTRACTS Group of contracts with a net cost on initial recognition 1 Group R million (Asset)/Liability SA Life and Invest Risk (GMM) UK Life Risk (GMM) Total Six months ended 31 December 2023 Estimates of present value of cash outflows (584) 1 595 1 011 Estimates of present value of cash inflows 478 (2 076) (1 598) Risk adjustment for non-financial Risk 11 26 37 Income recognised on initial recognition (for offset) (5) (73) (78) Contractual service margin (CSM) (100) (528) (628) Year ended 30 June 2023 Estimates of present value of cash outflows (1 241) 3 480 2 239 Estimates of present value of cash inflows 1 020 (4 130) (3 110) Risk adjustment for non-financial Risk 25 56 81 Income recognised on initial recognition (for offset) (13) (183) (196) Contractual service margin (CSM) (209) (777) (986) 1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition, that will reflect as a future cost relative to the insurance contract CSM that will release as future revenue. 2 Group of contracts with a net gain on initial recognition refers to those reinsurance contracts where at inception the full profit from the reinsurance contracts was recognised, which offset losses on onerous contracts at inception. D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued -- 84 of 105 -- 107 D 4.15 Contractual service margin The following table sets out when the group expects to recognise the remaining CSM in profit or loss after the reporting date for contracts not measured under the PAA: D 4.15.1 INSURANCE CONTRACTS ISSUED Group R million Years of expected release of the CSM <1 year 1 – 2 years 3 – 5 years 6 – 10 years >10 years Total Six months ended 31 SA Life and Invest Risk (GMM) Balance at beginning of the period 28 855 29 046 29 574 32 447 42 367 28 855 Accretion of interest 2 499 2 688 9 334 20 707 406 215 441 443 Recognised in income statement (2 308) (2 160) (6 461) (10 787) (448 582) (470 298) Balance at end of the period 29 046 29 574 32 447 42 367 – – SA Life and Invest Risk (VFA) Balance at beginning of the period 5 999 5 810 5 567 5 326 6 109 5 999 Accretion of interest 1 063 1 050 3 645 8 358 21 126 35 242 Recognised in income statement (1 252) (1 293) (3 886) (7 575) (27 235) (41 241) Balance at end of the period 5 810 5 567 5 326 6 109 – – UK Life Risk (GMM) Balance at beginning of the period 13 296 12 299 11 403 9 137 6 168 13 296 Accretion of interest 216 200 517 661 1 044 2 638 Recognised in income statement (1 213) (1 096) (2 783) (3 630) (7 212) (15 934) Balance at end of the period 12 299 11 403 9 137 6 168 – – Total balance at beginning of the period 48 150 Year ended 30 June 2023 SA Life and Invest Risk (GMM) Balance at beginning of the period 28 252 28 582 29 104 31 775 41 229 28 252 Accretion of interest 2 437 2 626 9 073 19 945 391 041 425 122 Recognised in income statement (2 107) (2 104) (6 402) (10 491) (432 270) (453 374) Balance at end of the period 28 582 29 104 31 775 41 229 – – SA Life and Invest Participating (VFA) Balance at beginning of the period 6 068 5 881 5 686 5 596 6 460 6 068 Accretion of interest 1 077 1 120 3 926 8 699 23 514 38 336 Recognised in income statement (1 264) (1 315) (4 016) (7 835) (29 974) (44 404) Balance at end of the period 5 881 5 686 5 596 6 460 – – UK Life Risk (GMM) Balance at beginning of the year 13 712 12 650 11 702 9 333 6 271 13 712 Accretion of interest 205 191 496 636 954 2 482 Recognised in income statement (1 267) (1 139) (2 865) (3 698) (7 225) (16 194) Balance at end of the year 12 650 11 702 9 333 6 271 – – Total balance at beginning of the period 48 032 D.4. Insurance and reinsurance contracts related disclosures continued -- 85 of 105 -- 108 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 D. NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued D.4. Insurance and reinsurance contracts related disclosures continued D 4.15 Contractual service margin continued D 4.15.2 REINSURANCE CONTRACTS HELD Group R million Years of expected release of the CSM <1 year 1 – 2 years 3 – 5 years 6 – 10 years >10 years Total Six months ended 31 December 2023 SA Life and Invest Risk (GMM) Balance at beginning of the period 4 985 5 068 5 167 5 670 6 802 4 985 Accretion of interest 439 461 1 535 3 146 48 864 54 445 Recognised in income statement (356) (362) (1 032) (2 014) (55 666) (59 430) Balance at end of the period 5 068 5 167 5 670 6 802 – – UK Life Risk (GMM) Balance at beginning of the period 5 251 4 879 4 543 3 689 2 565 5 251 Accretion of interest 111 102 252 318 552 1 335 Recognised in income statement (483) (438) (1 106) (1 442) (3 117) (6 586) Balance at end of the period 4 879 4 543 3 689 2 565 – – Total balance at beginning of the period 10 236 Year ended 30 June 2023 SA Life and Invest Risk (GMM) Balance at beginning of the year 4 829 4 907 5 002 5 467 6 506 4 829 Accretion of interest 423 445 1 478 3 009 45 918 51 273 Recognised in income statement (345) (350) (1 013) (1 970) (52 424) (56 102) Balance at end of the year 4 907 5 002 5 467 6 506 – – UK Life Risk (GMM) Balance at beginning of the year 4 997 4 622 4 284 3 438 2 345 4 997 Accretion of interest 87 80 198 251 389 1 005 Recognised in income statement (462) (418) (1 044) (1 344) (2 734) (6 002) Balance at end of the year 4 622 4 284 3 438 2 345 – – Total balance at beginning of the period 9 826 -- 86 of 105 -- 109 Review opinion External review and comparative information E -- 87 of 105 -- 110 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Independent auditors’ report To the shareholders of Discovery Limited Report on the restated IFRS 17 and Other Presentation Changes and Restated Financial information We have reviewed the restated impacted financial statement captions following the adoption of IFRS 17 “Insurance Contracts” as set out below as at 30 June 2023 and 1 July 2022 included in the Discovery Limited’s Interim Results for the six months ended 31 December 2023 (“Interim Financial Information”):  Assets arising from insurance contracts issued;  Assets arising from reinsurance contracts held;  Deferred tax asset;  Deferred acquisition costs;  Investment in equity-accounted investments;  Contract receivables and other receivables;  Cash and cash equivalents;  Other reserves;  Retained earnings;  Equity attributable to equity holders of the company;  Liabilities arising from insurance contracts issued;  Liabilities arising from reinsurance contracts held;  Deferred tax liability;  Other financial payables at amortised cost;  Investment contracts at fair value through profit or loss; and  Other payables and provisions, and the financial statement captions impacted by Other restatements and Other presentation changes as set out below as at 30 June 2023 and 1 July 2022 in the Interim Financial Information:  Intangible assets;  Deferred tax asset;  Contract receivables and other receivables;  Other reserves;  Retained earnings;  Equity attributable to equity holders of the company;  Other financial payables at amortised cost;  Deferred acquisition costs;  Assets arising from contracts with customers;  Third-party interest in consolidated funds;  Investment contracts at fair value through profit or loss;  Other payables and provisions;  Employee benefits; and  Assets arising from reinsurance contracts held which are included in the Interim Financial Information’s selected notes, and a Summary of material accounting policies (together the “restated IFRS 17 and Other Presentation Changes and Restated Financial information”). Directors’ Responsibility for the restated IFRS 17 and Other Presentation Changes and Restated Financial information The directors are responsible for the preparation and presentation of the restated IFRS 17 and Other Presentation Changes and Restated Financial information in all material respects, in accordance with the principles of IAS 34: Interim Financial Reporting (IAS 34) , and for such internal control as the directors determine is necessary to enable the preparation of the restated IFRS 17 and Other Presentation Changes and Restated Financial information that is free from material misstatement, whether due to fraud or error. E. REVIEW OPINION -- 88 of 105 -- 111 Auditors’ Responsibilities for the Review of the restated IFRS 17 and Other Presentation Changes and Restated Financial information Our responsibility is to express a conclusion on the restated IFRS 17 and Other Presentation Changes and Restated Financial information. We conducted our review in accordance with International Standard on Review Engagements (ISRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, read together with ISA 805 (Revised), Special Considerations – Audits of Single Financial Statements and Specific Elements, Accounts or Items of a Financial Statement. ISRE 2410 requires us to conclude whether anything has come to our attention that causes us to believe that the restated IFRS 17 and Other Presentation Changes and Restated Financial information is not prepared in all material respects in accordance with the principles of IAS 34. This Standard also requires us to comply with relevant ethical requirements. A review of the restated IFRS 17 and Other Presentation Changes and Restated financial information in accordance with ISRE 2410 is a limited assurance engagement. We perform procedures, primarily consisting of making inquiries of management and others within the entity, as appropriate, and applying analytical procedures, and evaluate the evidence obtained. The procedures performed in a review are substantially less than and differ in nature from those performed in an audit conducted in accordance with International Standards on Auditing. Accordingly, we do not express an audit opinion on the restated IFRS 17 and Other Presentation Changes and Restated Financial information. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the reviewed account balances as defined as restated IFRS 17 and Other Presentation Changes and Restated Financial information in the opening paragraph, forming part of the Interim Financial Information of Discovery Limited for the six months ended 31 December 2023, is not prepared, in all material respects, in accordance with the principles of IAS 34. KPMG Inc. Registered Auditor Per: Mark Danckwerts Chartered Accountant (SA) Registered Auditor Director 85 Empire Road Parktown 2193 South Africa 20 March 2024 Deloitte & Touche Registered Auditors Per: Stephen Munro Chartered Accountant (SA) Registered Auditor Partner 5 Magwa Crescent Waterfall City Waterfall 2090 South Africa 20 March 2024 -- 89 of 105 -- 112 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Embedded value statement Table 2: Value of in-force covered business Table 1: Group embedded value Table 3: Group embedded value earnings Table 4: Components of Group embedded value earnings Table 5: Experience variances Table 6: Methodology and assumption changes Table 7: Embedded value of new business Table 9: Embedded value sensitivity Table 8: Embedded value economic assumptions Table 10: Value of new business sensitivity -- 90 of 105 -- 113 Embedded value statement for the six months ended 31 December 2023 The embedded value of the Discovery Group consists of the following components:  the adjusted net worth attributed to the business at the valuation date;  plus: the present value of expected future shareholder cash flows from the in-force covered business;  less: the cost of required capital. The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate. The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements. The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of required capital. The value of new business is calculated using the current reporting date assumptions. The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance, Discovery Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business. In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth. IFRS 17 Insurance Contracts became effective for the Discovery Group from 1 July 2023, with comparative restatement of the preceding year, namely the financial year ended 30 June 2023, including a restatement of the opening Group statement of financial position as at 1 July 2022. The change in the accounting standard does not have a material impact on the embedded value for covered businesses. In respect of non- covered businesses which were impacted by the transition to IFRS 17, such as Discovery Insure and Ping An Health Insurance, the transitional impacts to the Group’s shareholder funds were experienced which would serve to change previously disclosed embedded values. These changes are immaterial in aggregate, and so the disclosure of prior periods in the embedded value statement have not been restated. The cumulative effect of the changes were recognised in the period for the six months ended 31 December 2023. TABLE 1: GROUP EMBEDDED VALUE R million 31 December 2023 31 December 2022 % change 30 June 2023 Shareholders’ funds1 52 206 57 184 (9) 63 974 Adjustment to shareholders’ funds from published basis2 (33 141) (41 885) (21) (45 688) Adjusted net worth3 19 065 15 299 25 18 286 Value of in-force covered business before cost of required capital 87 915 80 678 9 83 906 Cost of required capital (3 500) (3 518) (1) (4 016) Discovery Group embedded value 103 480 92 459 12 98 176 Number of shares (millions) 662.1 658.4 658.4 Embedded value per share R156.29 R140.43 11 R149.11 Diluted number of shares (millions) 663.7 667.0 661.3 Diluted embedded value per share4 R155.92 R138.63 12 R148.45 1 Shareholders’ funds and the adjustment to shareholders’ funds from the published basis for the comparative periods are on an IFRS 4 basis. The key differences in the adjustment to shareholders’ funds from the published basis between an IFRS 17 and IFRS 4 basis include the change to the net assets under insurance contracts for Life and VitalityLife and the recapture of the FinRe Liability and allowance for a deferred acquisition cost asset for VitalityHealth. 2 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing exchange rate of R23.57/GBP (June 2023: R23.99/GBP; December 2022: R20.45/GBP). R million 31 December 2023 31 December 2022 30 June 2023 Life net assets under insurance contracts (17 225) (25 721) (25 491) Vitality Life Limited net assets under insurance contracts (8 739) (9 415) (12 051) VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) (4 162) (3 848) (5 001) VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (12) (10) (13) Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture (2 916) (2 531) (2 969) Intangible assets (net of deferred tax) in covered businesses (820) (867) (893) Net preference share capital (779) (779) (779) Reversal of 1 Discovery Place IFRS 16 financial lease accounting 1 406 1 260 1 333 Equity settled share based payment mark-to-market adjustment 106 26 176 (33 141) (41 885) (45 688) In respect to the table directly above: • Prior to 31 December 2023, the adjustment for “VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax)” also included the adjustment for the FinRe Liability which has since been recaptured. • The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to- market value of the equity settled share based payments. -- 91 of 105 -- 114 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 3 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value: R million 31 December 2023 31 December 2022 30 June 2023 Shareholders’ funds 52 206 57 184 63 974 Adjustment to shareholders’ funds (33 141) (41 885) (45 688) Adjusted net worth 19 065 15 299 18 286 Excess of available capital over adjusted net worth 45 771 36 860 40 336 Available capital 64 836 52 159 58 622 Required capital 43 197 39 272 41 987 Excess available capital 21 639 12 887 16 635 The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available capital on a statutory solvency basis for covered business. This includes: – The net preference share capital of R779 million which is included as available capital. – The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth. – The difference between Life’s Pillar 1 Own Funds and its adjusted net worth. The following table sets out the required capital for each of the covered businesses: R million 31 December 2023 31 December 2022 30 June 2023 Health and Vitality 1 159 1 067 1 108 Life and Invest 27 716 25 872 26 011 VitalityHealth 4 312 3 235 4 238 VitalityLife 10 010 9 098 10 630 Total required capital 43 197 39 272 41 987 – For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. – For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement. – For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement. – For the VitalityLife business on the PAC licence, prior to 31 December 2023, the required capital was set equal to 1.5 times the UK Solvency I long-term insurance capital requirement as per the agreement with PAC following the long-term delay of the Part VII transfer. From 31 December 2023 the VitalityLife business on the PAC license is classified as an insurance contract under IFRS 17. In line with the terms of the contract, the 1.5 times the UK Solvency I long-term insurance capital requirement is now reserved for. As a result, this amount no longer contributes to Required Capital in the embedded value, reducing the cost of capital, and the release of the reserve is included in the value of in-force. For the business sold on the Vitality Life Limited licence, the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement. 4 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the impact is dilutive. This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements. Disclosure of prior periods in the embedded value statement have been restated accordingly. Embedded value statement continued for the six months ended 31 December 2023 -- 92 of 105 -- 115 TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS R million Value before cost of required capital Cost of required capital Value after cost of required capital at 31 December 2023 Health and Vitality 26 268 (516) 25 752 Life and Invest1 35 051 (1 763) 33 288 VitalityHealth 2 13 964 (750) 13 214 VitalityLife 2 12 632 (471) 12 161 Total 87 915 (3 500) 84 415 at 31 December 2022 Health and Vitality 26 406 (493) 25 913 Life and Invest1 34 164 (1 510) 32 654 VitalityHealth 2 10 586 (569) 10 017 VitalityLife2 9 522 (946) 8 576 Total 80 678 (3 518) 77 160 at 30 June 2023 Health and Vitality 25 985 (512) 25 473 Life and Invest1 33 301 (1 665) 31 636 VitalityHealth2 12 797 (698) 12 099 VitalityLife2 11 823 (1 141) 10 682 Total 83 906 (4 016) 79 890 1 Included in the Life and Invest value of in-force covered business is R2 080 million (June 2023: R2 005 million; December 2022: R1 889 million) in respect of investment management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth. 2 The value of in-force has been converted using the closing exchange rate of R23.57/GBP (June 2023: R23.99/GBP; December 2022: R20.45/GBP). -- 93 of 105 -- 116 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Embedded value statement continued for the six months ended 31 December 2023 TABLE 3: GROUP EMBEDDED VALUE EARNINGS Six months ended Year ended R million 31 December 2023 31 December 2022 30 June 2023 Embedded value at end of period 103 480 92 459 98 176 Less: embedded value at beginning of period (98 176) (86 258) (86 258) Increase in embedded value 5 304 6 201 11 918 Dividends paid 783 31 69 Transfer to hedging reserve 70 (32) (76) Employee share option schemes (306) (178) (553) IFRS 17 impact on non-covered businesses1 (79) – – Acquisition of subsidiaries with non-controlling interest – (1) (6) Embedded value earnings 5 772 6 021 11 352 Annualised return on opening embedded value 12.1% 14.4% 13.2% 1 The embedded value for prior periods has not been restated for the transition to IFRS 17. This item represents the difference between IFRS 4 and IFRS 17 equity on non-covered business, such as Discovery Insure (decrease in equity at 30 June 2023) and Ping An Health Insurance (increase in equity at 30 June 2023), and an opening IFRS balance sheet restatement as a result of prior period errors (decrease in equity at 30 June 2023). These impacts largely offset as at 30 June 2023. These impacts have not been included in the embedded value earnings and so a minor adjustment is required to reconcile the change from the embedded value at the beginning of the period. TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS Six months ended 31 December 2023 Six months ended 31 December 2022 Year ended 30 June 2023 R million Net worth Cost of required capital Value of in-force covered business Embedded value Embedded value Embedded value Total profit from new business (at point of sale) (2 512) (154) 3 350 684 940 1 440 Profit from existing business – Expected return 3 695 (39) 1 369 5 025 3 965 8 589 – Change in methodology and assumptions1 965 626 (925) 666 (237) (4 854) – Experience variances 208 55 616 879 2 073 3 204 Impairment, amortisation and fair value adjustment2 (30) – – (30) (29) (67) Increase in goodwill and intangibles (110) – – (110) (151) (263) Other initiatives3 78 – 11 89 (220) 24 Non-recurring expenses (159) – – (159) (106) (193) Acquisition costs4 (17) – (2) (19) (20) (48) Finance costs 5 (1 662) – – (1 662) (1 324) (2 848) Foreign exchange rate movements 6 (96) 24 (406) (478) 599 5 070 Other7 (6) – – (6) (5) 90 Return on shareholders’ funds5, 8 893 – – 893 536 1 208 Embedded value earnings 1 247 512 4 013 5 772 6 021 11 352 1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements). 2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure in Discovery Group Europe Limited. 3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up businesses (including Discovery Bank, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which relate to non-covered business are included in this item, as well as cR77 million of expenses which are currently incurred by the covered businesses but will be met by non-covered businesses in due course, and hence have not been included in the relevant covered businesses’ embedded value expense analysis. 4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the costs are not deducted from the value of new business. 5 Finance costs and return on shareholders’ funds are shown gross of intercompany charges (R781 million at 31 December 2023, R538 million at 31 December 2022 and R1 198 million at 30 June 2023). 6 This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value of in-force. 7 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth. 8 The return on shareholders’ funds is shown net of tax and management charges. -- 94 of 105 -- 117 TABLE 5: EXPERIENCE VARIANCES Health and Vitality Life and Invest VitalityHealth VitalityLife R million Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Total Renewal expenses 68 – 11 (2) (55) – 1 – 23 Lapses and surrenders 1, 2 (2) (133) 19 99 – 235 (95) 137 260 Mortality and morbidity – – (22) (10) (71) – 72 – (31) Policy alterations2 – (10) (323) 28 – – (1) (41) (347) Backdated cancellations – – – – – – – – – Premium and fee income 3 73 – (49) 201 63 – (34) (51) 203 Inflation-linked indexation – – (3) (82) – – – 218 133 Economic 4 – – 37 (84) 100 – – – 53 Commission – – – – – – – – – Tax 5 50 – 75 (69) 3 – 37 – 96 Reinsurance6 – – – – (1) – (51) (60) (112) Maintain modelling term7 – 160 – 55 – 48 – – 263 Vitality benefits 41 – – – – – 4 – 45 Other8 53 (1) 36 33 92 – 80 – 293 Total 283 16 (219) 169 131 283 13 203 879 1 For VitalityHealth, the lapse and surrender experience reflect improved retention rates from strong premium increases and expansion of existing schemes. For Health & Vitality, the lapse and surrender experience was driven by an increase in the number of employer groups who have widened the eligible schemes that employees can join beyond the Discovery Health Medical Scheme. Better than expected lapse experience has been observed for the other covered businesses. 2 For Life and Invest, the policy alterations experience relates mainly to persistent pressures within the economic environment. This is partially offset by positive experience on lapses. 3 Other than higher than expected premium and fee income, this experience variance item includes the impact of positive integration experience for individual life business in Life. 4 For Life and Invest, the experience includes lower than expected growth in asset values in the Invest business. For VitalityHealth, investment return continued to contribute to profitability as interest rates in the UK remain high. 5 The tax variance arises due to the timing difference between the expected tax payments and actual payments. 6 For VitalityLife, the reinsurance experience includes an increase in reinsurance premium provisions related to prior periods, and the greater than expected cost of financing reinsurance. 7 For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises because the total term of the in-force covered business is effectively increased by six months. 8 The key Other experience relates to cash flow timing variances in Life and Invest and profits / losses from companies within the Health, VitalityHealth and VitalityLife segments which are not part of covered business. -- 95 of 105 -- 118 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Embedded value statement continued for the six months ended 31 December 2023 TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES Health and Vitality Life and Invest VitalityHealth VitalityLife R million Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Net worth Value of in-force Total Modelling changes 1 – – 12 (98) – – – 241 155 Expenses – – – – – – – – – Lapses – – – – – – – – – Mortality and morbidity – – – – – – – – – Benefit changes – – – – – – – – – Vitality – – – – – – – – – Tax – – – – – – – – – Economic assumptions 2 – (840) 20 (668) – 643 – 971 126 Premium and fee income – 84 – – – – – – 84 Reinsurance and financing3 – – 693 (638) – – – 9 64 Other 4 – – 324 216 – – (84) (219) 237 Total – (756) 1 049 (1 188) – 643 (84) 1 002 666 1 For Life and Invest, the item reflects refinements to the data and models. For VitalityLife, the item reflects the reduction in cost of capital due to the implementation of the Solvency UK Risk Margin Reforms. 2 For Health and Vitality, and Life and Invest, the economic assumptions were updated in line with observed market nominal and real yield risk-free curves at 31 December 2023. For VitalityLife, the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest rates. Note that for VitalityLife, following the implementation of IFRS 17, the risk-free rate assumption is based on the Solvency II yield curves instead of a single interest rate derived from the curves. For VitalityHealth, the impact of updating the assumptions relative to the Solvency II yield curves results in an increase to the annuity factor. 3 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows arising from part of the negative reserves are monetised to match other positive policy liabilities. 4 The Other item includes, among other things, second order impacts relating to the adoption of IFRS 17 for covered business, which have not been captured as part of the opening IFRS equity restatement, such as taxation phasing and reallocations identified as part of the transition. -- 96 of 105 -- 119 TABLE 7: EMBEDDED VALUE OF NEW BUSINESS Six months ended Year ended R million 31 December 2023 31 December 2022 % Change 30 June 2023 Health and Vitality Present value of future profits from new business (at point of sale) 406 531 954 Cost of required capital (21) (20) (39) Present value of future profits from new business (at point of sale) after cost of required capital 385 511 (25) 915 New business annualised premium income1 2 200 2 238 (2) 4 959 Life and Invest Present value of future profits from new business (at point of sale)2 287 377 516 Cost of required capital (45) (48) (87) Present value of future profits from new business (at point of sale) after cost of required capital 242 329 (26) 429 New business annualised premium income3 1 576 1 496 5 2 965 Annualised profit margin4 2.0% 2.8% 1.8% Annualised profit margin excluding Invest business 4.3% 4.5% 2.5% VitalityHealth 5 Present value of future profits from new business (at point of sale) 245 80 269 Cost of required capital (53) (38) (87) Present value of future profits from new business (at point of sale) after cost of required capital 192 42 357 182 New business annualised premium income6 1 190 884 35 2 001 Annualised profit margin4 2.5% 0.7% 1.4% VitalityLife 7 Present value of future profits from new business (at point of sale) (100) 104 3 Cost of required capital (35) (46) (89) Present value of future profits from new business (at point of sale) after cost of required capital (135) 58 (333) (86) New business annualised premium income 667 540 24 1 124 Annualised profit margin4 (2.8%) 1.4% (1.0%) 1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business written during the period but only activated after 31 December 2023. The total Health and Vitality new business annualised premium income written over the period, inclusive of Sasolmed, was R7 052 million (June 2023: R9 051 million; December 2022: R4 604 million). 2 Included in the Life and Invest embedded value of new business is -R3 million (June 2023: R21 million; December 2022: R7 million) in respect of investment management services provided on off balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been recognised in the value of new business. 3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. The new business annualised premium income of R1 576 million (June 2023: R2 965 million; December 2022: R1 496 million) (single premium APE: R741 million (June 2023: R1 430 million; December 2022: R674 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business annualised premium income written over the period, including automatic premium increases of R1 184 million (June 2023: R2 208 million; December 2022: R1 130 million) and servicing increases of R387 million (June 2023: R716 million; December 2022: R363 million), was R3 147 million (June 2023: R5 889 million; December 2022: R2 990 million) (single premium APE: R778 million (June 2023: R1 499 million; December 2022: R708 million)). Single premium business is included at 10% of the value of the single premium. Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans are shown in Table 5 as experience variances and not included as new business. Term extensions on existing contracts are not included as new business. 4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums. 5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are shown in Table 8. 6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of new business written during the period but only activated after 31 December 2023. 7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due after the valuation date. -- 97 of 105 -- 120 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Embedded value statement continued for the six months ended 31 December 2023 Basis of preparation TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS 31 December 2023 31 December 2022 30 June 2023 Beta coefficient 0.75 0.75 0.75 Equity risk premium (%) 3.5 3.5 3.5 Risk discount rate (%) – Health and Vitality1 15.125 14.375 15.125 – Life and Invest1 15.625 14.375 15.875 – VitalityHealth 5.992 6.365 7.000 – VitalityLife 5.975 6.399 7.042 Rand/GBP exchange rate Closing 23.57 20.45 23.99 Average 23.43 20.38 21.43 Margin over Expense inflation to derive Medical inflation (%) South Africa 3.00 3.00 3.00 Expense inflation (%)2 South Africa – Health and Vitality 7.16 7.82 7.96 – Life and Invest 7.72 7.36 8.13 United Kingdom 3.65 3.75 3.75 Pre-tax investment return (%) South Africa – Cash1 11.50 10.25 11.75 – Life and Invest bonds3 13.00 11.75 13.25 – Health and Vitality bonds3 12.50 11.75 12.50 – Equity1 16.50 15.25 16.75 United Kingdom – VitalityHealth risk-free rate 3.37 3.74 4.38 – VitalityLife risk-free rate 3.35 3.77 4.42 – VitalityLife IFRS interest rate 3.35 4.24 3.98 – VitalityLife investment return 4.70 3.25 4.31 Long-term corporation tax rate (%) South Africa 27 27 27 United Kingdom 25 25 25 VitalityHealth Assumptions – Margin (net of tax and cost of capital) (%) 12.07 12.00 12.05 – Annuity Factor 6.63 6.49 6.28 Projection term – Health and Vitality 20 years 20 years 20 years – Discovery Life – VIF 40 years 40 years 40 years – Group Life 20 years 20 years 20 years – VitalityLife No cap No cap No cap – VitalityHealth4 20 years 20 years 20 years 1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds. 2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation. 3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown. 4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor. -- 98 of 105 -- 121 The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available, augmented by reinsurance and industry information. The Health and Vitality lapse assumptions were derived from the results of recent experience investigations. The VitalityHealth assumptions were derived from internal experience. VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group information. Renewal expense assumptions were based on the results of the latest expense and budget information. The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of an exceptional or non-recurring nature. The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE risk-free nominal yield curve. The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the net investment return assumption. The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory Authority yield curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption following the implementation of IFRS 17. The inflation rate is consistent with the long-term market view of inflation. From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium increases. The Margin assumption reflects assumed profit margins after tax and Cost of Capital. The assumptions underlying the Annuity Factor and Margin are set taking into account the current experience in the business at different durations. The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets. The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 3. -- 99 of 105 -- 122 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 123 Sensitivity to the embedded value assumptions The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 31 December 2023 to changes in the risk discount rate is included in the tables below. For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action such as risk premium increases where future experience is worse than the base assumptions. TABLE 9: EMBEDDED VALUE SENSITIVITY Health and Vitality Life and Invest VitalityHealth VitalityLife Embedded value % change R million Adjusted net worth Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital Value of in-force Cost of required capital Base 19 065 26 268 (516) 35 051 (1 763) 13 964 (750) 12 632 (471) 103 480 Impact of: Risk discount rate + 1% 19 065 24 836 (557) 32 071 (1 838) 13 235 (982) 11 719 (531) 97 018 (6) Risk discount rate – 1% 19 065 27 848 (471) 38 560 (1 653) 14 771 (491) 13 689 (371) 110 947 7 Lapses – 10% 19 065 27 113 (541) 37 976 (1 861) 16 460 (884) 13 319 (568) 110 079 6 Interest rates – 1%1 19 065 26 404 (498) 35 611 (1 736) 14 771 (793) 12 362 (621) 104 565 1 Equity and property market value – 10% 19 025 26 268 (516) 34 312 (1 758) 13 964 (750) 12 632 (471) 102 706 (1) Equity and property return + 1% 19 065 26 268 (516) 35 410 (1 766) 13 964 (750) 12 632 (471) 103 836 – Renewal expenses – 10% 19 065 28 903 (478) 35 740 (1 736) 15 031 (750) 12 886 (448) 108 213 5 Mortality and morbidity – 5% 19 065 26 268 (516) 37 309 (1 674) 16 310 (750) 13 045 (459) 108 598 5 Projection term + 1 year 19 065 26 571 (521) 35 134 (1 769) 14 079 (756) 12 632 (471) 103 964 – 1 All economic assumptions were reduced by 1%. The following table shows the effect of using different assumptions on the embedded value of new business. TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY Health and Vitality Life and Invest VitalityHealth VitalityLife Value of new business % change R million Value of new business Cost of required capital Value of new business Cost of required capital Value of new business Cost of required capital Value of new business Cost of required capital Base 406 (21) 287 (45) 245 (53) (100) (35) 684 Impact of: Risk discount rate + 1% 370 (23) 200 (47) 190 (69) (153) (39) 429 (37) Risk discount rate – 1% 445 (19) 386 (42) 307 (35) (39) (28) 975 43 Lapses - 10% 434 (23) 385 (48) 411 (62) 538 (41) 1 594 133 Interest rates – 1% 1 412 (20) 287 (44) 307 (56) (69) (47) 770 13 Equity and property return + 1% 406 (21) 299 (45) 245 (53) (100) (35) 696 2 Renewal expense – 10% 469 (20) 312 (44) 317 (53) (79) (33) 869 27 Mortality and morbidity – 5% 406 (21) 331 (43) 403 (53) (80) (34) 909 33 Projection term + 1 year 413 (21) 289 (45) 254 (53) (100) (35) 702 3 Acquisition costs – 10% 424 (21) 365 (45) 245 (53) 10 (35) 890 30 1 All economic assumptions were reduced by 1%. Embedded value statement continued for the six months ended 31 December 2023 -- 100 of 105 -- 124 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 Annexure A Income from non-insurance business lines New business annualised premium income -- 101 of 105 -- 125 Annexure A This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income measures. These measures enhance the comparability and understanding of the financial performance of the Group. NEW BUSINESS ANNUALISED PREMIUM INCOME for the six months ended 31 December 2023 The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, DHMS new business is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in respect of such services. Core business API, increased by 28% for the six months ended 31 December 2023 when compared to the corresponding prior period. R million Group December 2023 Unaudited Group December 2022 Unaudited % Change Discovery Health1 6 835 4 487 52 Discovery Life 1 519 1 485 2 Individual Life 1 444 1 355 7 Group Life 75 130 (42) Discovery Invest 1 629 1 505 8 Discovery Insure 666 616 8 Discovery Vitality 217 162 34 Other initiatives2 234 356 (34) Total new business API from SA Composite 11 100 8 611 29 VitalityHealth 1 135 890 28 VitalityLife 935 801 17 Total new business API from UK Composite 2 070 1 691 22 Total new business API from VG Composite: Ping An Health Insurance (PAHI) own license 1 027 804 28 New business API of Group 14 197 11 106 28 1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings such as GAP cover, FlexiCare cover and African Health (prior year number restated for Africa Health). 2 Other new businesses include the Umbrella Fund and Discovery Insure commercial. Calculation of New business API New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single premium policies It also includes both automatic premium increases and servicing increases on existing long-term insurance policies. The amounts exclude indirect taxes. The new business API in the table above differs from the new business API disclosed in the embedded value largely as a results of:  The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in table above, new business is included when the policy has been contractually committed.  ❚Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but excluded in the embedded value API values disclosed. Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business disclosures between the embedded value and the table above. . -- 102 of 105 -- 126 DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023 INCOME FROM NON-INSURANCE BUSINESS LINES for the six months ended 31 December 2023 (not included in new business API definition above) R million Group December 2023 Unaudited Group December 2022 Unaudited Change % Discovery Health – Income excluded from API measure 592 575 3 Discovery Bank 933 706 32 Discovery Bank – Net banking fee and commission income (NIR) 567 438 29 Discovery Bank – Net bank interest and similar income (NII) 366 268 37 Vitality Global income1 1 417 1 273 11 Vitality Network 942 754 25 Vitality Health International (excluding PAHI) 475 519 (8) Total income from non-insurance business lines 2 942 2 554 15 1 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and solution revenue from external clients, while that from internal clients and rewards is specifically excluded. -- 103 of 105 -- Transfer secretaries Computershare Investor Services (Pty) Limited (Registration number: 2004/003647/07) Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196 Private Bag X9000, Saxonwold, 2132 Sponsors and debt sponsors Rand Merchant Bank (a division of FirstRand Bank Limited) Secretary and registered office A Ceba, Discovery Limited (Incorporated in the Republic of South Africa) (Registration number: 1999/007789/06) Company tax reference number: 9652/003/71/7 JSE share code: DSY ISIN: ZAE000022331 JSE share code: DSBP ISIN: ZAE000158564 JSE company code: DSYI 1 Discovery Place, Sandton, 2196 PO Box 786722, Sandton, 2146 Tel: (011) 529 2888 Fax: (011) 539 8003 Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), L Chiume1, R Farber, WM Hlahla, FN Khanyile, D Macready, Dr TV Maphai2, T Mboweni, KC Ramon1, M Schreuder, B Swartzberg*, B van Kralingen, DM Viljoen* (Group Chief Financial Officer), SV Zilwa2. * Executive. 1 Appointed effective 18 September 2023. 2 Retired effective 16 November 2023. Debt officer DM Viljoen Interim financial results – prepared by G Pieterse CA(SA), J Symons CA(SA) – supervised by DM Viljoen CA(SA) Embedded value statement – prepared by P Bolink FASSA – supervised by A Rayner FASSA, FIA Administration -- 104 of 105 -- Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za Copyright 2021. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group. Registration number: 1999/007789/06. Companies in the Group are licensed insurers and authorised financial services providers. -- 105 of 105 --